{"nersets":[[{"setid":"PMC2883751","drugname":"midazolam","startOffset":340,"endOffset":349,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","prefix":"ssed in bacterial membranes. Recombinant P450 3A5 catalyzed ","suffix":" 1′-hydroxylation more efficiently than did P450 3A4 (","exact":"midazolam"},{"setid":"PMC2883751","drugname":"voriconazole","startOffset":193,"endOffset":205,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":"ance and inhibition of triazole antifungal drugs, including ","suffix":", emphasising polymorphic P450 3A5 expression in genotyped l","exact":"voriconazole"},{"setid":"PMC2883751","drugname":"voriconazole","startOffset":57,"endOffset":69,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","prefix":"                                                         ","suffix":" is of particular interest because of different metabolic pa","exact":"Voriconazole"}],[{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":246,"endOffset":255,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"receptor-positive tumours. Cytochrome P-450 2D6 metabolises ","suffix":" to metabolites that more readily bind the oestrogen recepto","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":461,"endOffset":470,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"se widely used drugs - when taken concurrently - may reduce ","suffix":"'s prevention of breast cancer recurrence. We studied citalo","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":822,"endOffset":831,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"ogen-receptor-positive breast cancer 1985-2001 and who took ","suffix":" for 1, 2, or most often for 5 years. We ascertained prescri","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":1141,"endOffset":1150,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"least one prescription for the SSRI citalopram while taking ","suffix":" (adjusted conditional odds ratio=0.85, 95% confidence inter","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":1259,"endOffset":1268,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"dence interval=0.42, 1.7). We also observed no reduction of ","suffix":" effectiveness among regular citalopram users (⩾30% overlap ","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":1333,"endOffset":1342,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"ctiveness among regular citalopram users (⩾30% overlap with ","suffix":" use). These results suggest that concurrent use of citalopr","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":246,"endOffset":255,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"receptor-positive tumours. Cytochrome P-450 2D6 metabolises ","suffix":" to metabolites that more readily bind the oestrogen recepto","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":461,"endOffset":470,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"se widely used drugs - when taken concurrently - may reduce ","suffix":"'s prevention of breast cancer recurrence. We studied citalo","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":822,"endOffset":831,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"ogen-receptor-positive breast cancer 1985-2001 and who took ","suffix":" for 1, 2, or most often for 5 years. We ascertained prescri","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":1141,"endOffset":1150,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"least one prescription for the SSRI citalopram while taking ","suffix":" (adjusted conditional odds ratio=0.85, 95% confidence inter","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":1259,"endOffset":1268,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"dence interval=0.42, 1.7). We also observed no reduction of ","suffix":" effectiveness among regular citalopram users (⩾30% overlap ","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":1333,"endOffset":1342,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"ctiveness among regular citalopram users (⩾30% overlap with ","suffix":" use). These results suggest that concurrent use of citalopr","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":1421,"endOffset":1430,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"s suggest that concurrent use of citalopram does not reduce ","suffix":"'s prevention of breast cancer recurrence.                  ","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":93,"endOffset":102,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"                        Breast cancer patients treated with ","suffix":" may also take other prescription medications that are metab","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":211,"endOffset":220,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"t are metabolised by some of the same enzymes that activate ","suffix":". For example, depression is a common comorbidity in breast ","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":139,"endOffset":148,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":"o date of the potential for drug-drug interaction to reduce ","suffix":"'s protection against breast cancer recurrence, we examined ","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":309,"endOffset":318,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":"h oestrogen-receptor-positive tumours who were treated with ","suffix":" for 1, 2, or most often for 5 years had a higher rate of re","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":211,"endOffset":220,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","prefix":"ed the oestrogen receptor protein and who were treated with ","suffix":" for at least 1 year; (b) group II women whose tumour did no","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":344,"endOffset":353,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","prefix":"press the oestrogen receptor protein, were not treated with ","suffix":", and who survived for at least one year; and (c) group III ","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":512,"endOffset":521,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","prefix":"excluded from this analysis. Group I women were assigned to ","suffix":" therapy protocols of 1, 2, or 5 years, depending on the gui","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":378,"endOffset":387,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[2]","prefix":" radiation therapy, receipt of chemotherapy, and receipt of ","suffix":" therapy) from the DBCG database.                           ","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":163,"endOffset":172,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[3]","prefix":"opram prescription, we calculated the percentage of time on ","suffix":" when they were simultaneously taking citalopram. We created","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":318,"endOffset":327,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[3]","prefix":"ttent citalopram use, defined as citalopram use overlapping ","suffix":" use for more than 0% but less than 30% of the time on tamox","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":382,"endOffset":391,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[3]","prefix":"xifen use for more than 0% but less than 30% of the time on ","suffix":" and (b) regular citalopram use, defined as citalopram use o","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":462,"endOffset":471,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[3]","prefix":"gular citalopram use, defined as citalopram use overlapping ","suffix":" use for 30% or more of the time on tamoxifen. We chose 30% ","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":507,"endOffset":516,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[3]","prefix":"se overlapping tamoxifen use for 30% or more of the time on ","suffix":". We chose 30% as the overlap boundary to allow sufficient s","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":681,"endOffset":690,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[3]","prefix":", while also investigating a substantial period of SSRI and ","suffix":" comedication.                                              ","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":782,"endOffset":791,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[3]/p[1]","prefix":" inhibitor or substrate, including other SSRI, while taking ","suffix":".                                                           ","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":167,"endOffset":176,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","prefix":"he two groups (oestrogen-receptor positive and treated with ","suffix":" or oestrogen-receptor negative and not treated with tamoxif","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":229,"endOffset":238,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","prefix":"moxifen or oestrogen-receptor negative and not treated with ","suffix":"). We computed the frequency and proportion of cases and con","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":346,"endOffset":355,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","prefix":"ases and controls within categories of assigned protocol of ","suffix":" duration, of citalopram use, of use of other CYP2D6 inhibit","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":109,"endOffset":118,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","prefix":"        Group I women who ever used citalopram while taking ","suffix":" did not have a higher rate of breast cancer recurrence than","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":224,"endOffset":233,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","prefix":"ecurrence than women who never used citalopram while taking ","suffix":" (","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":154,"endOffset":163,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"ort the hypothesis that citalopram, taken concurrently with ","suffix":", reduces tamoxifen's protective effect against breast cance","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":173,"endOffset":182,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"that citalopram, taken concurrently with tamoxifen, reduces ","suffix":"'s protective effect against breast cancer recurrence in ear","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":294,"endOffset":303,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":" centre, which also reported no substantial modification of ","suffix":" effectiveness by concomitant use of SSRI inhibitors of CYP2","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":134,"endOffset":143,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"ic question may be whether reduced concentrations of active ","suffix":" metabolites result in substantially reduced occupancy of th","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":149,"endOffset":158,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[9]","prefix":"udy yielded only 17 cases of breast cancer recurrence among ","suffix":"-treated women who had used citalopram while taking tamoxife","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":210,"endOffset":219,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[9]","prefix":"amoxifen-treated women who had used citalopram while taking ","suffix":". The study was designed with 80% power to detect an OR of 1","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":223,"endOffset":232,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[10]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[10]","prefix":"tration advisory committee recently recommended relabelling ","suffix":" with information on gene-drug and drug-drug interactions me","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":61,"endOffset":70,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"                                                            ","suffix":" remains an important adjuvant therapy to reduce the rate of","exact":"Tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":57,"endOffset":66,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"                                                         ","suffix":" is a selective oestrogen receptor modulator (","exact":"Tamoxifen"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":524,"endOffset":534,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"oxifen's prevention of breast cancer recurrence. We studied ","suffix":" use in 184 cases of breast cancer recurrence and 184 matche","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":1117,"endOffset":1127,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"trols (11%) received at least one prescription for the SSRI ","suffix":" while taking tamoxifen (adjusted conditional odds ratio=0.8","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":1297,"endOffset":1307,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"erved no reduction of tamoxifen effectiveness among regular ","suffix":" users (⩾30% overlap with tamoxifen use). These results sugg","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":1394,"endOffset":1404,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"amoxifen use). These results suggest that concurrent use of ","suffix":" does not reduce tamoxifen's prevention of breast cancer rec","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":430,"endOffset":440,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":"te of recurrence if they were concomitantly taking the SSRI ","suffix":" or its S-stereoisomer ('citalopram' from here onwards) than","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":554,"endOffset":564,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":") than if they were not. As described in more detail below, ","suffix":" was the most frequently prescribed SSRI in the study popula","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":703,"endOffset":713,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","prefix":"cluded group II women to estimate the direct association of ","suffix":" prescription with recurrence rate, if any. We further restr","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":1076,"endOffset":1086,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","prefix":"sed to ascertain use of prescription medications, including ","suffix":". Follow-up time began 1 year after the date of breast cance","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":524,"endOffset":534,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"oxifen's prevention of breast cancer recurrence. We studied ","suffix":" use in 184 cases of breast cancer recurrence and 184 matche","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":1117,"endOffset":1127,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"trols (11%) received at least one prescription for the SSRI ","suffix":" while taking tamoxifen (adjusted conditional odds ratio=0.8","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":1297,"endOffset":1307,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"erved no reduction of tamoxifen effectiveness among regular ","suffix":" users (⩾30% overlap with tamoxifen use). These results sugg","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":1394,"endOffset":1404,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"amoxifen use). These results suggest that concurrent use of ","suffix":" does not reduce tamoxifen's prevention of breast cancer rec","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":430,"endOffset":440,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":"te of recurrence if they were concomitantly taking the SSRI ","suffix":" or its S-stereoisomer ('citalopram' from here onwards) than","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":465,"endOffset":475,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":"mitantly taking the SSRI citalopram or its S-stereoisomer ('","suffix":"' from here onwards) than if they were not. As described in ","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":554,"endOffset":564,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":") than if they were not. As described in more detail below, ","suffix":" was the most frequently prescribed SSRI in the study popula","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":703,"endOffset":713,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","prefix":"cluded group II women to estimate the direct association of ","suffix":" prescription with recurrence rate, if any. We further restr","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":1076,"endOffset":1086,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","prefix":"sed to ascertain use of prescription medications, including ","suffix":". Follow-up time began 1 year after the date of breast cance","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":93,"endOffset":103,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[3]","prefix":"                            We collected data on receipt of ","suffix":" prescription and other potential CYP2D6 inhibitors (includi","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":127,"endOffset":137,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[2]","prefix":" classified cases and controls as those with no record of a ","suffix":" prescription during their follow-up time (never citalopram)","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":186,"endOffset":196,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[2]","prefix":" citalopram prescription during their follow-up time (never ","suffix":") and those with any record of prescription for citalopram d","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":244,"endOffset":254,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[2]","prefix":"r citalopram) and those with any record of prescription for ","suffix":" during their follow-up time (ever citalopram). We used a si","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":289,"endOffset":299,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[2]","prefix":"escription for citalopram during their follow-up time (ever ","suffix":"). We used a similar procedure to classify cases and control","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":98,"endOffset":108,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[3]","prefix":"                           For group I women who ever had a ","suffix":" prescription, we calculated the percentage of time on tamox","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":210,"endOffset":220,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[3]","prefix":"e of time on tamoxifen when they were simultaneously taking ","suffix":". We created categories of (a) intermittent citalopram use, ","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":264,"endOffset":274,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[3]","prefix":"aking citalopram. We created categories of (a) intermittent ","suffix":" use, defined as citalopram use overlapping tamoxifen use fo","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":291,"endOffset":301,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[3]","prefix":"d categories of (a) intermittent citalopram use, defined as ","suffix":" use overlapping tamoxifen use for more than 0% but less tha","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":408,"endOffset":418,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[3]","prefix":" but less than 30% of the time on tamoxifen and (b) regular ","suffix":" use, defined as citalopram use overlapping tamoxifen use fo","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":435,"endOffset":445,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[3]","prefix":"ime on tamoxifen and (b) regular citalopram use, defined as ","suffix":" use overlapping tamoxifen use for 30% or more of the time o","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":602,"endOffset":612,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[3]","prefix":"lap boundary to allow sufficient sample size in the regular ","suffix":" subgroup, while also investigating a substantial period of ","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":369,"endOffset":379,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","prefix":"n categories of assigned protocol of tamoxifen duration, of ","suffix":" use, of use of other CYP2D6 inhibitors or substrates, and o","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":519,"endOffset":529,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","prefix":" calculated the number of cases and controls ever receiving ","suffix":", the number of total prescriptions for citalopram summed ov","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":569,"endOffset":579,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","prefix":"receiving citalopram, the number of total prescriptions for ","suffix":" summed over all cases or controls, and the range of the num","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":664,"endOffset":674,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","prefix":" controls, and the range of the number of prescriptions for ","suffix":" received by each individual case or control.               ","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":101,"endOffset":111,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","prefix":"                    We estimated the rate ratio associating ","suffix":" prescription with breast cancer recurrence as the odds rati","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":230,"endOffset":240,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","prefix":"io (OR) in a conditional logistic regression including only ","suffix":" use as the exposure variable and conditioned on the matched","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":85,"endOffset":95,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","prefix":"                                Group I women who ever used ","suffix":" while taking tamoxifen did not have a higher rate of breast","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":200,"endOffset":210,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","prefix":" rate of breast cancer recurrence than women who never used ","suffix":" while taking tamoxifen (","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":118,"endOffset":128,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"he results of this study do not support the hypothesis that ","suffix":", taken concurrently with tamoxifen, reduces tamoxifen's pro","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":207,"endOffset":217,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"t, the majority of SSRI prescriptions in our study were for ","suffix":" or its S-stereoisomer, both originally manufactured by Lund","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":104,"endOffset":114,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"             Last, we do not know the indications for which ","suffix":" was prescribed to the study participants, although ordinari","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":817,"endOffset":827,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[8]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[8]","prefix":" have high sensitivity and specificity for ascertainment of ","suffix":" prescriptions in the source population. Furthermore, becaus","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":186,"endOffset":196,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[9]","prefix":"ancer recurrence among tamoxifen-treated women who had used ","suffix":" while taking tamoxifen. The study was designed with 80% pow","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":319,"endOffset":329,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"nufactured by Lundbeck, a company headquartered in Denmark. ","suffix":" is a modest inhibitor of ","exact":"Citalopram"},{"setid":"PMC2527838","drugname":"advantage","startOffset":71,"endOffset":80,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[9]","prefix":"                                              Despite these ","suffix":"s, the study yielded only 17 cases of breast cancer recurren","exact":"advantage"}],[{"setid":"PMC2764168","drugname":"tipranavir","startOffset":57,"endOffset":67,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"                                                         ","suffix":" coadministered with low-dose ritonavir (TPV/r) is an effect","exact":"Tipranavir"},{"setid":"PMC2764168","drugname":"tipranavir","startOffset":219,"endOffset":229,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","prefix":"d a single 10-mg dose of rosuvastatin on day 1, followed by ","suffix":" 500 mg-ritonavir 200 mg twice daily for 11 days (days 3 to ","exact":"tipranavir"},{"setid":"PMC2764168","drugname":"tipranavir","startOffset":714,"endOffset":724,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","prefix":"/r at steady state) for rosuvastatin and days 12 and 13 for ","suffix":" and ritonavir. A standard 670-kcal (33% fat) breakfast was ","exact":"tipranavir"},{"setid":"PMC2764168","drugname":"tipranavir","startOffset":1096,"endOffset":1106,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","prefix":"nd 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, and 12 h postdose for ","suffix":" and ritonavir and 0 h predose and 0.5, 1, 1.5, 2, 3, 4, 5, ","exact":"tipranavir"},{"setid":"PMC2764168","drugname":"tipranavir","startOffset":1437,"endOffset":1447,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","prefix":"s undertaken. The short-term safety and steady-state PKs of ","suffix":" and ritonavir coadministered with single-dose rosuvastatin ","exact":"tipranavir"},{"setid":"PMC2764168","drugname":"tipranavir","startOffset":608,"endOffset":618,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[1]","prefix":"0% adherence with study medication. The steady-state PKs of ","suffix":" were assessed on day 19 after ingestion of TPV/r alone and ","exact":"tipranavir"},{"setid":"PMC2764168","drugname":"tipranavir","startOffset":125,"endOffset":135,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"dentify pharmacokinetic (PK) drug-drug interactions between ","suffix":"-ritonavir (TPV/r) and rosuvastatin and atorvastatin, we con","exact":"tipranavir"},{"setid":"PMC2764168","drugname":"tipranavir","startOffset":219,"endOffset":229,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","prefix":"d a single 10-mg dose of rosuvastatin on day 1, followed by ","suffix":" 500 mg-ritonavir 200 mg twice daily for 11 days (days 3 to ","exact":"tipranavir"},{"setid":"PMC2764168","drugname":"tipranavir","startOffset":714,"endOffset":724,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","prefix":"/r at steady state) for rosuvastatin and days 12 and 13 for ","suffix":" and ritonavir. A standard 670-kcal (33% fat) breakfast was ","exact":"tipranavir"},{"setid":"PMC2764168","drugname":"tipranavir","startOffset":1096,"endOffset":1106,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","prefix":"nd 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, and 12 h postdose for ","suffix":" and ritonavir and 0 h predose and 0.5, 1, 1.5, 2, 3, 4, 5, ","exact":"tipranavir"},{"setid":"PMC2764168","drugname":"tipranavir","startOffset":1437,"endOffset":1447,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","prefix":"s undertaken. The short-term safety and steady-state PKs of ","suffix":" and ritonavir coadministered with single-dose rosuvastatin ","exact":"tipranavir"},{"setid":"PMC2764168","drugname":"tipranavir","startOffset":608,"endOffset":618,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[1]","prefix":"0% adherence with study medication. The steady-state PKs of ","suffix":" were assessed on day 19 after ingestion of TPV/r alone and ","exact":"tipranavir"},{"setid":"PMC2764168","drugname":"tipranavir","startOffset":91,"endOffset":101,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[2]","prefix":"                              Blood samples for analysis of ","suffix":" concentrations were collected in heparinized tubes on days ","exact":"tipranavir"},{"setid":"PMC2764168","drugname":"tipranavir","startOffset":141,"endOffset":151,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[9]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[9]/p[1]","prefix":"MS method was used to measure plasma drug concentrations of ","suffix":" and ritonavir (","exact":"tipranavir"},{"setid":"PMC2764168","drugname":"tipranavir","startOffset":385,"endOffset":395,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":"orvastatin PK results from one subject and the steady-state ","suffix":" PK results from another subject were excluded from all stat","exact":"tipranavir"},{"setid":"PMC2764168","drugname":"tipranavir","startOffset":125,"endOffset":135,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[2]","prefix":"le-dose atorvastatin did not affect the steady-state PKs of ","suffix":" (Table ","exact":"tipranavir"},{"setid":"PMC2764168","drugname":"ritonavir","startOffset":136,"endOffset":145,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"rmacokinetic (PK) drug-drug interactions between tipranavir-","suffix":" (TPV/r) and rosuvastatin and atorvastatin, we conducted two","exact":"ritonavir"},{"setid":"PMC2764168","drugname":"ritonavir","startOffset":136,"endOffset":145,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"rmacokinetic (PK) drug-drug interactions between tipranavir-","suffix":" (TPV/r) and rosuvastatin and atorvastatin, we conducted two","exact":"ritonavir"},{"setid":"PMC2764168","drugname":"ritonavir","startOffset":97,"endOffset":106,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"                    Tipranavir coadministered with low-dose ","suffix":" (TPV/r) is an effective treatment option in treatment-exper","exact":"ritonavir"},{"setid":"PMC2764168","drugname":"ritonavir","startOffset":237,"endOffset":246,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","prefix":"ose of rosuvastatin on day 1, followed by tipranavir 500 mg-","suffix":" 200 mg twice daily for 11 days (days 3 to 13), with a singl","exact":"ritonavir"},{"setid":"PMC2764168","drugname":"ritonavir","startOffset":729,"endOffset":738,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","prefix":"ate) for rosuvastatin and days 12 and 13 for tipranavir and ","suffix":". A standard 670-kcal (33% fat) breakfast was served to subj","exact":"ritonavir"},{"setid":"PMC2764168","drugname":"ritonavir","startOffset":1111,"endOffset":1120,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","prefix":" 2, 3, 4, 5, 6, 8, 10, and 12 h postdose for tipranavir and ","suffix":" and 0 h predose and 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, ","exact":"ritonavir"},{"setid":"PMC2764168","drugname":"ritonavir","startOffset":1452,"endOffset":1461,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","prefix":"he short-term safety and steady-state PKs of tipranavir and ","suffix":" coadministered with single-dose rosuvastatin (10 mg) were a","exact":"ritonavir"},{"setid":"PMC2764168","drugname":"ritonavir","startOffset":156,"endOffset":165,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[9]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[9]/p[1]","prefix":"sed to measure plasma drug concentrations of tipranavir and ","suffix":" (","exact":"ritonavir"},{"setid":"PMC2764168","drugname":"ritonavir","startOffset":173,"endOffset":182,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"tion studies evaluating the effect of another PI, lopinavir-","suffix":" (LPV/r), when coadministered with rosuvastatin at steady st","exact":"ritonavir"},{"setid":"PMC2764168","drugname":"ritonavir","startOffset":337,"endOffset":346,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[2]","prefix":", 6, 8, 10, and 12 h after ingestion of TPV/r (12 samples). ","suffix":" plasma concentrations were not measured in this study.     ","exact":"Ritonavir"},{"setid":"PMC2764168","drugname":"rosuvastatin","startOffset":158,"endOffset":170,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"-drug interactions between tipranavir-ritonavir (TPV/r) and ","suffix":" and atorvastatin, we conducted two prospective, open-label,","exact":"rosuvastatin"},{"setid":"PMC2764168","drugname":"rosuvastatin","startOffset":405,"endOffset":417,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":") for the area under the concentration-time curve (AUC) for ","suffix":" and 2.23 (90% CI, 1.83 to 2.72) for the maximum concentrati","exact":"rosuvastatin"},{"setid":"PMC2764168","drugname":"rosuvastatin","startOffset":158,"endOffset":170,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"-drug interactions between tipranavir-ritonavir (TPV/r) and ","suffix":" and atorvastatin, we conducted two prospective, open-label,","exact":"rosuvastatin"},{"setid":"PMC2764168","drugname":"rosuvastatin","startOffset":405,"endOffset":417,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":") for the area under the concentration-time curve (AUC) for ","suffix":" and 2.23 (90% CI, 1.83 to 2.72) for the maximum concentrati","exact":"rosuvastatin"},{"setid":"PMC2764168","drugname":"rosuvastatin","startOffset":66,"endOffset":78,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"                                                   However, ","suffix":" is unlikely to interact with TPV/r since it is not a CYP3A4","exact":"rosuvastatin"},{"setid":"PMC2764168","drugname":"rosuvastatin","startOffset":436,"endOffset":448,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"rug interactions between steady-state TPV/r and single-dose ","suffix":" (\"rosuvastatin study\") and atorvastatin (\"atorvastatin stud","exact":"rosuvastatin"},{"setid":"PMC2764168","drugname":"rosuvastatin","startOffset":451,"endOffset":463,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"s between steady-state TPV/r and single-dose rosuvastatin (\"","suffix":" study\") and atorvastatin (\"atorvastatin study\").           ","exact":"rosuvastatin"},{"setid":"PMC2764168","drugname":"rosuvastatin","startOffset":184,"endOffset":196,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","prefix":"dy-state PK study. Subjects received a single 10-mg dose of ","suffix":" on day 1, followed by tipranavir 500 mg-ritonavir 200 mg tw","exact":"rosuvastatin"},{"setid":"PMC2764168","drugname":"rosuvastatin","startOffset":322,"endOffset":334,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","prefix":"ily for 11 days (days 3 to 13), with a single 10-mg dose of ","suffix":" given on day 12. All study drug doses were given under dire","exact":"rosuvastatin"},{"setid":"PMC2764168","drugname":"rosuvastatin","startOffset":678,"endOffset":690,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","prefix":"f TPV/r) and days 12 to 14 (with TPV/r at steady state) for ","suffix":" and days 12 and 13 for tipranavir and ritonavir. A standard","exact":"rosuvastatin"},{"setid":"PMC2764168","drugname":"rosuvastatin","startOffset":1206,"endOffset":1218,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","prefix":"1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, and 48 h postdose for ","suffix":". A pharmacokinetic comparison of single-dose rosuvastatin w","exact":"rosuvastatin"},{"setid":"PMC2764168","drugname":"rosuvastatin","startOffset":1264,"endOffset":1276,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","prefix":"r rosuvastatin. A pharmacokinetic comparison of single-dose ","suffix":" with single-dose rosuvastatin coadministered with TPV/r 500","exact":"rosuvastatin"},{"setid":"PMC2764168","drugname":"rosuvastatin","startOffset":1294,"endOffset":1306,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","prefix":"tic comparison of single-dose rosuvastatin with single-dose ","suffix":" coadministered with TPV/r 500 mg/200 mg twice daily at stea","exact":"rosuvastatin"},{"setid":"PMC2764168","drugname":"rosuvastatin","startOffset":1494,"endOffset":1506,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","prefix":"of tipranavir and ritonavir coadministered with single-dose ","suffix":" (10 mg) were also evaluated.                               ","exact":"rosuvastatin"},{"setid":"PMC2764168","drugname":"rosuvastatin","startOffset":157,"endOffset":169,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/p[1]","prefix":"ped and validated by PPD (Richmond, VA) for the analysis of ","suffix":" in human plasma containing dipotassium EDTA. A 200-μl-sampl","exact":"rosuvastatin"},{"setid":"PMC2764168","drugname":"rosuvastatin","startOffset":259,"endOffset":271,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/p[2]","prefix":"e lower limit of quantitation was nominally 0.100 ng/ml for ","suffix":".                                                         ","exact":"rosuvastatin"},{"setid":"PMC2764168","drugname":"rosuvastatin","startOffset":205,"endOffset":217,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[11]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[11]/p[5]","prefix":" variation (CV) would range from 20% to 40% for the AUCs of ","suffix":" and atorvastatin. Therefore, a sample size of 20 would prov","exact":"rosuvastatin"},{"setid":"PMC2764168","drugname":"rosuvastatin","startOffset":331,"endOffset":343,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[11]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[11]/p[5]","prefix":"d provide >90% power to detect a ≥25% change in the AUCs of ","suffix":" and atorvastatin.                                          ","exact":"rosuvastatin"},{"setid":"PMC2764168","drugname":"rosuvastatin","startOffset":105,"endOffset":117,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","prefix":"                With TPV/r coadministration, the GM AUC for ","suffix":" was 38.6 ng·h/ml, a 37% increase compared with that of rosu","exact":"rosuvastatin"},{"setid":"PMC2764168","drugname":"rosuvastatin","startOffset":173,"endOffset":185,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","prefix":"atin was 38.6 ng·h/ml, a 37% increase compared with that of ","suffix":" alone (","exact":"rosuvastatin"},{"setid":"PMC2764168","drugname":"rosuvastatin","startOffset":125,"endOffset":137,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"g interaction was predicted to be unlikely to occur between ","suffix":" and TPV/r since rosuvastatin is not a known substrate, inhi","exact":"rosuvastatin"},{"setid":"PMC2764168","drugname":"rosuvastatin","startOffset":154,"endOffset":166,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"o be unlikely to occur between rosuvastatin and TPV/r since ","suffix":" is not a known substrate, inhibitor, or inducer of CYP3A4. ","exact":"rosuvastatin"},{"setid":"PMC2764168","drugname":"rosuvastatin","startOffset":239,"endOffset":251,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"wn substrate, inhibitor, or inducer of CYP3A4. Furthermore, ","suffix":" is not extensively metabolized, with approximately 10% of a","exact":"rosuvastatin"},{"setid":"PMC2764168","drugname":"rosuvastatin","startOffset":217,"endOffset":229,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"r PI, lopinavir-ritonavir (LPV/r), when coadministered with ","suffix":" at steady state. A prospective study conducted with healthy","exact":"rosuvastatin"},{"setid":"PMC2764168","drugname":"rosuvastatin","startOffset":312,"endOffset":324,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"spective study conducted with healthy volunteers found that ","suffix":" AUC","exact":"rosuvastatin"},{"setid":"PMC2764168","drugname":"rosuvastatin","startOffset":118,"endOffset":130,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"n conclusion, we observed a clinically relevant increase in ","suffix":" and atorvastatin concentrations during coadministration of ","exact":"rosuvastatin"},{"setid":"PMC2764168","drugname":"rosuvastatin","startOffset":269,"endOffset":281,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":" twice daily. Based on these results, a low initial dose of ","suffix":" (5 mg) and atorvastatin (10 mg) is recommended when combine","exact":"rosuvastatin"},{"setid":"PMC2764168","drugname":"rosuvastatin","startOffset":391,"endOffset":403,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"en combined with TPV/r, with careful clinical monitoring of ","suffix":"- or atorvastatin-related AEs, such as myopathy.            ","exact":"rosuvastatin"},{"setid":"PMC2764168","drugname":"rosuvastatin","startOffset":429,"endOffset":441,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/div[2]/p[2]","prefix":"tawa Hospital and the Ottawa Health Research Institute. The ","suffix":" study is supported by a GCRC grant (RR-00052) and an invest","exact":"rosuvastatin"},{"setid":"PMC2764168","drugname":"crestor","startOffset":188,"endOffset":195,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"t a CYP3A4 substrate and it is not extensively metabolized (","suffix":" package insert; AstraZeneca Pharmaceuticals, Wilmington, DE","exact":"Crestor"},{"setid":"PMC2764168","drugname":"rosuvastatin","startOffset":57,"endOffset":69,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"                                                         ","suffix":" is not a P-glycoprotein (Pgp) substrate, but it is a substr","exact":"Rosuvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":175,"endOffset":187,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"s between tipranavir-ritonavir (TPV/r) and rosuvastatin and ","suffix":", we conducted two prospective, open-label, single-arm, two-","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":175,"endOffset":187,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"s between tipranavir-ritonavir (TPV/r) and rosuvastatin and ","suffix":", we conducted two prospective, open-label, single-arm, two-","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":476,"endOffset":488,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"V/r and single-dose rosuvastatin (\"rosuvastatin study\") and ","suffix":" (\"atorvastatin study\").                                    ","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":491,"endOffset":503,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"dose rosuvastatin (\"rosuvastatin study\") and atorvastatin (\"","suffix":" study\").                                                   ","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":84,"endOffset":96,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[1]","prefix":"                                     The single-dose PKs of ","suffix":", orthohydroxy atorvastatin, and parahydroxy atorvastatin we","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":111,"endOffset":123,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[1]","prefix":"          The single-dose PKs of atorvastatin, orthohydroxy ","suffix":", and parahydroxy atorvastatin were assessed on day 1 after ","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":141,"endOffset":153,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[1]","prefix":"of atorvastatin, orthohydroxy atorvastatin, and parahydroxy ","suffix":" were assessed on day 1 after ingestion of 40 mg of atorvast","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":205,"endOffset":217,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[1]","prefix":"vastatin were assessed on day 1 after ingestion of 40 mg of ","suffix":" alone. From days 14 to 21, subjects received TPV/r 500 mg/2","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":766,"endOffset":778,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[1]","prefix":"on of TPV/r 500 mg/200 mg twice daily plus a single dose of ","suffix":" 10 mg, as an increase in atorvastatin concentrations was ex","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":804,"endOffset":816,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[1]","prefix":"plus a single dose of atorvastatin 10 mg, as an increase in ","suffix":" concentrations was expected in combination with steady-stat","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":944,"endOffset":956,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[1]","prefix":"at 500 mg/200 mg twice daily. Blood samples for analysis of ","suffix":" and hydroxy metabolites were collected on days 1 and 20 in ","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":1192,"endOffset":1204,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[1]","prefix":", 2, 3, 4, 5, 6, 8, 10, 12, 24, and 48 h after ingestion of ","suffix":" (14 samples).                                              ","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":82,"endOffset":94,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[3]","prefix":"                                       On PK sampling days, ","suffix":" and TPV/r were administered orally at 8 a.m. with 240 ml of","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":86,"endOffset":98,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[8]/p[1]","prefix":"                                   Plasma concentrations of ","suffix":" and its hydroxy metabolites were measured by validated liqu","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":117,"endOffset":129,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[11]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[11]/p[2]","prefix":"    Prior to statistical analysis of the effect of TPV/r on ","suffix":" (day 1 versus day 20), the atorvastatin AUC","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":157,"endOffset":169,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[11]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[11]/p[2]","prefix":" effect of TPV/r on atorvastatin (day 1 versus day 20), the ","suffix":" AUC","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":92,"endOffset":104,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[11]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[11]/p[3]","prefix":"                             In addition to the analysis of ","suffix":" and its hydroxy metabolites individually, the effect on tot","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":338,"endOffset":350,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[11]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[11]/p[3]","prefix":"ted as the sum of the time-specific molar concentrations of ","suffix":" (normalized for a 40-mg dose), orthohydroxy atorvastatin, a","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":395,"endOffset":407,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[11]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[11]/p[3]","prefix":"of atorvastatin (normalized for a 40-mg dose), orthohydroxy ","suffix":", and parahydroxy atorvastatin.                             ","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":425,"endOffset":437,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[11]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[11]/p[3]","prefix":"r a 40-mg dose), orthohydroxy atorvastatin, and parahydroxy ","suffix":".                                                         ","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":222,"endOffset":234,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[11]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[11]/p[5]","prefix":"ould range from 20% to 40% for the AUCs of rosuvastatin and ","suffix":". Therefore, a sample size of 20 would provide >90% power to","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":348,"endOffset":360,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[11]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[11]/p[5]","prefix":"wer to detect a ≥25% change in the AUCs of rosuvastatin and ","suffix":".                                                         ","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":323,"endOffset":335,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":" kg, and a median height of 168 (range, 158 to 189) cm. The ","suffix":" PK results from one subject and the steady-state tipranavir","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":95,"endOffset":107,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[1]","prefix":"                          TPV/r increased the dose-adjusted ","suffix":" AUC","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":73,"endOffset":85,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[2]","prefix":"                                                Single-dose ","suffix":" did not affect the steady-state PKs of tipranavir (Table ","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":161,"endOffset":173,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[7]/p[1]","prefix":"200 mg twice daily alone and in the presence of single-dose ","suffix":" was well tolerated in this study. There were no study disco","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":162,"endOffset":174,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"ediated interaction, inhibition of first-pass metabolism of ","suffix":", rather than inhibition of its systemic metabolism, may exp","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":264,"endOffset":276,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"s systemic metabolism, may explain the 8.6-fold increase in ","suffix":" ","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":135,"endOffset":147,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"observed a clinically relevant increase in rosuvastatin and ","suffix":" concentrations during coadministration of TPV/r 500 mg/200 ","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":293,"endOffset":305,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"hese results, a low initial dose of rosuvastatin (5 mg) and ","suffix":" (10 mg) is recommended when combined with TPV/r, with caref","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":408,"endOffset":420,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"TPV/r, with careful clinical monitoring of rosuvastatin- or ","suffix":"-related AEs, such as myopathy.                             ","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"caffeine","startOffset":862,"endOffset":870,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","prefix":" within 30 min before morning medication administration. No ","suffix":" or food was allowed until 5 h postdose. No grapefruit juice","exact":"caffeine"},{"setid":"PMC2764168","drugname":"edta","startOffset":1016,"endOffset":1020,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[1]","prefix":" and hydroxy metabolites were collected on days 1 and 20 in ","suffix":"-containing tubes by an indwelling catheter or the venipunct","exact":"EDTA"},{"setid":"PMC2764168","drugname":"edta","startOffset":363,"endOffset":367,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[8]/p[1]","prefix":"as ISs. Briefly, the analytes were extracted from 200 μl of ","suffix":" plasma by solid-phase extraction using C","exact":"EDTA"},{"setid":"PMC2764168","drugname":"edta","startOffset":1016,"endOffset":1020,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[1]","prefix":" and hydroxy metabolites were collected on days 1 and 20 in ","suffix":"-containing tubes by an indwelling catheter or the venipunct","exact":"EDTA"},{"setid":"PMC2764168","drugname":"edta","startOffset":209,"endOffset":213,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/p[1]","prefix":"ysis of rosuvastatin in human plasma containing dipotassium ","suffix":". A 200-μl-sample aliquot was fortified with 200 μl of inter","exact":"EDTA"},{"setid":"PMC2764168","drugname":"edta","startOffset":363,"endOffset":367,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[8]/p[1]","prefix":"as ISs. Briefly, the analytes were extracted from 200 μl of ","suffix":" plasma by solid-phase extraction using C","exact":"EDTA"},{"setid":"PMC2764168","drugname":"dipotassium edta","startOffset":197,"endOffset":213,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/p[1]","prefix":"for the analysis of rosuvastatin in human plasma containing ","suffix":". A 200-μl-sample aliquot was fortified with 200 μl of inter","exact":"dipotassium EDTA"},{"setid":"PMC2764168","drugname":"acetonitrile","startOffset":372,"endOffset":384,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/p[1]","prefix":"lytes were isolated by protein precipitation with 400 μl of ","suffix":". Sample extraction steps were controlled and automated usin","exact":"acetonitrile"},{"setid":"PMC2764168","drugname":"acetonitrile","startOffset":671,"endOffset":683,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/p[1]","prefix":"emaining residue was reconstituted with 150 μl of 20:80:0.1 ","suffix":"-water-formic acid (vol/vol/vol). The final extract was anal","exact":"acetonitrile"},{"setid":"PMC2764168","drugname":"acetonitrile","startOffset":372,"endOffset":384,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/p[1]","prefix":"lytes were isolated by protein precipitation with 400 μl of ","suffix":". Sample extraction steps were controlled and automated usin","exact":"acetonitrile"},{"setid":"PMC2764168","drugname":"acetonitrile","startOffset":671,"endOffset":683,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/p[1]","prefix":"emaining residue was reconstituted with 150 μl of 20:80:0.1 ","suffix":"-water-formic acid (vol/vol/vol). The final extract was anal","exact":"acetonitrile"},{"setid":"PMC2764168","drugname":"alanine","startOffset":143,"endOffset":150,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[7]/p[3]","prefix":"one subject with an asymptomatic DAIDS grade 3 elevation in ","suffix":" aminotransferase, there were no clinically relevant changes","exact":"alanine"},{"setid":"PMC2764168","drugname":"alanine","startOffset":347,"endOffset":354,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[7]/p[3]","prefix":"rom the median baseline were observed for triglycerides and ","suffix":" aminotransferase levels, which increased by 1.7-fold and 3.","exact":"alanine"},{"setid":"PMC2764168","drugname":"lopinavir","startOffset":163,"endOffset":172,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"ug interaction studies evaluating the effect of another PI, ","suffix":"-ritonavir (LPV/r), when coadministered with rosuvastatin at","exact":"lopinavir"}],[{"setid":"PMC1884432","drugname":"rifampicin","startOffset":94,"endOffset":104,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","prefix":"                               Previous work has shown that ","suffix":", a potent inducer of several cytochrome P450 (CYP) enzymes ","exact":"rifampicin"},{"setid":"PMC1884432","drugname":"rifampicin","startOffset":310,"endOffset":320,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","prefix":" 90%. This study was conducted to investigate the effect of ","suffix":" on the pharmacokinetics of pravastatin.                    ","exact":"rifampicin"},{"setid":"PMC1884432","drugname":"rifampicin","startOffset":193,"endOffset":203,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"s, 10 healthy volunteers received a 5-day pretreatment with ","suffix":" (600 mg daily) or placebo. On day 6, a single 40 mg dose of","exact":"rifampicin"},{"setid":"PMC1884432","drugname":"rifampicin","startOffset":76,"endOffset":86,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"                                                 During the ","suffix":" phase, the mean total area under the plasma concentration-t","exact":"rifampicin"},{"setid":"PMC1884432","drugname":"rifampicin","startOffset":235,"endOffset":245,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","prefix":"ingle oral dose to healthy subjects. However, the effect of ","suffix":" varied greatly between subjects. The mean rifampicin-induce","exact":"rifampicin"},{"setid":"PMC1884432","drugname":"rifampicin","startOffset":288,"endOffset":298,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","prefix":"ect of rifampicin varied greatly between subjects. The mean ","suffix":"-induced decrease in pravastatin concentration was considera","exact":"rifampicin"},{"setid":"PMC1884432","drugname":"rifampicin","startOffset":408,"endOffset":418,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","prefix":"n the phases was 4 weeks. Subjects were given either 600 mg ","suffix":" (Rifarm, Pharmacal, Helsinki, Finland) or matched placebo o","exact":"rifampicin"},{"setid":"PMC1884432","drugname":"rifampicin","startOffset":696,"endOffset":706,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","prefix":"h 150 ml water at 9 AM, that is 17 h after the last dose of ","suffix":". The subjects had fasted overnight, and a standard meal was","exact":"rifampicin"},{"setid":"PMC1884432","drugname":"rifampicin","startOffset":1032,"endOffset":1042,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","prefix":"s. The study design was otherwise identical to our previous ","suffix":"-simvastatin study [","exact":"rifampicin"},{"setid":"PMC1884432","drugname":"rifampicin","startOffset":277,"endOffset":287,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/p[1]","prefix":" calculated on the mean differences between the placebo and ","suffix":" phases for AUC(0-∞), ","exact":"rifampicin"},{"setid":"PMC1884432","drugname":"rifampicin","startOffset":68,"endOffset":78,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","prefix":"                                                 During the ","suffix":" phase, the mean AUC(0-∞) of pravastatin was 69% (range 24-2","exact":"rifampicin"},{"setid":"PMC1884432","drugname":"rifampicin","startOffset":76,"endOffset":86,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","prefix":"                                         The mean effect of ","suffix":" on the AUC of pravastatin in the present study was consider","exact":"rifampicin"},{"setid":"PMC1884432","drugname":"rifampicin","startOffset":159,"endOffset":169,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":" pravastatin were moderately decreased by pretreatment with ","suffix":". The mean AUC(0-∞) of pravastatin was decreased by 31%, but","exact":"rifampicin"},{"setid":"PMC1884432","drugname":"rifampicin","startOffset":346,"endOffset":356,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"e of the 10 subjects the AUC(0-∞) of pravastatin during the ","suffix":" phase was 50% or less of that during the placebo phase. How","exact":"rifampicin"},{"setid":"PMC1884432","drugname":"rifampicin","startOffset":502,"endOffset":512,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"e plasma concentrations of pravastatin increased during the ","suffix":" phase. The other pharmacokinetic variables studied were not","exact":"rifampicin"},{"setid":"PMC1884432","drugname":"rifampicin","startOffset":643,"endOffset":653,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":" a statistically significant degree. Although the effect of ","suffix":" was statistically significant, the possibility of chance fi","exact":"rifampicin"},{"setid":"PMC1884432","drugname":"rifampicin","startOffset":71,"endOffset":81,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"                                              The effect of ","suffix":" on pravastatin pharmacokinetics is not likely to be caused ","exact":"rifampicin"},{"setid":"PMC1884432","drugname":"rifampicin","startOffset":129,"endOffset":139,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":" showed that using an identical protocol, pretreatment with ","suffix":" greatly decreased the AUC(0-∞) of simvastatin and simvastat","exact":"rifampicin"},{"setid":"PMC1884432","drugname":"rifampicin","startOffset":72,"endOffset":82,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"                                             In conclusion, ","suffix":" had a relatively small but highly variable effect on the ph","exact":"rifampicin"},{"setid":"PMC1884432","drugname":"rifampicin","startOffset":267,"endOffset":277,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":" adjustment in some individuals if long-term treatment with ","suffix":" is needed.                                                 ","exact":"rifampicin"},{"setid":"PMC1884432","drugname":"rifampicin","startOffset":65,"endOffset":75,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","prefix":"                                                            ","suffix":" caused a statistically significant decrease in the plasma c","exact":"Rifampicin"},{"setid":"PMC1884432","drugname":"rifampicin","startOffset":57,"endOffset":67,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"                                                         ","suffix":" is a potent inducer of several cytochrome P450 (CYP) enzyme","exact":"Rifampicin"},{"setid":"PMC1884432","drugname":"rifampicin","startOffset":57,"endOffset":67,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"                                                         ","suffix":" decreases the total AUC of fluvastatin, a CYP2C9 substrate ","exact":"Rifampicin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":348,"endOffset":359,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","prefix":"stigate the effect of rifampicin on the pharmacokinetics of ","suffix":".                                                           ","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":264,"endOffset":275,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"(600 mg daily) or placebo. On day 6, a single 40 mg dose of ","suffix":" was administered orally. Plasma concentrations of pravastat","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":326,"endOffset":337,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"avastatin was administered orally. Plasma concentrations of ","suffix":" were measured up to 12 h by a sensitive LC-MS-MS method.   ","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":159,"endOffset":170,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"ean total area under the plasma concentration-time curve of ","suffix":" [AUC(0-∞)] was 69% (range 24-220%) of the corresponding val","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":151,"endOffset":162,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","prefix":"tically significant decrease in the plasma concentration of ","suffix":" given as a single oral dose to healthy subjects. However, t","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":319,"endOffset":330,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","prefix":"y between subjects. The mean rifampicin-induced decrease in ","suffix":" concentration was considerably smaller than that observed p","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":95,"endOffset":106,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"                      Unlike simvastatin, the metabolism of ","suffix":" is not significantly mediated by CYP enzymes [","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":527,"endOffset":538,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","prefix":"d placebo orally once daily at 4 p.m. for 5 days. On day 6, ","suffix":" (a single Pravachol 40 mg tablet, Bristol-Myers Squibb, New","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":812,"endOffset":823,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","prefix":"ndard meal was served 3 and 7 h after the administration of ","suffix":". Alcohol or strenuous exercise was not allowed for two days","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":157,"endOffset":168,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[1]","prefix":"n from a cannulated forearm vein prior to administration of ","suffix":" and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, and 12 h later, an","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":451,"endOffset":462,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[1]","prefix":"lected cumulatively from 0-12 h after the administration of ","suffix":".                                                         ","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":83,"endOffset":94,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","prefix":"                                      The concentrations of ","suffix":" in plasma and urine were measured by liquid chromatography-","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":107,"endOffset":118,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","prefix":"          During the rifampicin phase, the mean AUC(0-∞) of ","suffix":" was 69% (range 24-220%, ","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":101,"endOffset":112,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","prefix":"                The mean effect of rifampicin on the AUC of ","suffix":" in the present study was considerably smaller and more vari","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":100,"endOffset":111,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"                 In this study the plasma concentrations of ","suffix":" were moderately decreased by pretreatment with rifampicin. ","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":192,"endOffset":203,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"eased by pretreatment with rifampicin. The mean AUC(0-∞) of ","suffix":" was decreased by 31%, but there was considerable interindiv","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":323,"endOffset":334,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"idual variation. In five of the 10 subjects the AUC(0-∞) of ","suffix":" during the rifampicin phase was 50% or less of that during ","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":469,"endOffset":480,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"se. However, in three subjects the plasma concentrations of ","suffix":" increased during the rifampicin phase. The other pharmacoki","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":85,"endOffset":96,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"                                The effect of rifampicin on ","suffix":" pharmacokinetics is not likely to be caused by induction of","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":191,"endOffset":202,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"be caused by induction of CYP3A4 or P-glycoprotein, because ","suffix":" is not a substrate of P-glycoprotein, CYP3A4 or other CYP e","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":122,"endOffset":133,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"ronidation appears to be one of the predominant pathways of ","suffix":" metabolism [","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":160,"endOffset":171,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"small but highly variable effect on the pharmacokinetics of ","suffix":". The dose of pravastatin might need adjustment in some indi","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":185,"endOffset":196,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":" effect on the pharmacokinetics of pravastatin. The dose of ","suffix":" might need adjustment in some individuals if long-term trea","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravachol","startOffset":549,"endOffset":558,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","prefix":"daily at 4 p.m. for 5 days. On day 6, pravastatin (a single ","suffix":" 40 mg tablet, Bristol-Myers Squibb, New York, NY) was admin","exact":"Pravachol"},{"setid":"PMC1884432","drugname":"simvastatin","startOffset":221,"endOffset":232,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","prefix":"es and transporters, decreased the plasma concentrations of ","suffix":" acid by more than 90%. This study was conducted to investig","exact":"simvastatin"},{"setid":"PMC1884432","drugname":"simvastatin","startOffset":404,"endOffset":415,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","prefix":" was considerably smaller than that observed previously for ","suffix":".                                                           ","exact":"simvastatin"},{"setid":"PMC1884432","drugname":"simvastatin","startOffset":64,"endOffset":75,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"                                                     Unlike ","suffix":", the metabolism of pravastatin is not significantly mediate","exact":"simvastatin"},{"setid":"PMC1884432","drugname":"simvastatin","startOffset":1043,"endOffset":1054,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","prefix":"y design was otherwise identical to our previous rifampicin-","suffix":" study [","exact":"simvastatin"},{"setid":"PMC1884432","drugname":"simvastatin","startOffset":201,"endOffset":212,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","prefix":"siderably smaller and more variable than that on the AUC of ","suffix":" acid in our previous study using an identical protocol (","exact":"simvastatin"},{"setid":"PMC1884432","drugname":"simvastatin","startOffset":174,"endOffset":185,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"treatment with rifampicin greatly decreased the AUC(0-∞) of ","suffix":" and simvastatin acid in all of the 10 subjects studied [","exact":"simvastatin"},{"setid":"PMC1884432","drugname":"simvastatin","startOffset":190,"endOffset":201,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"ifampicin greatly decreased the AUC(0-∞) of simvastatin and ","suffix":" acid in all of the 10 subjects studied [","exact":"simvastatin"},{"setid":"PMC1884432","drugname":"fluvastatin","startOffset":95,"endOffset":106,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"                      Rifampicin decreases the total AUC of ","suffix":", a CYP2C9 substrate [","exact":"fluvastatin"}],[{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":83,"endOffset":94,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","prefix":"                                          The anticoagulant ","suffix":" is an oral, direct Factor Xa inhibitor for the management o","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":157,"endOffset":168,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"ubstrates or inhibitors of CYP3A4, P-gp and Bcrp (ABCG2) on ","suffix":" were studied in healthy volunteers.                        ","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":147,"endOffset":158,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"teract with midazolam (CYP3A4 probe substrate). Exposure to ","suffix":" when co-administered with midazolam was slightly decreased ","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":279,"endOffset":290,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"y 11% (95% confidence interval [CI] −28%, 7%) compared with ","suffix":" alone. The following drugs moderately affected rivaroxaban ","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":338,"endOffset":349,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":" rivaroxaban alone. The following drugs moderately affected ","suffix":" exposure, but not to a clinically relevant extent: erythrom","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":693,"endOffset":704,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":" 42% increase [95% CI 29%, 56%]). A significant increase in ","suffix":" exposure was demonstrated with the strong CYP3A4, P-gp/Bcrp","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":86,"endOffset":97,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","prefix":"                                       Results suggest that ","suffix":" may be co-administered with CYP3A4 and/or P-gp substrates/m","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":378,"endOffset":389,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","prefix":"protease inhibitors), which are multi-pathway inhibitors of ","suffix":" clearance and elimination.                                 ","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":80,"endOffset":91,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":"                                     The oral anticoagulant ","suffix":" is a highly selective, direct Factor Xa inhibitor for the p","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":182,"endOffset":193,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","prefix":"e the extent of potential interactions with single doses of ","suffix":" (10 mg or 20 mg) and steady-state ketoconazole (200 mg once","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":604,"endOffset":615,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","prefix":"the extent of the possible interaction between steady-state ","suffix":" (10 mg once daily) and high dose, steady-state ketoconazole","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":203,"endOffset":214,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","prefix":". In the study investigating potential interactions between ","suffix":" and steady-state ketoconazole 200 mg, subjects received ket","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":815,"endOffset":826,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","prefix":"e laboratory tests and to determine the pharmacokinetics of ","suffix":" and, where necessary, the pharmacokinetics of the potential","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":132,"endOffset":143,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/div[1]/p[1]","prefix":" was undertaken to determine potential interactions between ","suffix":" and a sensitive probe substrate for CYP3A4 alone, midazolam","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":163,"endOffset":174,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/div[1]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/div[1]/p[2]","prefix":"study, subjects were randomized to receive a single dose of ","suffix":" 20 mg alone, a single dose of midazolam 7.5 mg alone or the","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":152,"endOffset":163,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","prefix":"o determine the extent of the potential interaction between ","suffix":" and strong inhibitors of CYP3A4/2J2, P-gp and Bcrp (ABCG2),","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":172,"endOffset":183,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/p[1]","prefix":"stigated the potential interaction between a single dose of ","suffix":" and steady-state ketoconazole 200 mg once daily. In this op","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":331,"endOffset":342,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/p[1]","prefix":"study, subjects were randomized to receive a single dose of ","suffix":" 10 mg, alone or with ketoconazole (4 days of oral ketoconaz","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":429,"endOffset":440,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/p[1]","prefix":"onazole (4 days of oral ketoconazole 200 mg once daily with ","suffix":" given on day 4). Rivaroxaban was given under fasting condit","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":576,"endOffset":587,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/p[1]","prefix":"azole was given with food, except when co-administered with ","suffix":". After completion of this study, a publication suggested th","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":116,"endOffset":127,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[2]/p[1]","prefix":"         The potential interaction between a single dose of ","suffix":" and steady-state ritonavir was investigated in a non-random","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":246,"endOffset":257,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[2]/p[1]","prefix":"mized, open label study. Subjects received a single dose of ","suffix":" 10 mg on day 1, ritonavir 600 mg twice daily on days 3-7, a","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":371,"endOffset":382,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[2]/p[1]","prefix":"3-7, and ritonavir 600 mg twice daily plus a single dose of ","suffix":" on day 8. All study drugs were administered with food.     ","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":481,"endOffset":492,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[2]/p[2]","prefix":"alid for the safety analysis. All received a single dose of ","suffix":" 10 mg on day 1 and at least one dose of ritonavir (600 mg).","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":597,"endOffset":608,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[2]/p[2]","prefix":"navir (600 mg). Twelve subjects received the combination of ","suffix":" and ritonavir on day 8. However, none of the subjects recei","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":127,"endOffset":138,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[1]/p[1]","prefix":"single study investigated the potential interaction between ","suffix":" and clarithromycin, classified as a strong inhibitor of CYP","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":160,"endOffset":171,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[1]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[1]/p[2]","prefix":"study, subjects were randomized to receive a single dose of ","suffix":" 10 mg alone, or clarithromycin 500 mg twice daily for a per","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":127,"endOffset":138,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[2]/p[1]","prefix":"single study investigated the potential interaction between ","suffix":" and erythromycin, classified as a moderate inhibitor of CYP","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":161,"endOffset":172,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[2]/p[2]","prefix":"study, subjects were randomized to receive a single dose of ","suffix":" 10 mg alone, or erythromycin 500 mg three times daily given","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":291,"endOffset":302,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[2]/p[2]","prefix":"n for 4 days, with a single 500 mg dose given on day 5 with ","suffix":" 10 mg. All study drugs were administered with food and ther","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":127,"endOffset":138,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[3]/p[1]","prefix":"single study investigated the potential interaction between ","suffix":" and fluconazole, classified as a potent inhibitor of CYP2C9","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":200,"endOffset":211,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[3]/p[1]","prefix":"nd fluconazole, classified as a potent inhibitor of CYP2C9 (","suffix":" is not metabolized via CYP2C9), a moderate inhibitor of CYP","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":161,"endOffset":172,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[3]/p[2]","prefix":"study, subjects were randomized to receive a single dose of ","suffix":" 20 mg alone, or fluconazole 400 mg once daily given for 6 d","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":280,"endOffset":291,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[3]/p[2]","prefix":"iven for 6 days, with a concomitant administration of 20 mg ","suffix":" given on day 5. All study drugs were administered with food","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":110,"endOffset":121,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/p[1]","prefix":"               Pharmacokinetic parameters were derived from ","suffix":" plasma concentration-time profiles obtained by serial blood","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":369,"endOffset":380,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/p[1]","prefix":"tervals after drug administration. Quantitative analysis of ","suffix":" concentrations (plasma and urine) was performed using a ful","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":79,"endOffset":90,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/p[2]","prefix":"                                              The following ","suffix":" plasma pharmacokinetic parameters were assessed: area under","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":259,"endOffset":270,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/p[2]","prefix":"n the ketoconazole 400 mg study, in which multiple doses of ","suffix":" were given. Maximum drug concentration in plasma (","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":89,"endOffset":100,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/p[1]","prefix":"                                    The pharmacokinetics of ","suffix":", midazolam and its CYP3A4-mediated metabolite, α-hydroxy-mi","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":174,"endOffset":185,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/p[1]","prefix":"d its CYP3A4-mediated metabolite, α-hydroxy-midazolam, when ","suffix":" 20 mg and midazolam 7.5 mg were administered alone and in c","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":99,"endOffset":110,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[1]/p[1]","prefix":"                          The pharmacokinetic parameters of ","suffix":" 10 mg administered alone or in combination with ketoconazol","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":102,"endOffset":113,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[2]/p[1]","prefix":"                       The pharmacokinetics of steady-state ","suffix":" 10 mg (day 5) were compared with those of steady-state riva","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":169,"endOffset":180,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[2]/p[1]","prefix":"aban 10 mg (day 5) were compared with those of steady-state ","suffix":" 10 mg in combination with steady-state ketoconazole 400 mg ","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":328,"endOffset":339,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[2]/p[1]","prefix":"nistration with ketoconazole 400 mg significantly increased ","suffix":" plasma concentrations (","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":89,"endOffset":100,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[3]/p[1]","prefix":"                                    The pharmacokinetics of ","suffix":" 10 mg were compared after a single dose (day 1) with those ","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":323,"endOffset":334,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[3]/p[1]","prefix":"s of ritonavir were compared in the absence and presence of ","suffix":" (days 7 and 8, respectively). Steady-state ritonavir signif","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":89,"endOffset":100,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[1]/p[1]","prefix":"                                    The pharmacokinetics of ","suffix":" were compared after a single dose of rivaroxaban 10 mg was ","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":138,"endOffset":149,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[1]/p[1]","prefix":"inetics of rivaroxaban were compared after a single dose of ","suffix":" 10 mg was administered alone and co-administered with clari","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":399,"endOffset":410,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[1]/p[1]","prefix":"icantly increased the primary pharmacokinetic parameters of ","suffix":" (","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":96,"endOffset":107,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[2]/p[1]","prefix":"                             The pharmacokinetic effects of ","suffix":" 10 mg administered alone (day 5) and in combination with st","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":376,"endOffset":387,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[2]/p[1]","prefix":"rythromycin significantly increased the pharmacokinetics of ","suffix":" (","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":89,"endOffset":100,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[3]/p[1]","prefix":"                                    The pharmacokinetics of ","suffix":" were compared after a single dose of rivaroxaban 20 mg was ","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":138,"endOffset":149,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[3]/p[1]","prefix":"inetics of rivaroxaban were compared after a single dose of ","suffix":" 20 mg was administered alone and co-administered with fluco","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":389,"endOffset":400,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[3]/p[1]","prefix":"icantly increased the primary pharmacokinetic parameters of ","suffix":" (","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":272,"endOffset":283,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[1]","prefix":"hich was serious, were considered to be possibly related to ","suffix":" alone or a combination involving rivaroxaban. Of these, hea","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":317,"endOffset":328,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[1]","prefix":"bly related to rivaroxaban alone or a combination involving ","suffix":". Of these, headache (32 events) and fatigue (13 events) wer","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":144,"endOffset":155,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":"ic interaction studies in healthy subjects demonstrate that ","suffix":" does not interact with a probe substrate for CYP3A4 (midazo","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":242,"endOffset":253,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":"robe substrate for CYP3A4 (midazolam). Co-administration of ","suffix":" with a moderate CYP3A4 and P-gp inhibitor (erythromycin), a","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":515,"endOffset":526,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":"ithromycin), led to a statistically significant increase in ","suffix":" exposure. Of note, active renal secretion (CL","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":82,"endOffset":93,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"                                   The co-administration of ","suffix":" with midazolam had no effect on the pharmacokinetics of riv","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":150,"endOffset":161,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"ban with midazolam had no effect on the pharmacokinetics of ","suffix":", or on the pharmacokinetics of midazolam or its CYP3A4-medi","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":484,"endOffset":495,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"d no effect on the pharmacokinetics and pharmacodynamics of ","suffix":", or on the pharmacokinetics of digoxin or atorvastatin [","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":82,"endOffset":93,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","prefix":"                                   The co-administration of ","suffix":" and the frequently used antibiotic erythromycin, a moderate","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":172,"endOffset":183,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[6]","prefix":"s P-gp and Bcrp (ABCG2), are involved in the elimination of ","suffix":". Therefore, it was important to determine the clinical exte","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":283,"endOffset":294,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[6]","prefix":"ne the clinical extent of any potential interaction between ","suffix":" and drugs that are substrates for and/or inhibitors of thes","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":445,"endOffset":456,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[6]","prefix":"e studies suggest that the oral, direct Factor Xa inhibitor ","suffix":" does not interact to a clinically relevant extent with subs","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":787,"endOffset":798,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[6]","prefix":" HIV protease inhibitors. Therefore, the concomitant use of ","suffix":" with these agents should be avoided. The exception may be f","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":911,"endOffset":922,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[6]","prefix":"ay be fluconazole, which is expected to have less effect on ","suffix":" exposure and can be co-administered with caution [","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":65,"endOffset":76,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"                                                            ","suffix":" did not interact with midazolam (CYP3A4 probe substrate). E","exact":"Rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":57,"endOffset":68,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","prefix":"                                                         ","suffix":" is approved for the prevention of venous thromboembolism (o","exact":"Rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":57,"endOffset":68,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","prefix":"                                                         ","suffix":" has a dual mode of elimination. Approximately two-thirds of","exact":"Rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":57,"endOffset":68,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[4]","prefix":"                                                         ","suffix":" is metabolized via cytochrome P450 (CYP) 3A4/3A5, CYP2J2 an","exact":"Rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":458,"endOffset":469,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/p[1]","prefix":"onazole 200 mg once daily with rivaroxaban given on day 4). ","suffix":" was given under fasting conditions and ketoconazole was giv","exact":"Rivaroxaban"},{"setid":"PMC3769672","drugname":"midazolam","startOffset":99,"endOffset":108,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"                          Rivaroxaban did not interact with ","suffix":" (CYP3A4 probe substrate). Exposure to rivaroxaban when co-a","exact":"midazolam"},{"setid":"PMC3769672","drugname":"midazolam","startOffset":185,"endOffset":194,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"bstrate). Exposure to rivaroxaban when co-administered with ","suffix":" was slightly decreased by 11% (95% confidence interval [CI]","exact":"midazolam"},{"setid":"PMC3769672","drugname":"midazolam","startOffset":476,"endOffset":485,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","prefix":"y-state fluconazole (400 mg once daily) or a single dose of ","suffix":" (7.5 mg). An additional study was undertaken to determine t","exact":"midazolam"},{"setid":"PMC3769672","drugname":"midazolam","startOffset":194,"endOffset":203,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/div[1]/p[1]","prefix":"varoxaban and a sensitive probe substrate for CYP3A4 alone, ","suffix":" [","exact":"midazolam"},{"setid":"PMC3769672","drugname":"midazolam","startOffset":205,"endOffset":214,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/div[1]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/div[1]/p[2]","prefix":" a single dose of rivaroxaban 20 mg alone, a single dose of ","suffix":" 7.5 mg alone or the combination. All study drugs were given","exact":"midazolam"},{"setid":"PMC3769672","drugname":"midazolam","startOffset":202,"endOffset":211,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/p[4]","prefix":"nation with the potential interacting drug. In addition, as ","suffix":" is metabolized by CYP3A4 to α-hydroxy-midazolam [","exact":"midazolam"},{"setid":"PMC3769672","drugname":"midazolam","startOffset":250,"endOffset":259,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/p[4]","prefix":"ddition, as midazolam is metabolized by CYP3A4 to α-hydroxy-","suffix":" [","exact":"midazolam"},{"setid":"PMC3769672","drugname":"midazolam","startOffset":102,"endOffset":111,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/p[1]","prefix":"                       The pharmacokinetics of rivaroxaban, ","suffix":" and its CYP3A4-mediated metabolite, α-hydroxy-midazolam, wh","exact":"midazolam"},{"setid":"PMC3769672","drugname":"midazolam","startOffset":158,"endOffset":167,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/p[1]","prefix":"an, midazolam and its CYP3A4-mediated metabolite, α-hydroxy-","suffix":", when rivaroxaban 20 mg and midazolam 7.5 mg were administe","exact":"midazolam"},{"setid":"PMC3769672","drugname":"midazolam","startOffset":196,"endOffset":205,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/p[1]","prefix":"metabolite, α-hydroxy-midazolam, when rivaroxaban 20 mg and ","suffix":" 7.5 mg were administered alone and in combination are summa","exact":"midazolam"},{"setid":"PMC3769672","drugname":"midazolam","startOffset":209,"endOffset":218,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":"oxaban does not interact with a probe substrate for CYP3A4 (","suffix":"). Co-administration of rivaroxaban with a moderate CYP3A4 a","exact":"midazolam"},{"setid":"PMC3769672","drugname":"midazolam","startOffset":99,"endOffset":108,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"                  The co-administration of rivaroxaban with ","suffix":" had no effect on the pharmacokinetics of rivaroxaban, or on","exact":"midazolam"},{"setid":"PMC3769672","drugname":"midazolam","startOffset":193,"endOffset":202,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"rmacokinetics of rivaroxaban, or on the pharmacokinetics of ","suffix":" or its CYP3A4-mediated metabolites. Previous interaction st","exact":"midazolam"},{"setid":"PMC3769672","drugname":"erythromycin","startOffset":401,"endOffset":413,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"aroxaban exposure, but not to a clinically relevant extent: ","suffix":" (moderate CYP3A4/P-gp inhibitor; 34% increase [95% CI 23%, ","exact":"erythromycin"},{"setid":"PMC3769672","drugname":"erythromycin","startOffset":401,"endOffset":413,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"aroxaban exposure, but not to a clinically relevant extent: ","suffix":" (moderate CYP3A4/P-gp inhibitor; 34% increase [95% CI 23%, ","exact":"erythromycin"},{"setid":"PMC3769672","drugname":"erythromycin","startOffset":370,"endOffset":382,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","prefix":"ady-state clarithromycin (500 mg twice daily), steady-state ","suffix":" (500 mg three times daily), steady-state fluconazole (400 m","exact":"erythromycin"},{"setid":"PMC3769672","drugname":"erythromycin","startOffset":486,"endOffset":498,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","prefix":"fter administration of the drug combinations, except in the ","suffix":" interaction study, in which subjects were discharged 72 h a","exact":"erythromycin"},{"setid":"PMC3769672","drugname":"erythromycin","startOffset":143,"endOffset":155,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[2]/p[1]","prefix":"estigated the potential interaction between rivaroxaban and ","suffix":", classified as a moderate inhibitor of CYP3A4, and consider","exact":"erythromycin"},{"setid":"PMC3769672","drugname":"erythromycin","startOffset":189,"endOffset":201,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[2]/p[2]","prefix":"zed to receive a single dose of rivaroxaban 10 mg alone, or ","suffix":" 500 mg three times daily given for 4 days, with a single 50","exact":"erythromycin"},{"setid":"PMC3769672","drugname":"erythromycin","startOffset":185,"endOffset":197,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/p[3]","prefix":"n findings (in the ketoconazole, ritonavir, clarithromycin, ","suffix":" and fluconazole studies), the fraction of free (unbound) dr","exact":"erythromycin"},{"setid":"PMC3769672","drugname":"erythromycin","startOffset":178,"endOffset":190,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[2]/p[1]","prefix":"nistered alone (day 5) and in combination with steady-state ","suffix":" (500 mg three times daily for 4 days with a single 500 mg d","exact":"erythromycin"},{"setid":"PMC3769672","drugname":"erythromycin","startOffset":315,"endOffset":327,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[2]/p[1]","prefix":"n day 5) were analyzed. Co-administration with steady-state ","suffix":" significantly increased the pharmacokinetics of rivaroxaban","exact":"erythromycin"},{"setid":"PMC3769672","drugname":"erythromycin","startOffset":297,"endOffset":309,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":"n of rivaroxaban with a moderate CYP3A4 and P-gp inhibitor (","suffix":"), a moderate inhibitor of CYP3A4 and potentially Bcrp (ABCG","exact":"erythromycin"},{"setid":"PMC3769672","drugname":"erythromycin","startOffset":129,"endOffset":141,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","prefix":"istration of rivaroxaban and the frequently used antibiotic ","suffix":", a moderate CYP inhibitor and weak to moderate P-gp inhibit","exact":"erythromycin"},{"setid":"PMC3769672","drugname":"clarithromycin","startOffset":480,"endOffset":494,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"ate CYP3A4/P-gp inhibitor; 34% increase [95% CI 23%, 46%]), ","suffix":" (strong CYP3A4/moderate P-gp inhibitor; 54% increase [95% C","exact":"clarithromycin"},{"setid":"PMC3769672","drugname":"clarithromycin","startOffset":320,"endOffset":334,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","prefix":", steady-state ritonavir (600 mg twice daily), steady-state ","suffix":" (500 mg twice daily), steady-state erythromycin (500 mg thr","exact":"clarithromycin"},{"setid":"PMC3769672","drugname":"clarithromycin","startOffset":188,"endOffset":202,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[1]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[1]/p[2]","prefix":"zed to receive a single dose of rivaroxaban 10 mg alone, or ","suffix":" 500 mg twice daily for a period of 4 days under steady-stat","exact":"clarithromycin"},{"setid":"PMC3769672","drugname":"clarithromycin","startOffset":169,"endOffset":183,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/p[3]","prefix":"pated interaction findings (in the ketoconazole, ritonavir, ","suffix":", erythromycin and fluconazole studies), the fraction of fre","exact":"clarithromycin"},{"setid":"PMC3769672","drugname":"clarithromycin","startOffset":480,"endOffset":494,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"ate CYP3A4/P-gp inhibitor; 34% increase [95% CI 23%, 46%]), ","suffix":" (strong CYP3A4/moderate P-gp inhibitor; 54% increase [95% C","exact":"clarithromycin"},{"setid":"PMC3769672","drugname":"clarithromycin","startOffset":320,"endOffset":334,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","prefix":", steady-state ritonavir (600 mg twice daily), steady-state ","suffix":" (500 mg twice daily), steady-state erythromycin (500 mg thr","exact":"clarithromycin"},{"setid":"PMC3769672","drugname":"clarithromycin","startOffset":143,"endOffset":157,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[1]/p[1]","prefix":"estigated the potential interaction between rivaroxaban and ","suffix":", classified as a strong inhibitor of CYP3A4, and considered","exact":"clarithromycin"},{"setid":"PMC3769672","drugname":"clarithromycin","startOffset":188,"endOffset":202,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[1]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[1]/p[2]","prefix":"zed to receive a single dose of rivaroxaban 10 mg alone, or ","suffix":" 500 mg twice daily for a period of 4 days under steady-stat","exact":"clarithromycin"},{"setid":"PMC3769672","drugname":"clarithromycin","startOffset":169,"endOffset":183,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/p[3]","prefix":"pated interaction findings (in the ketoconazole, ritonavir, ","suffix":", erythromycin and fluconazole studies), the fraction of fre","exact":"clarithromycin"},{"setid":"PMC3769672","drugname":"clarithromycin","startOffset":204,"endOffset":218,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[1]/p[1]","prefix":"xaban 10 mg was administered alone and co-administered with ","suffix":" 500 mg after 4 days of pretreatment with clarithromycin 500","exact":"clarithromycin"},{"setid":"PMC3769672","drugname":"clarithromycin","startOffset":260,"endOffset":274,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[1]/p[1]","prefix":"ith clarithromycin 500 mg after 4 days of pretreatment with ","suffix":" 500 mg twice daily. Co-administration with clarithromycin s","exact":"clarithromycin"},{"setid":"PMC3769672","drugname":"clarithromycin","startOffset":318,"endOffset":332,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[1]/p[1]","prefix":"h clarithromycin 500 mg twice daily. Co-administration with ","suffix":" significantly increased the primary pharmacokinetic paramet","exact":"clarithromycin"},{"setid":"PMC3769672","drugname":"clarithromycin","startOffset":451,"endOffset":465,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":" strong inhibitor of CYP3A4 and moderate inhibitor of P-gp (","suffix":"), led to a statistically significant increase in rivaroxaba","exact":"clarithromycin"},{"setid":"PMC3769672","drugname":"fluconazole","startOffset":571,"endOffset":582,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"oderate P-gp inhibitor; 54% increase [95% CI 44%, 64%]) and ","suffix":" (moderate CYP3A4, possible Bcrp [ABCG2] inhibitor; 42% incr","exact":"fluconazole"},{"setid":"PMC3769672","drugname":"fluconazole","startOffset":143,"endOffset":154,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[3]/p[1]","prefix":"estigated the potential interaction between rivaroxaban and ","suffix":", classified as a potent inhibitor of CYP2C9 (rivaroxaban is","exact":"fluconazole"},{"setid":"PMC3769672","drugname":"fluconazole","startOffset":202,"endOffset":213,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/p[3]","prefix":"e ketoconazole, ritonavir, clarithromycin, erythromycin and ","suffix":" studies), the fraction of free (unbound) drug in plasma (","exact":"fluconazole"},{"setid":"PMC3769672","drugname":"fluconazole","startOffset":204,"endOffset":215,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[3]/p[1]","prefix":"xaban 20 mg was administered alone and co-administered with ","suffix":" 400 mg after 4 days of pretreatment with fluconazole 400 mg","exact":"fluconazole"},{"setid":"PMC3769672","drugname":"fluconazole","startOffset":372,"endOffset":383,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":"a moderate inhibitor of CYP3A4 and potentially Bcrp (ABCG2, ","suffix":"), and a strong inhibitor of CYP3A4 and moderate inhibitor o","exact":"fluconazole"},{"setid":"PMC3769672","drugname":"fluconazole","startOffset":297,"endOffset":308,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","prefix":"nhibitors (mainly comprising azole-antimycotics, apart from ","suffix":", and HIV protease inhibitors), which are multi-pathway inhi","exact":"fluconazole"},{"setid":"PMC3769672","drugname":"fluconazole","startOffset":571,"endOffset":582,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"oderate P-gp inhibitor; 54% increase [95% CI 44%, 64%]) and ","suffix":" (moderate CYP3A4, possible Bcrp [ABCG2] inhibitor; 42% incr","exact":"fluconazole"},{"setid":"PMC3769672","drugname":"fluconazole","startOffset":297,"endOffset":308,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","prefix":"nhibitors (mainly comprising azole-antimycotics, apart from ","suffix":", and HIV protease inhibitors), which are multi-pathway inhi","exact":"fluconazole"},{"setid":"PMC3769672","drugname":"fluconazole","startOffset":424,"endOffset":435,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","prefix":"state erythromycin (500 mg three times daily), steady-state ","suffix":" (400 mg once daily) or a single dose of midazolam (7.5 mg).","exact":"fluconazole"},{"setid":"PMC3769672","drugname":"fluconazole","startOffset":143,"endOffset":154,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[3]/p[1]","prefix":"estigated the potential interaction between rivaroxaban and ","suffix":", classified as a potent inhibitor of CYP2C9 (rivaroxaban is","exact":"fluconazole"},{"setid":"PMC3769672","drugname":"fluconazole","startOffset":189,"endOffset":200,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[3]/p[2]","prefix":"zed to receive a single dose of rivaroxaban 20 mg alone, or ","suffix":" 400 mg once daily given for 6 days, with a concomitant admi","exact":"fluconazole"},{"setid":"PMC3769672","drugname":"fluconazole","startOffset":202,"endOffset":213,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/p[3]","prefix":"e ketoconazole, ritonavir, clarithromycin, erythromycin and ","suffix":" studies), the fraction of free (unbound) drug in plasma (","exact":"fluconazole"},{"setid":"PMC3769672","drugname":"fluconazole","startOffset":204,"endOffset":215,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[3]/p[1]","prefix":"xaban 20 mg was administered alone and co-administered with ","suffix":" 400 mg after 4 days of pretreatment with fluconazole 400 mg","exact":"fluconazole"},{"setid":"PMC3769672","drugname":"fluconazole","startOffset":257,"endOffset":268,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[3]/p[1]","prefix":"d with fluconazole 400 mg after 4 days of pretreatment with ","suffix":" 400 mg once daily. Co-administration with fluconazole signi","exact":"fluconazole"},{"setid":"PMC3769672","drugname":"fluconazole","startOffset":311,"endOffset":322,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[3]/p[1]","prefix":" with fluconazole 400 mg once daily. Co-administration with ","suffix":" significantly increased the primary pharmacokinetic paramet","exact":"fluconazole"},{"setid":"PMC3769672","drugname":"fluconazole","startOffset":372,"endOffset":383,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":"a moderate inhibitor of CYP3A4 and potentially Bcrp (ABCG2, ","suffix":"), and a strong inhibitor of CYP3A4 and moderate inhibitor o","exact":"fluconazole"},{"setid":"PMC3769672","drugname":"fluconazole","startOffset":857,"endOffset":868,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[6]","prefix":"n with these agents should be avoided. The exception may be ","suffix":", which is expected to have less effect on rivaroxaban expos","exact":"fluconazole"},{"setid":"PMC3769672","drugname":"ketoconazole","startOffset":818,"endOffset":830,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"p/Bcrp (ABCG2) inhibitors (and potential CYP2J2 inhibitors) ","suffix":" (158% increase [95% CI 136%, 182%] for a 400 mg once daily ","exact":"ketoconazole"},{"setid":"PMC3769672","drugname":"ketoconazole","startOffset":228,"endOffset":240,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","prefix":"ngle doses of rivaroxaban (10 mg or 20 mg) and steady-state ","suffix":" (200 mg once daily), steady-state ritonavir (600 mg twice d","exact":"ketoconazole"},{"setid":"PMC3769672","drugname":"ketoconazole","startOffset":663,"endOffset":675,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","prefix":" rivaroxaban (10 mg once daily) and high dose, steady-state ","suffix":" (400 mg once daily).                                       ","exact":"ketoconazole"},{"setid":"PMC3769672","drugname":"ketoconazole","startOffset":232,"endOffset":244,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","prefix":"potential interactions between rivaroxaban and steady-state ","suffix":" 200 mg, subjects received ketoconazole for 72 h as outpatie","exact":"ketoconazole"},{"setid":"PMC3769672","drugname":"ketoconazole","startOffset":271,"endOffset":283,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","prefix":"ban and steady-state ketoconazole 200 mg, subjects received ","suffix":" for 72 h as outpatients. Subjects were kept in-house for 72","exact":"ketoconazole"},{"setid":"PMC3769672","drugname":"ketoconazole","startOffset":224,"endOffset":236,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","prefix":"and strong inhibitors of CYP3A4/2J2, P-gp and Bcrp (ABCG2), ","suffix":" and ritonavir [","exact":"ketoconazole"},{"setid":"PMC3769672","drugname":"ketoconazole","startOffset":77,"endOffset":89,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/p[1]","prefix":"                                                The initial ","suffix":" interaction study investigated the potential interaction be","exact":"ketoconazole"},{"setid":"PMC3769672","drugname":"ketoconazole","startOffset":201,"endOffset":213,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/p[1]","prefix":"ction between a single dose of rivaroxaban and steady-state ","suffix":" 200 mg once daily. In this open label, two way crossover st","exact":"ketoconazole"},{"setid":"PMC3769672","drugname":"ketoconazole","startOffset":364,"endOffset":376,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/p[1]","prefix":"o receive a single dose of rivaroxaban 10 mg, alone or with ","suffix":" (4 days of oral ketoconazole 200 mg once daily with rivarox","exact":"ketoconazole"},{"setid":"PMC3769672","drugname":"ketoconazole","startOffset":393,"endOffset":405,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/p[1]","prefix":"varoxaban 10 mg, alone or with ketoconazole (4 days of oral ","suffix":" 200 mg once daily with rivaroxaban given on day 4). Rivarox","exact":"ketoconazole"},{"setid":"PMC3769672","drugname":"ketoconazole","startOffset":509,"endOffset":521,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/p[1]","prefix":" day 4). Rivaroxaban was given under fasting conditions and ","suffix":" was given with food, except when co-administered with rivar","exact":"ketoconazole"},{"setid":"PMC3769672","drugname":"ketoconazole","startOffset":650,"endOffset":662,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/p[1]","prefix":"fter completion of this study, a publication suggested that ","suffix":" 400 mg may lead to higher inhibition of CYP ","exact":"ketoconazole"},{"setid":"PMC3769672","drugname":"ketoconazole","startOffset":72,"endOffset":84,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/p[2]","prefix":"                                                     In the ","suffix":" 200 mg study, 12 subjects were enrolled. All completed the ","exact":"ketoconazole"},{"setid":"PMC3769672","drugname":"ketoconazole","startOffset":308,"endOffset":320,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/p[2]","prefix":"4-41 years) and their mean weight was 86.4 ± 9.2 kg. In the ","suffix":" 400 mg study, a total of 20 subjects were enrolled. All com","exact":"ketoconazole"},{"setid":"PMC3769672","drugname":"ketoconazole","startOffset":205,"endOffset":217,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/p[2]","prefix":"under the plasma concentration-time curve (AUC(0,τ)) in the ","suffix":" 400 mg study, in which multiple doses of rivaroxaban were g","exact":"ketoconazole"},{"setid":"PMC3769672","drugname":"ketoconazole","startOffset":144,"endOffset":156,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/p[3]","prefix":"erpretation of the anticipated interaction findings (in the ","suffix":", ritonavir, clarithromycin, erythromycin and fluconazole st","exact":"ketoconazole"},{"setid":"PMC3769672","drugname":"ketoconazole","startOffset":72,"endOffset":84,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[3]/p[2]","prefix":"                                                     In the ","suffix":" 400 mg once daily and ritonavir studies, both using sequent","exact":"ketoconazole"},{"setid":"PMC3769672","drugname":"ketoconazole","startOffset":159,"endOffset":171,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[1]/p[1]","prefix":"rivaroxaban 10 mg administered alone or in combination with ","suffix":" 200 mg once daily are shown in ","exact":"ketoconazole"},{"setid":"PMC3769672","drugname":"ketoconazole","startOffset":220,"endOffset":232,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[2]/p[1]","prefix":"dy-state rivaroxaban 10 mg in combination with steady-state ","suffix":" 400 mg once daily (day 10). Co-administration with ketocona","exact":"ketoconazole"},{"setid":"PMC3769672","drugname":"ketoconazole","startOffset":284,"endOffset":296,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[2]/p[1]","prefix":"conazole 400 mg once daily (day 10). Co-administration with ","suffix":" 400 mg significantly increased rivaroxaban plasma concentra","exact":"ketoconazole"},{"setid":"PMC3769672","drugname":"ketoconazole","startOffset":818,"endOffset":830,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"p/Bcrp (ABCG2) inhibitors (and potential CYP2J2 inhibitors) ","suffix":" (158% increase [95% CI 136%, 182%] for a 400 mg once daily ","exact":"ketoconazole"},{"setid":"PMC3769672","drugname":"ketoconazole","startOffset":228,"endOffset":240,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","prefix":"ngle doses of rivaroxaban (10 mg or 20 mg) and steady-state ","suffix":" (200 mg once daily), steady-state ritonavir (600 mg twice d","exact":"ketoconazole"},{"setid":"PMC3769672","drugname":"ketoconazole","startOffset":663,"endOffset":675,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","prefix":" rivaroxaban (10 mg once daily) and high dose, steady-state ","suffix":" (400 mg once daily).                                       ","exact":"ketoconazole"},{"setid":"PMC3769672","drugname":"ketoconazole","startOffset":232,"endOffset":244,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","prefix":"potential interactions between rivaroxaban and steady-state ","suffix":" 200 mg, subjects received ketoconazole for 72 h as outpatie","exact":"ketoconazole"},{"setid":"PMC3769672","drugname":"ketoconazole","startOffset":271,"endOffset":283,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","prefix":"ban and steady-state ketoconazole 200 mg, subjects received ","suffix":" for 72 h as outpatients. Subjects were kept in-house for 72","exact":"ketoconazole"},{"setid":"PMC3769672","drugname":"ketoconazole","startOffset":224,"endOffset":236,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","prefix":"and strong inhibitors of CYP3A4/2J2, P-gp and Bcrp (ABCG2), ","suffix":" and ritonavir [","exact":"ketoconazole"},{"setid":"PMC3769672","drugname":"ketoconazole","startOffset":77,"endOffset":89,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/p[1]","prefix":"                                                The initial ","suffix":" interaction study investigated the potential interaction be","exact":"ketoconazole"},{"setid":"PMC3769672","drugname":"ketoconazole","startOffset":201,"endOffset":213,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/p[1]","prefix":"ction between a single dose of rivaroxaban and steady-state ","suffix":" 200 mg once daily. In this open label, two way crossover st","exact":"ketoconazole"},{"setid":"PMC3769672","drugname":"ketoconazole","startOffset":364,"endOffset":376,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/p[1]","prefix":"o receive a single dose of rivaroxaban 10 mg, alone or with ","suffix":" (4 days of oral ketoconazole 200 mg once daily with rivarox","exact":"ketoconazole"},{"setid":"PMC3769672","drugname":"ketoconazole","startOffset":393,"endOffset":405,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/p[1]","prefix":"varoxaban 10 mg, alone or with ketoconazole (4 days of oral ","suffix":" 200 mg once daily with rivaroxaban given on day 4). Rivarox","exact":"ketoconazole"},{"setid":"PMC3769672","drugname":"ketoconazole","startOffset":509,"endOffset":521,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/p[1]","prefix":" day 4). Rivaroxaban was given under fasting conditions and ","suffix":" was given with food, except when co-administered with rivar","exact":"ketoconazole"},{"setid":"PMC3769672","drugname":"ketoconazole","startOffset":650,"endOffset":662,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/p[1]","prefix":"fter completion of this study, a publication suggested that ","suffix":" 400 mg may lead to higher inhibition of CYP ","exact":"ketoconazole"},{"setid":"PMC3769672","drugname":"ketoconazole","startOffset":72,"endOffset":84,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/p[2]","prefix":"                                                     In the ","suffix":" 200 mg study, 12 subjects were enrolled. All completed the ","exact":"ketoconazole"},{"setid":"PMC3769672","drugname":"ketoconazole","startOffset":308,"endOffset":320,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/p[2]","prefix":"4-41 years) and their mean weight was 86.4 ± 9.2 kg. In the ","suffix":" 400 mg study, a total of 20 subjects were enrolled. All com","exact":"ketoconazole"},{"setid":"PMC3769672","drugname":"ketoconazole","startOffset":205,"endOffset":217,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/p[2]","prefix":"under the plasma concentration-time curve (AUC(0,τ)) in the ","suffix":" 400 mg study, in which multiple doses of rivaroxaban were g","exact":"ketoconazole"},{"setid":"PMC3769672","drugname":"ketoconazole","startOffset":144,"endOffset":156,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/p[3]","prefix":"erpretation of the anticipated interaction findings (in the ","suffix":", ritonavir, clarithromycin, erythromycin and fluconazole st","exact":"ketoconazole"},{"setid":"PMC3769672","drugname":"ketoconazole","startOffset":72,"endOffset":84,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[3]/p[2]","prefix":"                                                     In the ","suffix":" 400 mg once daily and ritonavir studies, both using sequent","exact":"ketoconazole"},{"setid":"PMC3769672","drugname":"ketoconazole","startOffset":159,"endOffset":171,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[1]/p[1]","prefix":"rivaroxaban 10 mg administered alone or in combination with ","suffix":" 200 mg once daily are shown in ","exact":"ketoconazole"},{"setid":"PMC3769672","drugname":"ketoconazole","startOffset":220,"endOffset":232,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[2]/p[1]","prefix":"dy-state rivaroxaban 10 mg in combination with steady-state ","suffix":" 400 mg once daily (day 10). Co-administration with ketocona","exact":"ketoconazole"},{"setid":"PMC3769672","drugname":"ketoconazole","startOffset":284,"endOffset":296,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[2]/p[1]","prefix":"conazole 400 mg once daily (day 10). Co-administration with ","suffix":" 400 mg significantly increased rivaroxaban plasma concentra","exact":"ketoconazole"},{"setid":"PMC3769672","drugname":"ritonavir","startOffset":900,"endOffset":909,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"rease [95% CI 136%, 182%] for a 400 mg once daily dose) and ","suffix":" (153% increase [95% CI 134%, 174%]).                       ","exact":"ritonavir"},{"setid":"PMC3769672","drugname":"ritonavir","startOffset":241,"endOffset":250,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","prefix":"tors of CYP3A4/2J2, P-gp and Bcrp (ABCG2), ketoconazole and ","suffix":" [","exact":"ritonavir"},{"setid":"PMC3769672","drugname":"ritonavir","startOffset":145,"endOffset":154,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[2]/p[1]","prefix":"ction between a single dose of rivaroxaban and steady-state ","suffix":" was investigated in a non-randomized, open label study. Sub","exact":"ritonavir"},{"setid":"PMC3769672","drugname":"ritonavir","startOffset":320,"endOffset":329,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[2]/p[1]","prefix":" mg on day 1, ritonavir 600 mg twice daily on days 3-7, and ","suffix":" 600 mg twice daily plus a single dose of rivaroxaban on day","exact":"ritonavir"},{"setid":"PMC3769672","drugname":"ritonavir","startOffset":533,"endOffset":542,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[2]/p[2]","prefix":"dose of rivaroxaban 10 mg on day 1 and at least one dose of ","suffix":" (600 mg). Twelve subjects received the combination of rivar","exact":"ritonavir"},{"setid":"PMC3769672","drugname":"ritonavir","startOffset":613,"endOffset":622,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[2]/p[2]","prefix":"Twelve subjects received the combination of rivaroxaban and ","suffix":" on day 8. However, none of the subjects received the second","exact":"ritonavir"},{"setid":"PMC3769672","drugname":"ritonavir","startOffset":107,"endOffset":116,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[3]/p[2]","prefix":"                  In the ketoconazole 400 mg once daily and ","suffix":" studies, both using sequential designs, the pharmacokinetic","exact":"ritonavir"},{"setid":"PMC3769672","drugname":"ritonavir","startOffset":378,"endOffset":387,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[3]/p[1]","prefix":"e of rivaroxaban (days 7 and 8, respectively). Steady-state ","suffix":" significantly increased the AUC and ","exact":"ritonavir"},{"setid":"PMC3769672","drugname":"ritonavir","startOffset":900,"endOffset":909,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"rease [95% CI 136%, 182%] for a 400 mg once daily dose) and ","suffix":" (153% increase [95% CI 134%, 174%]).                       ","exact":"ritonavir"},{"setid":"PMC3769672","drugname":"ritonavir","startOffset":275,"endOffset":284,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","prefix":"steady-state ketoconazole (200 mg once daily), steady-state ","suffix":" (600 mg twice daily), steady-state clarithromycin (500 mg t","exact":"ritonavir"},{"setid":"PMC3769672","drugname":"ritonavir","startOffset":241,"endOffset":250,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","prefix":"tors of CYP3A4/2J2, P-gp and Bcrp (ABCG2), ketoconazole and ","suffix":" [","exact":"ritonavir"},{"setid":"PMC3769672","drugname":"ritonavir","startOffset":145,"endOffset":154,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[2]/p[1]","prefix":"ction between a single dose of rivaroxaban and steady-state ","suffix":" was investigated in a non-randomized, open label study. Sub","exact":"ritonavir"},{"setid":"PMC3769672","drugname":"ritonavir","startOffset":274,"endOffset":283,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[2]/p[1]","prefix":"jects received a single dose of rivaroxaban 10 mg on day 1, ","suffix":" 600 mg twice daily on days 3-7, and ritonavir 600 mg twice ","exact":"ritonavir"},{"setid":"PMC3769672","drugname":"ritonavir","startOffset":320,"endOffset":329,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[2]/p[1]","prefix":" mg on day 1, ritonavir 600 mg twice daily on days 3-7, and ","suffix":" 600 mg twice daily plus a single dose of rivaroxaban on day","exact":"ritonavir"},{"setid":"PMC3769672","drugname":"ritonavir","startOffset":533,"endOffset":542,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[2]/p[2]","prefix":"dose of rivaroxaban 10 mg on day 1 and at least one dose of ","suffix":" (600 mg). Twelve subjects received the combination of rivar","exact":"ritonavir"},{"setid":"PMC3769672","drugname":"ritonavir","startOffset":613,"endOffset":622,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[2]/p[2]","prefix":"Twelve subjects received the combination of rivaroxaban and ","suffix":" on day 8. However, none of the subjects received the second","exact":"ritonavir"},{"setid":"PMC3769672","drugname":"ritonavir","startOffset":691,"endOffset":700,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[2]/p[2]","prefix":". However, none of the subjects received the second dose of ","suffix":" on day 8 because of tolerability issues, which were conside","exact":"ritonavir"},{"setid":"PMC3769672","drugname":"ritonavir","startOffset":781,"endOffset":790,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[2]/p[2]","prefix":"tolerability issues, which were considered to be related to ","suffix":". Four subjects withdrew from the study owing to adverse eve","exact":"ritonavir"},{"setid":"PMC3769672","drugname":"ritonavir","startOffset":870,"endOffset":879,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[2]/p[2]","prefix":"drew from the study owing to adverse events while receiving ","suffix":" alone (see below). Therefore, 12 subjects were valid for th","exact":"ritonavir"},{"setid":"PMC3769672","drugname":"ritonavir","startOffset":158,"endOffset":167,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/p[3]","prefix":" the anticipated interaction findings (in the ketoconazole, ","suffix":", clarithromycin, erythromycin and fluconazole studies), the","exact":"ritonavir"},{"setid":"PMC3769672","drugname":"ritonavir","startOffset":107,"endOffset":116,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[3]/p[2]","prefix":"                  In the ketoconazole 400 mg once daily and ","suffix":" studies, both using sequential designs, the pharmacokinetic","exact":"ritonavir"},{"setid":"PMC3769672","drugname":"ritonavir","startOffset":193,"endOffset":202,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[3]/p[1]","prefix":"le dose (day 1) with those of a single dose of steady-state ","suffix":" 600 mg twice daily (day 8). In addition, the pharmacokineti","exact":"ritonavir"},{"setid":"PMC3769672","drugname":"ritonavir","startOffset":268,"endOffset":277,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[3]/p[1]","prefix":"g twice daily (day 8). In addition, the pharmacokinetics of ","suffix":" were compared in the absence and presence of rivaroxaban (d","exact":"ritonavir"},{"setid":"PMC3769672","drugname":"ritonavir","startOffset":378,"endOffset":387,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[3]/p[1]","prefix":"e of rivaroxaban (days 7 and 8, respectively). Steady-state ","suffix":" significantly increased the AUC and ","exact":"ritonavir"},{"setid":"PMC3769672","drugname":"ritonavir","startOffset":491,"endOffset":500,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[1]","prefix":"hanges in ECG or vital signs were observed. Subjects taking ","suffix":" exhibited adverse events consistent with its established sa","exact":"ritonavir"},{"setid":"PMC3769672","drugname":"digoxin","startOffset":273,"endOffset":280,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"3A4-mediated metabolites. Previous interaction studies with ","suffix":" (a pure P-gp substrate with a narrow therapeutic window) an","exact":"digoxin"},{"setid":"PMC3769672","drugname":"digoxin","startOffset":527,"endOffset":534,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"rmacodynamics of rivaroxaban, or on the pharmacokinetics of ","suffix":" or atorvastatin [","exact":"digoxin"},{"setid":"PMC3769672","drugname":"atorvastatin","startOffset":342,"endOffset":354,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"a pure P-gp substrate with a narrow therapeutic window) and ","suffix":" (a substrate of both CYP3A4 and P-gp) in healthy subjects d","exact":"atorvastatin"},{"setid":"PMC3769672","drugname":"atorvastatin","startOffset":538,"endOffset":550,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"cs of rivaroxaban, or on the pharmacokinetics of digoxin or ","suffix":" [","exact":"atorvastatin"}],[{"setid":"PMC1874466","drugname":"rosuvastatin","startOffset":163,"endOffset":175,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"rial 24 healthy adult volunteers were randomized to receive ","suffix":" 10 mg orally each morning (07.00 h) or evening (18.00 h) fo","exact":"rosuvastatin"},{"setid":"PMC1874466","drugname":"rosuvastatin","startOffset":334,"endOffset":346,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"d, volunteers received the alternative regimen for 14 days. ","suffix":" was administered in the absence of food.                   ","exact":"Rosuvastatin"},{"setid":"PMC1874466","drugname":"rosuvastatin","startOffset":57,"endOffset":69,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":"                                                         ","suffix":" (Crestor®) is a new and highly effective inhibitor of HMG-C","exact":"Rosuvastatin"},{"setid":"PMC1874466","drugname":"rosuvastatin","startOffset":61,"endOffset":73,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/p[1]","prefix":"                                                            ","suffix":" proved to be well tolerated over the two 14 day treatment p","exact":"Rosuvastatin"},{"setid":"PMC1874466","drugname":"rosuvastatin","startOffset":142,"endOffset":154,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","prefix":"pid-regulating effects and steady-state pharmacokinetics of ","suffix":", a new synthetic hydroxy methylglutaryl-coenzyme A (HMG-CoA","exact":"rosuvastatin"},{"setid":"PMC1874466","drugname":"rosuvastatin","startOffset":163,"endOffset":175,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"rial 24 healthy adult volunteers were randomized to receive ","suffix":" 10 mg orally each morning (07.00 h) or evening (18.00 h) fo","exact":"rosuvastatin"},{"setid":"PMC1874466","drugname":"rosuvastatin","startOffset":117,"endOffset":129,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","prefix":"        The pharmacodynamic effects and pharmacokinetics of ","suffix":" are not dependent on time of dosing. Morning or evening adm","exact":"rosuvastatin"},{"setid":"PMC1874466","drugname":"rosuvastatin","startOffset":262,"endOffset":274,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":"eatment of patients with dyslipidaemia. In clinical trials, ","suffix":" (1-80 mg) produced reductions in LDL-C, total cholesterol (","exact":"rosuvastatin"},{"setid":"PMC1874466","drugname":"rosuvastatin","startOffset":81,"endOffset":93,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[4]","prefix":"                                    The pharmacokinetics of ","suffix":" following single- and multiple-dose administration of the d","exact":"rosuvastatin"},{"setid":"PMC1874466","drugname":"rosuvastatin","startOffset":166,"endOffset":178,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[5]","prefix":" the pharmacodynamics and multiple-dose pharmacokinetics of ","suffix":" following morning and evening administration in healthy adu","exact":"rosuvastatin"},{"setid":"PMC1874466","drugname":"rosuvastatin","startOffset":130,"endOffset":142,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","prefix":"volunteers were randomized to receive a single oral dose of ","suffix":" (10 mg) each morning (approximately 07.00 h) or evening (ap","exact":"rosuvastatin"},{"setid":"PMC1874466","drugname":"rosuvastatin","startOffset":495,"endOffset":507,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","prefix":"required to fast for a minimum of 2 h before and after each ","suffix":" dose, and for at least 12 h (overnight) before collection o","exact":"rosuvastatin"},{"setid":"PMC1874466","drugname":"rosuvastatin","startOffset":195,"endOffset":207,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","prefix":"concentrations before administration of the morning dose of ","suffix":" (morning dosing) or before the morning meal (evening dosing","exact":"rosuvastatin"},{"setid":"PMC1874466","drugname":"rosuvastatin","startOffset":124,"endOffset":136,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","prefix":"ial venous blood samples (7 ml) for determination of plasma ","suffix":" concentrations were collected at 0.5 h predose and at fixed","exact":"rosuvastatin"},{"setid":"PMC1874466","drugname":"rosuvastatin","startOffset":288,"endOffset":300,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","prefix":"6, 8, 10, 12, 18, 24, 48, and 72 h) after administration of ","suffix":" on treatment day 14. Blood samples were also collected at 0","exact":"rosuvastatin"},{"setid":"PMC1874466","drugname":"rosuvastatin","startOffset":68,"endOffset":80,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[2]","prefix":"                                                     Plasma ","suffix":" concentration-time data were analysed by standard noncompar","exact":"rosuvastatin"},{"setid":"PMC1874466","drugname":"rosuvastatin","startOffset":155,"endOffset":167,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","prefix":" LDL-C were obtained following once daily administration of ","suffix":" 10 mg in the morning or evening. After 14 days of treatment","exact":"rosuvastatin"},{"setid":"PMC1874466","drugname":"rosuvastatin","startOffset":151,"endOffset":163,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[4]","prefix":"n LDL-C, TC, TG, and ApoB are consistent with the effect of ","suffix":". The small reductions in HDL-C and ApoA-I are atypical.    ","exact":"rosuvastatin"},{"setid":"PMC1874466","drugname":"rosuvastatin","startOffset":94,"endOffset":106,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[1]","prefix":"                           From inspection of trough plasma ","suffix":" concentration-time profiles, it was apparent that steady st","exact":"rosuvastatin"},{"setid":"PMC1874466","drugname":"rosuvastatin","startOffset":222,"endOffset":234,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[1]","prefix":"y state was attained within 8 days of initiating once-daily ","suffix":" administration (with both morning and evening dosing regime","exact":"rosuvastatin"},{"setid":"PMC1874466","drugname":"rosuvastatin","startOffset":353,"endOffset":365,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[1]","prefix":"ens). Under steady-state conditions, the mean trough plasma ","suffix":" concentration was approximately 0.6 ng ml","exact":"rosuvastatin"},{"setid":"PMC1874466","drugname":"rosuvastatin","startOffset":96,"endOffset":108,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[2]","prefix":"                         The apparent rate of absorption of ","suffix":" was essentially the same following morning and evening dosi","exact":"rosuvastatin"},{"setid":"PMC1874466","drugname":"rosuvastatin","startOffset":264,"endOffset":276,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/p[2]","prefix":"ateral leads), which occurred 3.5 h after the first dose of ","suffix":". The volunteer was asymptomatic and the T-wave abnormality ","exact":"rosuvastatin"},{"setid":"PMC1874466","drugname":"rosuvastatin","startOffset":152,"endOffset":164,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":" the pharmacodynamics and multiple-dose pharmacokinetics of ","suffix":" following morning and evening administration in healthy vol","exact":"rosuvastatin"},{"setid":"PMC1874466","drugname":"rosuvastatin","startOffset":255,"endOffset":267,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":"administration in healthy volunteers. The results show that ","suffix":" was equally effective in lowering serum LDL-C concentration","exact":"rosuvastatin"},{"setid":"PMC1874466","drugname":"rosuvastatin","startOffset":437,"endOffset":449,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":"ing with this finding, the steady-state pharmacokinetics of ","suffix":" were very similar after morning and evening administration.","exact":"rosuvastatin"},{"setid":"PMC1874466","drugname":"rosuvastatin","startOffset":618,"endOffset":630,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":"r both pharmacodynamics and pharmacokinetics differentiates ","suffix":" from other marketed statins.                               ","exact":"rosuvastatin"},{"setid":"PMC1874466","drugname":"rosuvastatin","startOffset":227,"endOffset":239,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","prefix":" in hypercholesterolaemic patients following treatment with ","suffix":" 10 mg once daily for 6 weeks (approximately −48%) [","exact":"rosuvastatin"},{"setid":"PMC1874466","drugname":"rosuvastatin","startOffset":139,"endOffset":151,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","prefix":"ults of this trial indicate that the therapeutic benefit of ","suffix":" is not dose-time de-pendent, and that morning or evening ad","exact":"rosuvastatin"},{"setid":"PMC1874466","drugname":"rosuvastatin","startOffset":310,"endOffset":322,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","prefix":"gulating lipid levels. In addition, the pharmacokinetics of ","suffix":" were independent of time of dosing.                        ","exact":"rosuvastatin"},{"setid":"PMC1874466","drugname":"crestor","startOffset":71,"endOffset":78,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":"                                              Rosuvastatin (","suffix":"®) is a new and highly effective inhibitor of HMG-CoA reduct","exact":"Crestor"},{"setid":"PMC1874466","drugname":"cholesterol","startOffset":348,"endOffset":359,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","prefix":"on in volunteers with fasting serum low-density lipoprotein ","suffix":" (LDL-C) concentrations < 4.14 mmol l","exact":"cholesterol"},{"setid":"PMC1874466","drugname":"cholesterol","startOffset":321,"endOffset":332,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":" rosuvastatin (1-80 mg) produced reductions in LDL-C, total ","suffix":" (TC), and triglycerides (TG), and increases in high-density","exact":"cholesterol"},{"setid":"PMC1874466","drugname":"cholesterol","startOffset":242,"endOffset":253,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"erapy, and are the most effective agents for reducing serum ","suffix":" concentrations and cardiovascular mortality [","exact":"cholesterol"},{"setid":"PMC1874466","drugname":"cholesterol","startOffset":348,"endOffset":359,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","prefix":"on in volunteers with fasting serum low-density lipoprotein ","suffix":" (LDL-C) concentrations < 4.14 mmol l","exact":"cholesterol"},{"setid":"PMC1874466","drugname":"cholesterol","startOffset":242,"endOffset":253,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"erapy, and are the most effective agents for reducing serum ","suffix":" concentrations and cardiovascular mortality [","exact":"cholesterol"},{"setid":"PMC1874466","drugname":"cholesterol","startOffset":321,"endOffset":332,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":" rosuvastatin (1-80 mg) produced reductions in LDL-C, total ","suffix":" (TC), and triglycerides (TG), and increases in high-density","exact":"cholesterol"},{"setid":"PMC1874466","drugname":"cholesterol","startOffset":405,"endOffset":416,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":"iglycerides (TG), and increases in high-density lipoprotein ","suffix":" (HDL-C) [","exact":"cholesterol"},{"setid":"PMC1874466","drugname":"cholesterol","startOffset":176,"endOffset":187,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","prefix":"is trial (−41 to −44%) closely match those obtained in hyper","suffix":"aemic patients following treatment with rosuvastatin 10 mg o","exact":"cholesterol"},{"setid":"PMC1874466","drugname":"fluvastatin","startOffset":57,"endOffset":68,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"                                                         ","suffix":" [","exact":"Fluvastatin"}],[{"setid":"PMC2598705","drugname":"simvastatin","startOffset":184,"endOffset":195,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[1]","prefix":"gerous. Protease inhibitors (PIs) inhibit the metabolism of ","suffix":", and co‐administration is contraindicated. Despite this, we","exact":"simvastatin"},{"setid":"PMC2598705","drugname":"simvastatin","startOffset":306,"endOffset":317,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[1]","prefix":" this, we have seen a recent cluster of patients prescribed ","suffix":" whilst on PIs.                                             ","exact":"simvastatin"},{"setid":"PMC2598705","drugname":"simvastatin","startOffset":250,"endOffset":261,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[2]","prefix":"the patient and his general practitioner (GP), stating that ","suffix":" is not recommended with his antiretroviral combination, but","exact":"simvastatin"},{"setid":"PMC2598705","drugname":"simvastatin","startOffset":314,"endOffset":325,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[3]","prefix":" and mentioned that her cholesterol was 8.5. Her GP started ","suffix":". The patient took the first dose but stopped after reading ","exact":"simvastatin"},{"setid":"PMC2598705","drugname":"simvastatin","startOffset":269,"endOffset":280,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[4]","prefix":"is GP about current medications. Pravastatin was changed to ","suffix":" by his GP 6 years later.                                   ","exact":"simvastatin"},{"setid":"PMC2598705","drugname":"simvastatin","startOffset":160,"endOffset":171,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[5]","prefix":"on protease inhibitors (PIs) have recently been switched to ","suffix":" by GPs. None have suffered adverse consequences, although s","exact":"simvastatin"},{"setid":"PMC2598705","drugname":"simvastatin","startOffset":195,"endOffset":206,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[6]","prefix":"hibit cytochrome P450 (CYP) 3A4 activity, which metabolises ","suffix":" and atorvastatin. Simvastatin exposure is increased by up t","exact":"simvastatin"},{"setid":"PMC2598705","drugname":"simvastatin","startOffset":224,"endOffset":235,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[7]","prefix":"CYP3A4 metabolism, and reduces the concentrations of active ","suffix":", atorvastatin and pravastatin by 58%, 34% and 40%, respecti","exact":"simvastatin"},{"setid":"PMC2598705","drugname":"simvastatin","startOffset":184,"endOffset":195,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[8]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[8]","prefix":"dications where possible, and this is driving the switch to ","suffix":". Simvastatin is also available without prescription in phar","exact":"simvastatin"},{"setid":"PMC2598705","drugname":"simvastatin","startOffset":477,"endOffset":488,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[8]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[8]","prefix":"bout potential drug interactions. Where PIs are being used, ","suffix":" must be avoided.                                           ","exact":"simvastatin"},{"setid":"PMC2598705","drugname":"simvastatin","startOffset":368,"endOffset":379,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[2]","prefix":"bination, but low dose atorvastatin or pravastatin is safe. ","suffix":" was prescribed by the GP.                                  ","exact":"Simvastatin"},{"setid":"PMC2598705","drugname":"simvastatin","startOffset":225,"endOffset":236,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[6]","prefix":"4 activity, which metabolises simvastatin and atorvastatin. ","suffix":" exposure is increased by up to 3000% by PIs,","exact":"Simvastatin"},{"setid":"PMC2598705","drugname":"simvastatin","startOffset":197,"endOffset":208,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[8]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[8]","prefix":"re possible, and this is driving the switch to simvastatin. ","suffix":" is also available without prescription in pharmacies. These","exact":"Simvastatin"},{"setid":"PMC2598705","drugname":"abacavir","startOffset":86,"endOffset":94,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[2]","prefix":"                               A 58‐year‐old man was taking ","suffix":", lamivudine, atazanavir and ritonavir. His HIV physician no","exact":"abacavir"},{"setid":"PMC2598705","drugname":"lamivudine","startOffset":96,"endOffset":106,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[2]","prefix":"                     A 58‐year‐old man was taking abacavir, ","suffix":", atazanavir and ritonavir. His HIV physician noted raised c","exact":"lamivudine"},{"setid":"PMC2598705","drugname":"lamivudine","startOffset":97,"endOffset":107,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[4]","prefix":"                    A 53‐year‐old man was taking stavudine, ","suffix":" and nelfinavir. Pravastatin was started by his HIV physicia","exact":"lamivudine"},{"setid":"PMC2598705","drugname":"atazanavir","startOffset":108,"endOffset":118,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[2]","prefix":"         A 58‐year‐old man was taking abacavir, lamivudine, ","suffix":" and ritonavir. His HIV physician noted raised cholesterol a","exact":"atazanavir"},{"setid":"PMC2598705","drugname":"atazanavir","startOffset":111,"endOffset":121,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[3]","prefix":"      A 52‐year‐old woman was taking didanosine, efavirenz, ","suffix":" and ritonavir, as well as gliclazide, doxazosin and bendrof","exact":"atazanavir"},{"setid":"PMC2598705","drugname":"atazanavir","startOffset":108,"endOffset":118,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[2]","prefix":"         A 58‐year‐old man was taking abacavir, lamivudine, ","suffix":" and ritonavir. His HIV physician noted raised cholesterol a","exact":"atazanavir"},{"setid":"PMC2598705","drugname":"atazanavir","startOffset":111,"endOffset":121,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[3]","prefix":"      A 52‐year‐old woman was taking didanosine, efavirenz, ","suffix":" and ritonavir, as well as gliclazide, doxazosin and bendrof","exact":"atazanavir"},{"setid":"PMC2598705","drugname":"atazanavir","startOffset":83,"endOffset":93,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[6]","prefix":"                                  PIs, including ritonavir, ","suffix":", lopinavir, saquinavir and nelfinavir, inhibit cytochrome P","exact":"atazanavir"},{"setid":"PMC2598705","drugname":"ritonavir","startOffset":123,"endOffset":132,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[2]","prefix":"ear‐old man was taking abacavir, lamivudine, atazanavir and ","suffix":". His HIV physician noted raised cholesterol and wrote to th","exact":"ritonavir"},{"setid":"PMC2598705","drugname":"ritonavir","startOffset":126,"endOffset":135,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[3]","prefix":"‐old woman was taking didanosine, efavirenz, atazanavir and ","suffix":", as well as gliclazide, doxazosin and bendrofluazide. A let","exact":"ritonavir"},{"setid":"PMC2598705","drugname":"ritonavir","startOffset":123,"endOffset":132,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[2]","prefix":"ear‐old man was taking abacavir, lamivudine, atazanavir and ","suffix":". His HIV physician noted raised cholesterol and wrote to th","exact":"ritonavir"},{"setid":"PMC2598705","drugname":"ritonavir","startOffset":126,"endOffset":135,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[3]","prefix":"‐old woman was taking didanosine, efavirenz, atazanavir and ","suffix":", as well as gliclazide, doxazosin and bendrofluazide. A let","exact":"ritonavir"},{"setid":"PMC2598705","drugname":"ritonavir","startOffset":72,"endOffset":81,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[6]","prefix":"                                             PIs, including ","suffix":", atazanavir, lopinavir, saquinavir and nelfinavir, inhibit ","exact":"ritonavir"},{"setid":"PMC2598705","drugname":"cholesterol","startOffset":165,"endOffset":176,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[2]","prefix":"e, atazanavir and ritonavir. His HIV physician noted raised ","suffix":" and wrote to the patient and his general practitioner (GP),","exact":"cholesterol"},{"setid":"PMC2598705","drugname":"cholesterol","startOffset":278,"endOffset":289,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[3]","prefix":"ian to her GP listed her medications and mentioned that her ","suffix":" was 8.5. Her GP started simvastatin. The patient took the f","exact":"cholesterol"},{"setid":"PMC2598705","drugname":"atorvastatin","startOffset":331,"endOffset":343,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[2]","prefix":"commended with his antiretroviral combination, but low dose ","suffix":" or pravastatin is safe. Simvastatin was prescribed by the G","exact":"atorvastatin"},{"setid":"PMC2598705","drugname":"atorvastatin","startOffset":211,"endOffset":223,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[6]","prefix":" P450 (CYP) 3A4 activity, which metabolises simvastatin and ","suffix":". Simvastatin exposure is increased by up to 3000% by PIs,","exact":"atorvastatin"},{"setid":"PMC2598705","drugname":"atorvastatin","startOffset":331,"endOffset":343,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[2]","prefix":"commended with his antiretroviral combination, but low dose ","suffix":" or pravastatin is safe. Simvastatin was prescribed by the G","exact":"atorvastatin"},{"setid":"PMC2598705","drugname":"atorvastatin","startOffset":211,"endOffset":223,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[6]","prefix":" P450 (CYP) 3A4 activity, which metabolises simvastatin and ","suffix":". Simvastatin exposure is increased by up to 3000% by PIs,","exact":"atorvastatin"},{"setid":"PMC2598705","drugname":"atorvastatin","startOffset":237,"endOffset":249,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[7]","prefix":"lism, and reduces the concentrations of active simvastatin, ","suffix":" and pravastatin by 58%, 34% and 40%, respectively.","exact":"atorvastatin"},{"setid":"PMC2598705","drugname":"pravastatin","startOffset":347,"endOffset":358,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[2]","prefix":"is antiretroviral combination, but low dose atorvastatin or ","suffix":" is safe. Simvastatin was prescribed by the GP.             ","exact":"pravastatin"},{"setid":"PMC2598705","drugname":"pravastatin","startOffset":254,"endOffset":265,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[7]","prefix":" the concentrations of active simvastatin, atorvastatin and ","suffix":" by 58%, 34% and 40%, respectively.","exact":"pravastatin"},{"setid":"PMC2598705","drugname":"pravastatin","startOffset":124,"endOffset":135,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[4]","prefix":"ar‐old man was taking stavudine, lamivudine and nelfinavir. ","suffix":" was started by his HIV physician, and letters were written ","exact":"Pravastatin"},{"setid":"PMC2598705","drugname":"pravastatin","startOffset":242,"endOffset":253,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[4]","prefix":"were written regularly to his GP about current medications. ","suffix":" was changed to simvastatin by his GP 6 years later.        ","exact":"Pravastatin"},{"setid":"PMC2598705","drugname":"pravastatin","startOffset":124,"endOffset":135,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[4]","prefix":"ar‐old man was taking stavudine, lamivudine and nelfinavir. ","suffix":" was started by his HIV physician, and letters were written ","exact":"Pravastatin"},{"setid":"PMC2598705","drugname":"pravastatin","startOffset":242,"endOffset":253,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[4]","prefix":"were written regularly to his GP about current medications. ","suffix":" was changed to simvastatin by his GP 6 years later.        ","exact":"Pravastatin"},{"setid":"PMC2598705","drugname":"didanosine","startOffset":88,"endOffset":98,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[3]","prefix":"                             A 52‐year‐old woman was taking ","suffix":", efavirenz, atazanavir and ritonavir, as well as gliclazide","exact":"didanosine"},{"setid":"PMC2598705","drugname":"efavirenz","startOffset":100,"endOffset":109,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[3]","prefix":"                 A 52‐year‐old woman was taking didanosine, ","suffix":", atazanavir and ritonavir, as well as gliclazide, doxazosin","exact":"efavirenz"},{"setid":"PMC2598705","drugname":"efavirenz","startOffset":100,"endOffset":109,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[3]","prefix":"                 A 52‐year‐old woman was taking didanosine, ","suffix":", atazanavir and ritonavir, as well as gliclazide, doxazosin","exact":"efavirenz"},{"setid":"PMC2598705","drugname":"efavirenz","startOffset":86,"endOffset":95,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[7]","prefix":"                               It should also be noted that ","suffix":", a non‐nucleoside reverse transcriptase inhibitor, is an in","exact":"efavirenz"},{"setid":"PMC2598705","drugname":"gliclazide","startOffset":148,"endOffset":158,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[3]","prefix":"didanosine, efavirenz, atazanavir and ritonavir, as well as ","suffix":", doxazosin and bendrofluazide. A letter from her HIV physic","exact":"gliclazide"},{"setid":"PMC2598705","drugname":"doxazosin","startOffset":160,"endOffset":169,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[3]","prefix":"efavirenz, atazanavir and ritonavir, as well as gliclazide, ","suffix":" and bendrofluazide. A letter from her HIV physician to her ","exact":"doxazosin"},{"setid":"PMC2598705","drugname":"bendrofluazide","startOffset":174,"endOffset":188,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[3]","prefix":"zanavir and ritonavir, as well as gliclazide, doxazosin and ","suffix":". A letter from her HIV physician to her GP listed her medic","exact":"bendrofluazide"},{"setid":"PMC2598705","drugname":"stavudine","startOffset":86,"endOffset":95,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[4]","prefix":"                               A 53‐year‐old man was taking ","suffix":", lamivudine and nelfinavir. Pravastatin was started by his ","exact":"stavudine"},{"setid":"PMC2598705","drugname":"nelfinavir","startOffset":112,"endOffset":122,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[4]","prefix":"     A 53‐year‐old man was taking stavudine, lamivudine and ","suffix":". Pravastatin was started by his HIV physician, and letters ","exact":"nelfinavir"},{"setid":"PMC2598705","drugname":"nelfinavir","startOffset":121,"endOffset":131,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[6]","prefix":" including ritonavir, atazanavir, lopinavir, saquinavir and ","suffix":", inhibit cytochrome P450 (CYP) 3A4 activity, which metaboli","exact":"nelfinavir"},{"setid":"PMC2598705","drugname":"lopinavir","startOffset":95,"endOffset":104,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[6]","prefix":"                      PIs, including ritonavir, atazanavir, ","suffix":", saquinavir and nelfinavir, inhibit cytochrome P450 (CYP) 3","exact":"lopinavir"},{"setid":"PMC2598705","drugname":"saquinavir","startOffset":106,"endOffset":116,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[6]","prefix":"           PIs, including ritonavir, atazanavir, lopinavir, ","suffix":" and nelfinavir, inhibit cytochrome P450 (CYP) 3A4 activity,","exact":"saquinavir"}],[{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":97,"endOffset":109,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"                            Following coadministration with ","suffix":", rosuvastatin geometric least square mean AUC(0,","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":274,"endOffset":286,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","prefix":". Volunteers were randomized to receive daily oral doses of ","suffix":" 400 mg (1 × 200-mg tablet every 12 h) or matching placebo (","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":586,"endOffset":598,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","prefix":"mg (1 × 80-mg encapsulated tablet) with the morning dose of ","suffix":" or placebo. Volunteers then remained in the Clinical Pharma","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":339,"endOffset":351,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[1]","prefix":"mples were taken before administration of the first dose of ","suffix":" or placebo on day 1 of the second dosing period. Blood samp","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":151,"endOffset":163,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[1]","prefix":"en before and 2 h after administration of the first dose of ","suffix":" or placebo on days 4, 5, 6 and 7 of each dosing period. Blo","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":183,"endOffset":195,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[8]/p[1]","prefix":"dence interval (CI) for the treatment ratio (rosuvastatin + ","suffix":"/rosuvastatin + placebo) of the geometric least square means","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":74,"endOffset":86,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[4]","prefix":"                                           Rosuvastatin and ","suffix":" were well tolerated when coadministered. There were no seri","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":122,"endOffset":134,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"inistration of rosuvastatin and the potent CYP3A4 inhibitor ","suffix":" did not produce any change in pharmacokinetics of the forme","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":235,"endOffset":247,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"netics of the former. Furthermore, the results suggest that ","suffix":" had no effect on the systemic clearance of rosuvastatin, as","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":72,"endOffset":84,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"                                             In conclusion, ","suffix":" did not affect the pharmacokinetics of rosuvastatin in heal","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":189,"endOffset":201,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"astatin in healthy subjects. Therefore, coadministration of ","suffix":" and rosuvastatin is unlikely to increase the risk of toxici","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":364,"endOffset":376,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/div[2]/p[1]","prefix":"Sciences Inc. (Montreal, Quebec, Canada) for performing the ","suffix":" assays, Olise M. Nwose MB BS for his support of this trial,","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":65,"endOffset":77,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","prefix":"                                                            ","suffix":" did not produce any change in rosuvastatin pharmacokinetics","exact":"Ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":57,"endOffset":69,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[6]","prefix":"                                                         ","suffix":" is also known to inhibit the activity of transport protein ","exact":"Ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":208,"endOffset":220,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"ion for, or induction or inhibition of, transport proteins. ","suffix":" is known to have inhibitory effects on the transport protei","exact":"Ketoconazole"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":111,"endOffset":123,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"              Following coadministration with ketoconazole, ","suffix":" geometric least square mean AUC(0,","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":108,"endOffset":120,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","prefix":"                 Ketoconazole did not produce any change in ","suffix":" pharmacokinetics in healthy subjects. The data suggest that","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":271,"endOffset":283,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","prefix":"r P-gp-mediated transport contributes to the elimination of ","suffix":".                                                           ","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":300,"endOffset":312,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"eatment of patients with dyslipidaemia. In clinical trials, ","suffix":" (1-80 mg) produced highly significant dose-dependent reduct","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":81,"endOffset":93,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"                                    The pharmacokinetics of ","suffix":" following single- and multiple-dose administration of the d","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":72,"endOffset":84,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":"                                             Elimination of ","suffix":" is primarily via the liver. In a clinical trial [","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":398,"endOffset":410,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","prefix":"uring the washout period following the first dosing period (","suffix":" + placebo)]. This withdrawal was considered unlikely to hav","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":510,"endOffset":522,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","prefix":" dosing period, volunteers were given a single oral dose of ","suffix":" 80 mg (1 × 80-mg encapsulated tablet) with the morning dose","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":255,"endOffset":267,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[2]","prefix":" the first dose on day 1 until 96 h after administration of ","suffix":" in each dosing period), the consumption of caffeine-contain","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":433,"endOffset":445,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[2]","prefix":"om midnight before day 1 until 96 h after administration of ","suffix":" in each dosing period), and concomitant medications (none p","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":86,"endOffset":98,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[1]","prefix":"                                   Blood samples (9 ml) for ","suffix":" assay were taken before administration of rosuvastatin on d","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":141,"endOffset":153,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[1]","prefix":" for rosuvastatin assay were taken before administration of ","suffix":" on day 4 of each dosing period and 0.5, 1, 2, 3, 4, 5, 6, 8","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":89,"endOffset":101,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","prefix":"                                The blood samples taken for ","suffix":" assay were also used to obtain plasma for active and total ","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":168,"endOffset":180,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[8]/p[1]","prefix":"t the 90% confidence interval (CI) for the treatment ratio (","suffix":" + ketoconazole/rosuvastatin + placebo) of the geometric lea","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":196,"endOffset":208,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[8]/p[1]","prefix":"l (CI) for the treatment ratio (rosuvastatin + ketoconazole/","suffix":" + placebo) of the geometric least square means (gls","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":64,"endOffset":76,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[8]/p[2]","prefix":"                                                         As ","suffix":" AUC [or AUC(0,","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":151,"endOffset":163,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","prefix":"ma concentration-time curves measured to a common point for ","suffix":" and active and total HMG-CoA reductase inhibitors indicated","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":287,"endOffset":299,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","prefix":"t, within the accuracy and precision s of the methods used, ","suffix":" accounted for essentially all of the circulating active inh","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":77,"endOffset":89,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"                                        Coadministration of ","suffix":" and the potent CYP3A4 inhibitor ketoconazole did not produc","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":291,"endOffset":303,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"hat ketoconazole had no effect on the systemic clearance of ","suffix":", as individual plasma concentration profiles, including the","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":72,"endOffset":84,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"                                             In contrast to ","suffix":", atorvastatin [","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":175,"endOffset":187,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"oncentrations were measured in this trial. The finding that ","suffix":" accounted for essentially all of the circulating active inh","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":384,"endOffset":396,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"e(s). The finding that the active inhibitors, and therefore ","suffix":", constituted the majority of the total inhibitors indicates","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":700,"endOffset":712,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":" support for previous data indicating limited metabolism of ","suffix":" [","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":124,"endOffset":136,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"lusion, ketoconazole did not affect the pharmacokinetics of ","suffix":" in healthy subjects. Therefore, coadministration of ketocon","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":206,"endOffset":218,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"y subjects. Therefore, coadministration of ketoconazole and ","suffix":" is unlikely to increase the risk of toxicity at therapeutic","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":288,"endOffset":300,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"ly to increase the risk of toxicity at therapeutic doses of ","suffix":". The data suggest that neither cytochrome P450 3A4 nor P-gp","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":414,"endOffset":426,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"r P-gp-mediated transport contributes to the elimination of ","suffix":".                                                     ","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":137,"endOffset":149,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/div[2]/p[1]","prefix":"k Quintiles Scotland Ltd (Edinburgh, UK) for performing the ","suffix":" assays, Medical Research Laboratories (Highland Heights, Ke","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":57,"endOffset":69,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"                                                         ","suffix":" (Crestor®) is an inhibitor of 3-hydroxy-3-methylglutaryl co","exact":"Rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":57,"endOffset":69,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[4]","prefix":"                                                         ","suffix":" and ketoconazole were well tolerated when coadministered. T","exact":"Rosuvastatin"},{"setid":"PMC1884190","drugname":"crestor","startOffset":71,"endOffset":78,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"                                              Rosuvastatin (","suffix":"®) is an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A ","exact":"Crestor"},{"setid":"PMC1884190","drugname":"cholesterol","startOffset":187,"endOffset":198,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"coenzyme A (HMG-CoA) reductase, the rate-limiting enzyme in ","suffix":" biosynthesis, and is effective for the treatment of patient","exact":"cholesterol"},{"setid":"PMC1884190","drugname":"cholesterol","startOffset":404,"endOffset":415,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"ficant dose-dependent reductions in low-density lipoprotein ","suffix":" (up to 65%) and was well-tolerated [","exact":"cholesterol"},{"setid":"PMC1884190","drugname":"atorvastatin","startOffset":105,"endOffset":117,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[4]","prefix":"            Some of the other HMG-CoA reductase inhibitors (","suffix":" [","exact":"atorvastatin"},{"setid":"PMC1884190","drugname":"atorvastatin","startOffset":86,"endOffset":98,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"                               In contrast to rosuvastatin, ","suffix":" [","exact":"atorvastatin"},{"setid":"PMC1884190","drugname":"atorvastatin","startOffset":105,"endOffset":117,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[4]","prefix":"            Some of the other HMG-CoA reductase inhibitors (","suffix":" [","exact":"atorvastatin"},{"setid":"PMC1884190","drugname":"atorvastatin","startOffset":86,"endOffset":98,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"                               In contrast to rosuvastatin, ","suffix":" [","exact":"atorvastatin"},{"setid":"PMC1884190","drugname":"atorvastatin","startOffset":404,"endOffset":416,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"ts metabolites may be affected. For example, in the case of ","suffix":", following coadministration with itraconazole, the mean AUC","exact":"atorvastatin"},{"setid":"PMC1884190","drugname":"atorvastatin","startOffset":587,"endOffset":599,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"ased 1.6- and 1.7-fold, respectively; the mean AUC(0,72) of ","suffix":" acid and lactone was increased 3.2- and 4.1-fold, respectiv","exact":"atorvastatin"},{"setid":"PMC1884190","drugname":"atorvastatin","startOffset":724,"endOffset":736,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"and the mean AUC(0,72) of the principal metabolite 2-hydroxy","suffix":" acid and its lactone was decreased by 57% and 38%, respecti","exact":"atorvastatin"},{"setid":"PMC1884190","drugname":"itraconazole","startOffset":450,"endOffset":462,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"n the case of atorvastatin, following coadministration with ","suffix":", the mean AUC(0,72) of the active and total inhibitors was ","exact":"itraconazole"},{"setid":"PMC1884190","drugname":"alanine","startOffset":417,"endOffset":424,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","prefix":" haematology, or urinalysis results, or if total bilirubin, ","suffix":" aminotransferase, aspartate aminotransferase, alkaline phos","exact":"alanine"},{"setid":"PMC1884190","drugname":"caffeine","startOffset":311,"endOffset":319,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[2]","prefix":" of rosuvastatin in each dosing period), the consumption of ","suffix":"-containing drinks/food and smoking (none permitted from mid","exact":"caffeine"},{"setid":"PMC1884190","drugname":"heparin","startOffset":460,"endOffset":467,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[1]","prefix":" Blood samples were collected into tubes containing lithium ","suffix":" anticoagulant and centrifuged within 30 min. Plasma was the","exact":"heparin"},{"setid":"PMC1884190","drugname":"sodium acetate","startOffset":572,"endOffset":586,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[1]","prefix":" Plasma was then harvested from the samples, mixed 1:1 with ","suffix":" buffer 0.1 ","exact":"sodium acetate"},{"setid":"PMC1884190","drugname":"acetonitrile","startOffset":388,"endOffset":400,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","prefix":" drug-related components were isolated from plasma by using ","suffix":" : acetone (95 : 5) to precipitate plasma proteins. The supe","exact":"acetonitrile"},{"setid":"PMC1884190","drugname":"acetone","startOffset":403,"endOffset":410,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","prefix":"omponents were isolated from plasma by using acetonitrile : ","suffix":" (95 : 5) to precipitate plasma proteins. The supernatant wa","exact":"acetone"},{"setid":"PMC1884190","drugname":"edta","startOffset":271,"endOffset":275,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[1]","prefix":" period. Blood samples were collected into tubes containing ","suffix":" anticoagulant and centrifuged. Plasma was then harvested fr","exact":"EDTA"}],[{"setid":"PMC3922121","drugname":"atorvastatin","startOffset":260,"endOffset":272,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":" incorporating genomic and clinical variables to avoid high ","suffix":" and rosuvastatin levels is described; further study will de","exact":"atorvastatin"},{"setid":"PMC3922121","drugname":"atorvastatin","startOffset":167,"endOffset":179,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","prefix":"London Health Sciences Center (LHSC, London, Canada) taking ","suffix":" or rosuvastatin daily to participate. Patients were exclude","exact":"atorvastatin"},{"setid":"PMC3922121","drugname":"atorvastatin","startOffset":261,"endOffset":273,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","prefix":" to participate. Patients were excluded if they were taking ","suffix":" or rosuvastatin in an alternate day dosing regimen, or if t","exact":"atorvastatin"},{"setid":"PMC3922121","drugname":"atorvastatin","startOffset":362,"endOffset":374,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","prefix":"ate day dosing regimen, or if they had not taken their last ","suffix":" or rosuvastatin dose within 24 hours of their clinic visit ","exact":"atorvastatin"},{"setid":"PMC3922121","drugname":"atorvastatin","startOffset":479,"endOffset":491,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","prefix":"r clinic visit and blood draw. All patients had been taking ","suffix":" or rosuvastatin at the same dose for at least six weeks pri","exact":"atorvastatin"},{"setid":"PMC3922121","drugname":"atorvastatin","startOffset":266,"endOffset":278,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[1]","prefix":"ated in 300 μL acetonitrile containing internal standard d5-","suffix":" or d6-rosuvastatin, and centrifuged at 14,000 rpm for 20 mi","exact":"atorvastatin"},{"setid":"PMC3922121","drugname":"atorvastatin","startOffset":617,"endOffset":629,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[1]","prefix":"dient to ratio of 10:90. Concentrations of rosuvastatin and ","suffix":" were measured by liquid chromatography-mass spectrometry (L","exact":"atorvastatin"},{"setid":"PMC3922121","drugname":"atorvastatin","startOffset":95,"endOffset":107,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"                              In total, 299 patients taking ","suffix":" or rosuvastatin were prospectively recruited at an outpatie","exact":"atorvastatin"},{"setid":"PMC3922121","drugname":"atorvastatin","startOffset":260,"endOffset":272,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":" incorporating genomic and clinical variables to avoid high ","suffix":" and rosuvastatin levels is described; further study will de","exact":"atorvastatin"},{"setid":"PMC3922121","drugname":"atorvastatin","startOffset":167,"endOffset":179,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","prefix":"London Health Sciences Center (LHSC, London, Canada) taking ","suffix":" or rosuvastatin daily to participate. Patients were exclude","exact":"atorvastatin"},{"setid":"PMC3922121","drugname":"atorvastatin","startOffset":261,"endOffset":273,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","prefix":" to participate. Patients were excluded if they were taking ","suffix":" or rosuvastatin in an alternate day dosing regimen, or if t","exact":"atorvastatin"},{"setid":"PMC3922121","drugname":"atorvastatin","startOffset":362,"endOffset":374,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","prefix":"ate day dosing regimen, or if they had not taken their last ","suffix":" or rosuvastatin dose within 24 hours of their clinic visit ","exact":"atorvastatin"},{"setid":"PMC3922121","drugname":"atorvastatin","startOffset":479,"endOffset":491,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","prefix":"r clinic visit and blood draw. All patients had been taking ","suffix":" or rosuvastatin at the same dose for at least six weeks pri","exact":"atorvastatin"},{"setid":"PMC3922121","drugname":"atorvastatin","startOffset":266,"endOffset":278,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[1]","prefix":"ated in 300 μL acetonitrile containing internal standard d5-","suffix":" or d6-rosuvastatin, and centrifuged at 14,000 rpm for 20 mi","exact":"atorvastatin"},{"setid":"PMC3922121","drugname":"atorvastatin","startOffset":617,"endOffset":629,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[1]","prefix":"dient to ratio of 10:90. Concentrations of rosuvastatin and ","suffix":" were measured by liquid chromatography-mass spectrometry (L","exact":"atorvastatin"},{"setid":"PMC3922121","drugname":"atorvastatin","startOffset":163,"endOffset":175,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","prefix":"ld or higher variability between patients on the same daily ","suffix":" dose (","exact":"atorvastatin"},{"setid":"PMC3922121","drugname":"atorvastatin","startOffset":119,"endOffset":131,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","prefix":"  Multiple linear regression analysis indicated that plasma ","suffix":" concentration was higher in individuals with the ","exact":"atorvastatin"},{"setid":"PMC3922121","drugname":"atorvastatin","startOffset":115,"endOffset":127,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":"      The mean lathosterol concentration in patients taking ","suffix":" was 3.9 μg/mL (SD 2.1) and rosuvastatin was 3.4 μg/mL (2.2)","exact":"atorvastatin"},{"setid":"PMC3922121","drugname":"atorvastatin","startOffset":208,"endOffset":220,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":"1) and rosuvastatin was 3.4 μg/mL (2.2). In patients taking ","suffix":", lathosterol concentration was lower in patients taking a h","exact":"atorvastatin"},{"setid":"PMC3922121","drugname":"atorvastatin","startOffset":294,"endOffset":306,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":"concentration was lower in patients taking a higher dose of ","suffix":" (p < 0.01), however, there was no significant association b","exact":"atorvastatin"},{"setid":"PMC3922121","drugname":"atorvastatin","startOffset":389,"endOffset":401,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":"here was no significant association between rosuvastatin or ","suffix":" concentrations and lathosterol concentration detected in th","exact":"atorvastatin"},{"setid":"PMC3922121","drugname":"atorvastatin","startOffset":246,"endOffset":258,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[8]/p[1]","prefix":"s (n = 579). The first cohort contained 224 patients taking ","suffix":" and 37 patients taking rosuvastatin in the context of routi","exact":"atorvastatin"},{"setid":"PMC3922121","drugname":"atorvastatin","startOffset":423,"endOffset":435,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[8]/p[1]","prefix":"n the U.S.; the second cohort contained 121 patients taking ","suffix":" and 198 patients taking rosuvastatin treated in a lipid cli","exact":"atorvastatin"},{"setid":"PMC3922121","drugname":"atorvastatin","startOffset":116,"endOffset":128,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[8]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[8]/p[3]","prefix":"     Among 67 patients on high-dose rosuvastatin (40 mg) or ","suffix":" (80 mg), nearly 50% exceeded the maximum dose recommended b","exact":"atorvastatin"},{"setid":"PMC3922121","drugname":"atorvastatin","startOffset":298,"endOffset":310,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[8]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[8]/p[3]","prefix":"developing intolerance. Of the 16 patients taking high-dose ","suffix":" (80 mg) within our cohort derived from an EMR-linked bioban","exact":"atorvastatin"},{"setid":"PMC3922121","drugname":"atorvastatin","startOffset":463,"endOffset":475,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[8]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[8]/p[3]","prefix":"nded dose, and only 7 of these patients were still on 80 mg ","suffix":" one year later. Conversely, all (7 of 7) subjects predicted","exact":"atorvastatin"},{"setid":"PMC3922121","drugname":"atorvastatin","startOffset":595,"endOffset":607,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[8]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[8]/p[3]","prefix":" by our algorithm to tolerate 80 mg were still on high-dose ","suffix":" one year later, however, this result was not statistically ","exact":"atorvastatin"},{"setid":"PMC3922121","drugname":"atorvastatin","startOffset":173,"endOffset":185,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"drug transporter polymorphisms and plasma concentrations of ","suffix":" and rosuvastatin in a real world population. We found a mar","exact":"atorvastatin"},{"setid":"PMC3922121","drugname":"atorvastatin","startOffset":151,"endOffset":163,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"as a significant factor in predicting the concentrations of ","suffix":" and rosuvastatin in patients. Age has been recognized as a ","exact":"atorvastatin"},{"setid":"PMC3922121","drugname":"atorvastatin","startOffset":118,"endOffset":130,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[9]","prefix":"t the highest available dose, nearly 50% of patients taking ","suffix":" or rosuvastatin exceeded the maximum genotype-based dose re","exact":"atorvastatin"},{"setid":"PMC3922121","drugname":"atorvastatin","startOffset":561,"endOffset":573,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[9]","prefix":" most useful when a patient is starting the highest dose of ","suffix":" or rosuvastatin, bearing in mind that ","exact":"atorvastatin"},{"setid":"PMC3922121","drugname":"atorvastatin","startOffset":86,"endOffset":98,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[10]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[10]","prefix":"                               Here we present the range of ","suffix":" and rosuvastatin concentrations in a patient population, pr","exact":"atorvastatin"},{"setid":"PMC3922121","drugname":"rosuvastatin","startOffset":111,"endOffset":123,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"              In total, 299 patients taking atorvastatin or ","suffix":" were prospectively recruited at an outpatient referral cent","exact":"rosuvastatin"},{"setid":"PMC3922121","drugname":"rosuvastatin","startOffset":277,"endOffset":289,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"nomic and clinical variables to avoid high atorvastatin and ","suffix":" levels is described; further study will determine if this a","exact":"rosuvastatin"},{"setid":"PMC3922121","drugname":"rosuvastatin","startOffset":183,"endOffset":195,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","prefix":"iences Center (LHSC, London, Canada) taking atorvastatin or ","suffix":" daily to participate. Patients were excluded if they were t","exact":"rosuvastatin"},{"setid":"PMC3922121","drugname":"rosuvastatin","startOffset":277,"endOffset":289,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","prefix":" Patients were excluded if they were taking atorvastatin or ","suffix":" in an alternate day dosing regimen, or if they had not take","exact":"rosuvastatin"},{"setid":"PMC3922121","drugname":"rosuvastatin","startOffset":378,"endOffset":390,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","prefix":"egimen, or if they had not taken their last atorvastatin or ","suffix":" dose within 24 hours of their clinic visit and blood draw. ","exact":"rosuvastatin"},{"setid":"PMC3922121","drugname":"rosuvastatin","startOffset":495,"endOffset":507,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","prefix":"nd blood draw. All patients had been taking atorvastatin or ","suffix":" at the same dose for at least six weeks prior to participat","exact":"rosuvastatin"},{"setid":"PMC3922121","drugname":"rosuvastatin","startOffset":285,"endOffset":297,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[1]","prefix":"onitrile containing internal standard d5-atorvastatin or d6-","suffix":", and centrifuged at 14,000 rpm for 20 minutes at 4 °C. The ","exact":"rosuvastatin"},{"setid":"PMC3922121","drugname":"rosuvastatin","startOffset":600,"endOffset":612,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[1]","prefix":"70:30, with a gradient to ratio of 10:90. Concentrations of ","suffix":" and atorvastatin were measured by liquid chromatography-mas","exact":"rosuvastatin"},{"setid":"PMC3922121","drugname":"rosuvastatin","startOffset":81,"endOffset":93,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[10]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[10]/p[2]","prefix":"                                        For log-transformed ","suffix":" concentration, the effect sizes detectable with a power of ","exact":"rosuvastatin"},{"setid":"PMC3922121","drugname":"rosuvastatin","startOffset":109,"endOffset":121,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","prefix":"            We observed up to 45-fold variability in plasma ","suffix":" concentration among individuals on the same dose (","exact":"rosuvastatin"},{"setid":"PMC3922121","drugname":"rosuvastatin","startOffset":147,"endOffset":159,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[2]","prefix":"ociation of clinical and pharmacogenetic variables with the ","suffix":" levels observed, we performed multiple linear regression an","exact":"rosuvastatin"},{"setid":"PMC3922121","drugname":"rosuvastatin","startOffset":411,"endOffset":423,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[2]","prefix":". Multiple linear regression analysis indicated that plasma ","suffix":" concentration was higher in individuals with the reduced fu","exact":"rosuvastatin"},{"setid":"PMC3922121","drugname":"rosuvastatin","startOffset":72,"endOffset":84,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","prefix":"                                                 Similar to ","suffix":", we observed 45-fold or higher variability between patients","exact":"rosuvastatin"},{"setid":"PMC3922121","drugname":"rosuvastatin","startOffset":155,"endOffset":167,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":" in patients taking atorvastatin was 3.9 μg/mL (SD 2.1) and ","suffix":" was 3.4 μg/mL (2.2). In patients taking atorvastatin, latho","exact":"rosuvastatin"},{"setid":"PMC3922121","drugname":"rosuvastatin","startOffset":373,"endOffset":385,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":".01), however, there was no significant association between ","suffix":" or atorvastatin concentrations and lathosterol concentratio","exact":"rosuvastatin"},{"setid":"PMC3922121","drugname":"rosuvastatin","startOffset":287,"endOffset":299,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[1]","prefix":"n combination with plasma statin concentration. We examined ","suffix":" acid concentrations in patients taking 40 mg rosuvastatin d","exact":"rosuvastatin"},{"setid":"PMC3922121","drugname":"rosuvastatin","startOffset":345,"endOffset":357,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[1]","prefix":"d rosuvastatin acid concentrations in patients taking 40 mg ","suffix":" daily, for whom no higher dose or more potent statin is ava","exact":"rosuvastatin"},{"setid":"PMC3922121","drugname":"rosuvastatin","startOffset":681,"endOffset":693,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[1]","prefix":"nts who were not at target LDL-C (n = 12) had a mean plasma ","suffix":" concentration of 9.183 ng/mL (SD 1.6; 13.6 hours post dose)","exact":"rosuvastatin"},{"setid":"PMC3922121","drugname":"rosuvastatin","startOffset":282,"endOffset":294,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[8]/p[1]","prefix":"ned 224 patients taking atorvastatin and 37 patients taking ","suffix":" in the context of routine clinical care at a large academic","exact":"rosuvastatin"},{"setid":"PMC3922121","drugname":"rosuvastatin","startOffset":460,"endOffset":472,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[8]/p[1]","prefix":"ed 121 patients taking atorvastatin and 198 patients taking ","suffix":" treated in a lipid clinic at a large academic center in Can","exact":"rosuvastatin"},{"setid":"PMC3922121","drugname":"rosuvastatin","startOffset":92,"endOffset":104,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[8]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[8]/p[3]","prefix":"                             Among 67 patients on high-dose ","suffix":" (40 mg) or atorvastatin (80 mg), nearly 50% exceeded the ma","exact":"rosuvastatin"},{"setid":"PMC3922121","drugname":"rosuvastatin","startOffset":190,"endOffset":202,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"polymorphisms and plasma concentrations of atorvastatin and ","suffix":" in a real world population. We found a marked, 45-fold inte","exact":"rosuvastatin"},{"setid":"PMC3922121","drugname":"rosuvastatin","startOffset":558,"endOffset":570,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"level. Indeed, nearly 90% of the explainable variability in ","suffix":" concentration can be accounted for by two reduced function ","exact":"rosuvastatin"},{"setid":"PMC3922121","drugname":"rosuvastatin","startOffset":168,"endOffset":180,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"factor in predicting the concentrations of atorvastatin and ","suffix":" in patients. Age has been recognized as a clinical risk fac","exact":"rosuvastatin"},{"setid":"PMC3922121","drugname":"rosuvastatin","startOffset":134,"endOffset":146,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[9]","prefix":"ailable dose, nearly 50% of patients taking atorvastatin or ","suffix":" exceeded the maximum genotype-based dose recommended by our","exact":"rosuvastatin"},{"setid":"PMC3922121","drugname":"rosuvastatin","startOffset":577,"endOffset":589,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[9]","prefix":"n a patient is starting the highest dose of atorvastatin or ","suffix":", bearing in mind that ","exact":"rosuvastatin"},{"setid":"PMC3922121","drugname":"rosuvastatin","startOffset":103,"endOffset":115,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[10]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[10]","prefix":"              Here we present the range of atorvastatin and ","suffix":" concentrations in a patient population, providing a framewo","exact":"rosuvastatin"},{"setid":"PMC3922121","drugname":"rosuvastatin","startOffset":366,"endOffset":378,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[10]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[10]","prefix":"statin transporter polymorphisms. In the clinical review of ","suffix":" originally submitted to the US FDA, all patients with serio","exact":"rosuvastatin"},{"setid":"PMC3922121","drugname":"rosuvastatin","startOffset":509,"endOffset":521,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[10]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[10]","prefix":"events for whom drug levels were available (n = 6) had high ","suffix":" concentrations (> 50 ng/mL; ","exact":"rosuvastatin"},{"setid":"PMC3922121","drugname":"crestor","startOffset":62,"endOffset":69,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[10]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[10]/a[1]","prefix":"tp://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-366_","suffix":"_Medr_P4.pdf","exact":"Crestor"},{"setid":"PMC3922121","drugname":"cholesterol","startOffset":292,"endOffset":303,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"by lowering plasma concentration of low-density lipoprotein ","suffix":" (LDL-C)","exact":"cholesterol"},{"setid":"PMC3922121","drugname":"cholesterol","startOffset":463,"endOffset":474,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":"ss the efficacy of statin-mediated inhibition of endogenous ","suffix":" synthesis, as well as its relationship to statin concentrat","exact":"cholesterol"},{"setid":"PMC3922121","drugname":"cholesterol","startOffset":699,"endOffset":710,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","prefix":"to 80 mg one week prior to blood sampling to achieve better ","suffix":" lowering. The study was conducted between August 2009 and M","exact":"cholesterol"},{"setid":"PMC3922121","drugname":"cholesterol","startOffset":292,"endOffset":303,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"by lowering plasma concentration of low-density lipoprotein ","suffix":" (LDL-C)","exact":"cholesterol"},{"setid":"PMC3922121","drugname":"cholesterol","startOffset":291,"endOffset":302,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":"al situation, is not well understood. We measured 4β-hydroxy","suffix":" concentration as a marker of CYP3A metabolic activity in vi","exact":"cholesterol"},{"setid":"PMC3922121","drugname":"cholesterol","startOffset":463,"endOffset":474,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":"ss the efficacy of statin-mediated inhibition of endogenous ","suffix":" synthesis, as well as its relationship to statin concentrat","exact":"cholesterol"},{"setid":"PMC3922121","drugname":"cholesterol","startOffset":699,"endOffset":710,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","prefix":"to 80 mg one week prior to blood sampling to achieve better ","suffix":" lowering. The study was conducted between August 2009 and M","exact":"cholesterol"},{"setid":"PMC3922121","drugname":"cholesterol","startOffset":67,"endOffset":78,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[8]/p[1]","prefix":"                                                      Total ","suffix":" was measured by the enzymatic colorimetric method, using th","exact":"cholesterol"},{"setid":"PMC3922121","drugname":"cholesterol","startOffset":530,"endOffset":541,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":"tion. In both groups, lathosterol was associated with total ","suffix":", and was higher in patients taking ezetimibe (","exact":"cholesterol"},{"setid":"PMC3922121","drugname":"cholesterol","startOffset":236,"endOffset":247,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":" basis for this variability has remained elusive. 4β-hydroxy","suffix":" is produced by CYP3A enzymes from cholesterol, and has been","exact":"cholesterol"},{"setid":"PMC3922121","drugname":"cholesterol","startOffset":282,"endOffset":293,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"ve. 4β-hydroxycholesterol is produced by CYP3A enzymes from ","suffix":", and has been proposed to be a marker of CYP3A activity in ","exact":"cholesterol"},{"setid":"PMC3922121","drugname":"cholesterol","startOffset":95,"endOffset":106,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[7]","prefix":"                      Lathosterol is a late intermediate in ","suffix":" synthesis that can be used to measure the efficacy of stati","exact":"cholesterol"},{"setid":"PMC3922121","drugname":"cholesterol","startOffset":140,"endOffset":151,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[8]/p[1]","prefix":"as measured by the enzymatic colorimetric method, using the ","suffix":" E kit from Wako (Richmond, VA). Samples were measured in tr","exact":"Cholesterol"},{"setid":"PMC3922121","drugname":"edta","startOffset":110,"endOffset":114,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","prefix":"           A single venous 8 mL blood sample was drawn into ","suffix":"-containing tubes, and placed immediately on ice. Samples we","exact":"EDTA"},{"setid":"PMC3922121","drugname":"acetonitrile","startOffset":221,"endOffset":233,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[1]","prefix":"ada). Plasma aliquots of 100 μL were precipitated in 300 μL ","suffix":" containing internal standard d5-atorvastatin or d6-rosuvast","exact":"acetonitrile"},{"setid":"PMC3922121","drugname":"acetonitrile","startOffset":503,"endOffset":515,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[1]","prefix":" phases 0.05% formic acid in water and 0.05% formic acid in ","suffix":", starting at a ratio of 70:30, with a gradient to ratio of ","exact":"acetonitrile"},{"setid":"PMC3922121","drugname":"acetonitrile","startOffset":221,"endOffset":233,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[1]","prefix":"ada). Plasma aliquots of 100 μL were precipitated in 300 μL ","suffix":" containing internal standard d5-atorvastatin or d6-rosuvast","exact":"acetonitrile"},{"setid":"PMC3922121","drugname":"acetonitrile","startOffset":503,"endOffset":515,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[1]","prefix":" phases 0.05% formic acid in water and 0.05% formic acid in ","suffix":", starting at a ratio of 70:30, with a gradient to ratio of ","exact":"acetonitrile"},{"setid":"PMC3922121","drugname":"ezetimibe","startOffset":577,"endOffset":586,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":"d with total cholesterol, and was higher in patients taking ","suffix":" (","exact":"ezetimibe"}],[{"setid":"PMC3571969","drugname":"cholesterol","startOffset":80,"endOffset":91,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","prefix":"                                     His values were: total ","suffix":" 277.7 mg/dL, triglycerides 448.2 mg/dL, HDL-C 36.7 mg/dl, f","exact":"cholesterol"},{"setid":"PMC3571969","drugname":"cholesterol","startOffset":377,"endOffset":388,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[4]","prefix":"evel (349 mg/dL), CK was in the normal range (121 U/l), but ","suffix":" showed further increase (310.5 mg/dL). Taking the lipid lev","exact":"cholesterol"},{"setid":"PMC3571969","drugname":"cholesterol","startOffset":161,"endOffset":172,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","prefix":"ond control. This time both the values of triglycerides and ","suffix":" showed improvement, 154.1 and 249.8 mg/dL, respectively. Ho","exact":"cholesterol"},{"setid":"PMC3571969","drugname":"cholesterol","startOffset":585,"endOffset":596,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[8]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[8]","prefix":"es (AST: 131.3; ALT: 95.5 U/l), and in LDH (386 U/l). Serum ","suffix":" level remained elevated (257.2 mg/dL), triglycerides reache","exact":"cholesterol"},{"setid":"PMC3571969","drugname":"cholesterol","startOffset":369,"endOffset":380,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[9]","prefix":"transaminases were normal, dyslipidaemia was reduced (total ","suffix":" and triglycerides levels were 238.3 and 216.1 mg/dL, respec","exact":"cholesterol"},{"setid":"PMC3571969","drugname":"cholesterol","startOffset":673,"endOffset":684,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[20]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[20]","prefix":"-fold higher triglyceride and the moderately elevated total ","suffix":" at the beginning. Third, unfortunately at the first blood t","exact":"cholesterol"},{"setid":"PMC3571969","drugname":"cholesterol","startOffset":752,"endOffset":763,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[20]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[20]","prefix":"beginning. Third, unfortunately at the first blood test LDL-","suffix":" could not have been evaluated because of the disturbing eff","exact":"cholesterol"},{"setid":"PMC3571969","drugname":"cholesterol","startOffset":895,"endOffset":906,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[20]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[20]","prefix":"d triglyceride. Later at the control blood tests only total ","suffix":" was measured. LDL-cholesterol is an essential parameter of ","exact":"cholesterol"},{"setid":"PMC3571969","drugname":"cholesterol","startOffset":925,"endOffset":936,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[20]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[20]","prefix":"ontrol blood tests only total cholesterol was measured. LDL-","suffix":" is an essential parameter of cardiovascular risk stratifica","exact":"cholesterol"},{"setid":"PMC3571969","drugname":"cholesterol","startOffset":133,"endOffset":144,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":"syndrome; TG: Triglyceride; HDL-C: High-density lipoprotein ","suffix":"; ESC/EAS: European Society of Cardiology and the European A","exact":"cholesterol"},{"setid":"PMC3571969","drugname":"fenofibrate","startOffset":708,"endOffset":719,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","prefix":"es and lack of lifestyle modification possibilities, 160 mg ","suffix":" per day was applied. The patient was also informed about th","exact":"fenofibrate"},{"setid":"PMC3571969","drugname":"fenofibrate","startOffset":229,"endOffset":240,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[14]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[14]","prefix":"was probably the atrovastatin as compared with gemfibrozil, ","suffix":" were found to be less prone to make complications when used","exact":"fenofibrate"},{"setid":"PMC3571969","drugname":"fenofibrate","startOffset":466,"endOffset":477,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[20]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[20]","prefix":"general practitioner sometimes limit our success. Secondly, ","suffix":" was administered first instead of atrovastatin. This choice","exact":"fenofibrate"},{"setid":"PMC3571969","drugname":"fenofibrate","startOffset":81,"endOffset":92,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","prefix":"                                    In conclusion, although ","suffix":" and statin combination therapy is supposed to be safe, myop","exact":"fenofibrate"},{"setid":"PMC3571969","drugname":"nebivolol","startOffset":538,"endOffset":547,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","prefix":"h lipid lowering medications. The incidental interaction of ","suffix":" with statins or fibrates is also need to be clarified in th","exact":"nebivolol"},{"setid":"PMC3571969","drugname":"alanine","startOffset":594,"endOffset":601,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","prefix":"s, like creatine kinase (CK), aspartate transaminase (AST), ","suffix":" transaminase (ALT) and gamma glutamyl transpeptidase (GGT) ","exact":"alanine"},{"setid":"PMC3571969","drugname":"alanine","startOffset":283,"endOffset":290,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":"ety; CK: Creatine kinase; AST: Aspartate transaminase; ALT: ","suffix":" transaminases; GGT: Gamma glutamyl transpeptidase; LDH: Lac","exact":"Alanine"},{"setid":"PMC3571969","drugname":"urea","startOffset":760,"endOffset":764,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","prefix":"/l, 23 U/l and 36 U/l, respectively). Renal function (blood ","suffix":" nitrogen: 7.6 mmol/l, serum creatinine: 97 μmol/L, glomerul","exact":"urea"},{"setid":"PMC3571969","drugname":"creatinine","startOffset":793,"endOffset":803,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","prefix":"ly). Renal function (blood urea nitrogen: 7.6 mmol/l, serum ","suffix":": 97 μmol/L, glomerular filtration rate: >60 ml/min) was als","exact":"creatinine"},{"setid":"PMC3571969","drugname":"aspirin","startOffset":208,"endOffset":215,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","prefix":"ate regarding taking the prescribed medications (except for ","suffix":", because of bad family experience). About lifestyle modific","exact":"aspirin"},{"setid":"PMC3571969","drugname":"varenicline","startOffset":854,"endOffset":865,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","prefix":"-effects of the lipid-lowering therapy. Because of smoking, ","suffix":" therapy was prescribed as well, as the patient previously f","exact":"varenicline"},{"setid":"PMC3571969","drugname":"varenicline","startOffset":157,"endOffset":168,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[4]","prefix":"ithout any symptoms, and mentioned that he had begun taking ","suffix":" only one week earlier. Laboratory parameters revealed the e","exact":"varenicline"},{"setid":"PMC3571969","drugname":"varenicline","startOffset":854,"endOffset":865,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","prefix":"-effects of the lipid-lowering therapy. Because of smoking, ","suffix":" therapy was prescribed as well, as the patient previously f","exact":"varenicline"},{"setid":"PMC3571969","drugname":"varenicline","startOffset":157,"endOffset":168,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[4]","prefix":"ithout any symptoms, and mentioned that he had begun taking ","suffix":" only one week earlier. Laboratory parameters revealed the e","exact":"varenicline"},{"setid":"PMC3571969","drugname":"varenicline","startOffset":79,"endOffset":90,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[6]","prefix":"                                      He had stopped taking ","suffix":" after 2 weeks, and had taken the three types of medicines t","exact":"varenicline"},{"setid":"PMC3571969","drugname":"varenicline","startOffset":179,"endOffset":190,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[6]","prefix":" the three types of medicines together (statin, fibrate and ","suffix":") only one week long. He did not smoke since then. The irreg","exact":"varenicline"},{"setid":"PMC3571969","drugname":"varenicline","startOffset":622,"endOffset":633,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[9]","prefix":" takes 1 gram omega-3 fatty acid per day, and thanks to the ","suffix":" therapy he does not smoke.                                 ","exact":"varenicline"},{"setid":"PMC3571969","drugname":"varenicline","startOffset":161,"endOffset":172,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[17]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[17]","prefix":"ibrate therapy-induced rhabdomyolysis could be connected to ","suffix":" intake. The theoretical background of this interaction is b","exact":"varenicline"},{"setid":"PMC3571969","drugname":"varenicline","startOffset":320,"endOffset":331,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[17]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[17]","prefix":"brach et al., who found two metabolites in human excreta of ","suffix":": one of them is the N-carbamoylglucuronide, catalyzed by th","exact":"varenicline"},{"setid":"PMC3571969","drugname":"atorvastatin","startOffset":538,"endOffset":550,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[4]","prefix":"r risk of the patient due to MetS into consideration, 20 mg ","suffix":" per day was added to the therapy. Similarly, a control labo","exact":"atorvastatin"},{"setid":"PMC3571969","drugname":"atorvastatin","startOffset":538,"endOffset":550,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[4]","prefix":"r risk of the patient due to MetS into consideration, 20 mg ","suffix":" per day was added to the therapy. Similarly, a control labo","exact":"atorvastatin"},{"setid":"PMC3571969","drugname":"lactate","startOffset":223,"endOffset":230,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[8]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[8]","prefix":"vated, while GGT remained in the normal range (38 U/l). The ","suffix":" dehydrogenase (LDH) level was also increased, 463 U/l. Stat","exact":"lactate"},{"setid":"PMC3571969","drugname":"lactate","startOffset":347,"endOffset":354,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":"ine transaminases; GGT: Gamma glutamyl transpeptidase; LDH: ","suffix":" dehydrogenase; CYP: Cytochrome P enzyme; GFR: Glomerular fi","exact":"Lactate"},{"setid":"PMC3571969","drugname":"thyroid-stimulating hormone","startOffset":796,"endOffset":823,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[8]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[8]","prefix":"normalities, and the thyroid function test was also normal (","suffix":" 1.42 μU/ml). As the patient remained asymptomatic, and the ","exact":"thyroid-stimulating hormone"},{"setid":"PMC3571969","drugname":"gemfibrozil","startOffset":216,"endOffset":227,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[14]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[14]","prefix":" cause of it was probably the atrovastatin as compared with ","suffix":", fenofibrate were found to be less prone to make complicati","exact":"gemfibrozil"},{"setid":"PMC3571969","drugname":"ethanol","startOffset":254,"endOffset":261,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[16]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[16]","prefix":"-induced statin-myopathy as in low amounts (12.7-38.1 ml of ","suffix":" per day in men) it was not found to be harmful [","exact":"ethanol"}],[{"setid":"PMC2602841","drugname":"sitagliptin","startOffset":208,"endOffset":219,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"ess, and tenderness after starting treatment with high dose ","suffix":" while on simvastatin. The patient had acute renal failure a","exact":"sitagliptin"},{"setid":"PMC2602841","drugname":"sitagliptin","startOffset":330,"endOffset":341,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"failure and rhabdomyolysis which resolved with cessation of ","suffix":", simvastatin, ezetimibe, diuretics and olmesartan. All drug","exact":"sitagliptin"},{"setid":"PMC2602841","drugname":"sitagliptin","startOffset":410,"endOffset":421,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"atin, ezetimibe, diuretics and olmesartan. All drugs except ","suffix":" and ezetimibe, simvastatin were resumed, and the patient wa","exact":"sitagliptin"},{"setid":"PMC2602841","drugname":"sitagliptin","startOffset":208,"endOffset":219,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"ess, and tenderness after starting treatment with high dose ","suffix":" while on simvastatin. The patient had acute renal failure a","exact":"sitagliptin"},{"setid":"PMC2602841","drugname":"sitagliptin","startOffset":330,"endOffset":341,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"failure and rhabdomyolysis which resolved with cessation of ","suffix":", simvastatin, ezetimibe, diuretics and olmesartan. All drug","exact":"sitagliptin"},{"setid":"PMC2602841","drugname":"sitagliptin","startOffset":410,"endOffset":421,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"atin, ezetimibe, diuretics and olmesartan. All drugs except ","suffix":" and ezetimibe, simvastatin were resumed, and the patient wa","exact":"sitagliptin"},{"setid":"PMC2602841","drugname":"sitagliptin","startOffset":79,"endOffset":90,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"                                              High doses of ","suffix":" may have worsened this patient's renal failure and precipit","exact":"sitagliptin"},{"setid":"PMC2602841","drugname":"sitagliptin","startOffset":250,"endOffset":261,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"ating levels of simvastatin. Given the high likelihood that ","suffix":" will be co-administered with statins and renally active med","exact":"sitagliptin"},{"setid":"PMC2602841","drugname":"sitagliptin","startOffset":368,"endOffset":379,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"ly active medications, further study of long-term safety of ","suffix":" in renal sufficiency may be warranted.                     ","exact":"sitagliptin"},{"setid":"PMC2602841","drugname":"sitagliptin","startOffset":416,"endOffset":427,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"reased glucagon production. The most common side effects of ","suffix":" include headache and pharyngitis, and few serious adverse e","exact":"sitagliptin"},{"setid":"PMC2602841","drugname":"sitagliptin","startOffset":880,"endOffset":891,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":" in renal insufficiency. Single dose studies suggested that ","suffix":" may be used in the setting of renal insufficiency, but data","exact":"sitagliptin"},{"setid":"PMC2602841","drugname":"sitagliptin","startOffset":1150,"endOffset":1161,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"al failure and rhabdomyolysis after starting treatment with ","suffix":".                                                     ","exact":"sitagliptin"},{"setid":"PMC2602841","drugname":"sitagliptin","startOffset":673,"endOffset":684,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","prefix":"ibe 10 mg daily was added without incident. He began taking ","suffix":" 50 mg daily 6 weeks prior to presentation, increasing his d","exact":"sitagliptin"},{"setid":"PMC2602841","drugname":"sitagliptin","startOffset":798,"endOffset":809,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","prefix":" his dose 3 weeks later to 100 mg daily. One week after the ","suffix":" dose was increased, he noted the onset of pain and tenderne","exact":"sitagliptin"},{"setid":"PMC2602841","drugname":"sitagliptin","startOffset":1287,"endOffset":1298,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","prefix":"cute renal failure, and olmesartan, bumetanide, metolazone, ","suffix":", simvastatin, and ezetimibe were all stopped. His creatine ","exact":"sitagliptin"},{"setid":"PMC2602841","drugname":"sitagliptin","startOffset":1522,"endOffset":1533,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","prefix":" resumed all medications except simvastatin, ezetimibe, and ","suffix":". He later started lovastatin which was increased to a dose ","exact":"sitagliptin"},{"setid":"PMC2602841","drugname":"sitagliptin","startOffset":113,"endOffset":124,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":"    Rhabdomyolysis was not reported in clinical trials with ","suffix":", although it is a well-documented side effect of statins. T","exact":"sitagliptin"},{"setid":"PMC2602841","drugname":"sitagliptin","startOffset":402,"endOffset":413,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":"of myopathy. At presentation, the patient was taking 100 mg ","suffix":", double the recommended dose given his renal function. (","exact":"sitagliptin"},{"setid":"PMC2602841","drugname":"sitagliptin","startOffset":76,"endOffset":87,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","prefix":"                                         The association of ","suffix":" and renal insufficiency in this case is classified as \"poss","exact":"sitagliptin"},{"setid":"PMC2602841","drugname":"sitagliptin","startOffset":487,"endOffset":498,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","prefix":"uggesting that this event was precipitated by initiation of ","suffix":" therapy.                                                   ","exact":"sitagliptin"},{"setid":"PMC2602841","drugname":"sitagliptin","startOffset":88,"endOffset":99,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","prefix":"                             Given the high likelihood that ","suffix":" will be co-administered with renally active drugs and stati","exact":"sitagliptin"},{"setid":"PMC2602841","drugname":"sitagliptin","startOffset":268,"endOffset":279,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","prefix":"t that additional studies regarding the long-term safety of ","suffix":" in renal insufficiency may be warranted.                   ","exact":"sitagliptin"},{"setid":"PMC2602841","drugname":"sitagliptin","startOffset":65,"endOffset":76,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","prefix":"                                                            ","suffix":" is a new oral glucose lowering medication which acts via th","exact":"Sitagliptin"},{"setid":"PMC2602841","drugname":"sitagliptin","startOffset":57,"endOffset":68,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"                                                         ","suffix":", a new oral glucose lowering medication, is already used wi","exact":"Sitagliptin"},{"setid":"PMC2602841","drugname":"simvastatin","startOffset":229,"endOffset":240,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"fter starting treatment with high dose sitagliptin while on ","suffix":". The patient had acute renal failure and rhabdomyolysis whi","exact":"simvastatin"},{"setid":"PMC2602841","drugname":"simvastatin","startOffset":343,"endOffset":354,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"habdomyolysis which resolved with cessation of sitagliptin, ","suffix":", ezetimibe, diuretics and olmesartan. All drugs except sita","exact":"simvastatin"},{"setid":"PMC2602841","drugname":"simvastatin","startOffset":437,"endOffset":448,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"and olmesartan. All drugs except sitagliptin and ezetimibe, ","suffix":" were resumed, and the patient was subsequently started on l","exact":"simvastatin"},{"setid":"PMC2602841","drugname":"simvastatin","startOffset":206,"endOffset":217,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"ipitated rhabdomyolysis by increasing circulating levels of ","suffix":". Given the high likelihood that sitagliptin will be co-admi","exact":"simvastatin"},{"setid":"PMC2602841","drugname":"simvastatin","startOffset":477,"endOffset":488,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","prefix":"tolazone, amiodarone, bumetanide, glipizide, levothyroxine, ","suffix":", and ezetimibe. Four months prior to presentation, his simv","exact":"simvastatin"},{"setid":"PMC2602841","drugname":"simvastatin","startOffset":544,"endOffset":555,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","prefix":"atin, and ezetimibe. Four months prior to presentation, his ","suffix":" dose had been increased from 40 to 80 mg daily and ezetimib","exact":"simvastatin"},{"setid":"PMC2602841","drugname":"simvastatin","startOffset":1300,"endOffset":1311,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","prefix":"ilure, and olmesartan, bumetanide, metolazone, sitagliptin, ","suffix":", and ezetimibe were all stopped. His creatine kinase levels","exact":"simvastatin"},{"setid":"PMC2602841","drugname":"simvastatin","startOffset":1494,"endOffset":1505,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","prefix":"o baseline within 7 days. He resumed all medications except ","suffix":", ezetimibe, and sitagliptin. He later started lovastatin wh","exact":"simvastatin"},{"setid":"PMC2602841","drugname":"simvastatin","startOffset":229,"endOffset":240,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"fter starting treatment with high dose sitagliptin while on ","suffix":". The patient had acute renal failure and rhabdomyolysis whi","exact":"simvastatin"},{"setid":"PMC2602841","drugname":"simvastatin","startOffset":343,"endOffset":354,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"habdomyolysis which resolved with cessation of sitagliptin, ","suffix":", ezetimibe, diuretics and olmesartan. All drugs except sita","exact":"simvastatin"},{"setid":"PMC2602841","drugname":"simvastatin","startOffset":437,"endOffset":448,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"and olmesartan. All drugs except sitagliptin and ezetimibe, ","suffix":" were resumed, and the patient was subsequently started on l","exact":"simvastatin"},{"setid":"PMC2602841","drugname":"simvastatin","startOffset":206,"endOffset":217,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"ipitated rhabdomyolysis by increasing circulating levels of ","suffix":". Given the high likelihood that sitagliptin will be co-admi","exact":"simvastatin"},{"setid":"PMC2602841","drugname":"simvastatin","startOffset":477,"endOffset":488,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","prefix":"tolazone, amiodarone, bumetanide, glipizide, levothyroxine, ","suffix":", and ezetimibe. Four months prior to presentation, his simv","exact":"simvastatin"},{"setid":"PMC2602841","drugname":"simvastatin","startOffset":544,"endOffset":555,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","prefix":"atin, and ezetimibe. Four months prior to presentation, his ","suffix":" dose had been increased from 40 to 80 mg daily and ezetimib","exact":"simvastatin"},{"setid":"PMC2602841","drugname":"simvastatin","startOffset":1300,"endOffset":1311,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","prefix":"ilure, and olmesartan, bumetanide, metolazone, sitagliptin, ","suffix":", and ezetimibe were all stopped. His creatine kinase levels","exact":"simvastatin"},{"setid":"PMC2602841","drugname":"simvastatin","startOffset":1494,"endOffset":1505,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","prefix":"o baseline within 7 days. He resumed all medications except ","suffix":", ezetimibe, and sitagliptin. He later started lovastatin wh","exact":"simvastatin"},{"setid":"PMC2602841","drugname":"simvastatin","startOffset":311,"endOffset":322,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","prefix":"s had been stable for months, and the patient had tolerated ","suffix":" and ezetemibe for at least 4 months prior to the onset of s","exact":"simvastatin"},{"setid":"PMC2602841","drugname":"ezetimibe","startOffset":356,"endOffset":365,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":" which resolved with cessation of sitagliptin, simvastatin, ","suffix":", diuretics and olmesartan. All drugs except sitagliptin and","exact":"ezetimibe"},{"setid":"PMC2602841","drugname":"ezetimibe","startOffset":426,"endOffset":435,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":" diuretics and olmesartan. All drugs except sitagliptin and ","suffix":", simvastatin were resumed, and the patient was subsequently","exact":"ezetimibe"},{"setid":"PMC2602841","drugname":"ezetimibe","startOffset":494,"endOffset":503,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","prefix":"one, bumetanide, glipizide, levothyroxine, simvastatin, and ","suffix":". Four months prior to presentation, his simvastatin dose ha","exact":"ezetimibe"},{"setid":"PMC2602841","drugname":"ezetimibe","startOffset":607,"endOffset":616,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","prefix":"vastatin dose had been increased from 40 to 80 mg daily and ","suffix":" 10 mg daily was added without incident. He began taking sit","exact":"ezetimibe"},{"setid":"PMC2602841","drugname":"ezetimibe","startOffset":1317,"endOffset":1326,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","prefix":"rtan, bumetanide, metolazone, sitagliptin, simvastatin, and ","suffix":" were all stopped. His creatine kinase levels fell, his symp","exact":"ezetimibe"},{"setid":"PMC2602841","drugname":"ezetimibe","startOffset":1507,"endOffset":1516,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","prefix":"thin 7 days. He resumed all medications except simvastatin, ","suffix":", and sitagliptin. He later started lovastatin which was inc","exact":"ezetimibe"},{"setid":"PMC2602841","drugname":"olmesartan","startOffset":381,"endOffset":391,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"ation of sitagliptin, simvastatin, ezetimibe, diuretics and ","suffix":". All drugs except sitagliptin and ezetimibe, simvastatin we","exact":"olmesartan"},{"setid":"PMC2602841","drugname":"olmesartan","startOffset":382,"endOffset":392,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","prefix":" 204 μmol/L. His medications included aspirin, clopidogrel, ","suffix":", carvedilol, insulin, metolazone, amiodarone, bumetanide, g","exact":"olmesartan"},{"setid":"PMC2602841","drugname":"olmesartan","startOffset":1251,"endOffset":1261,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","prefix":"o hospital with rhabdomyolysis and acute renal failure, and ","suffix":", bumetanide, metolazone, sitagliptin, simvastatin, and ezet","exact":"olmesartan"},{"setid":"PMC2602841","drugname":"lovastatin","startOffset":507,"endOffset":517,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"n were resumed, and the patient was subsequently started on ","suffix":" without recurrence of rhabdomyolysis.                      ","exact":"lovastatin"},{"setid":"PMC2602841","drugname":"lovastatin","startOffset":1552,"endOffset":1562,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","prefix":"t simvastatin, ezetimibe, and sitagliptin. He later started ","suffix":" which was increased to a dose of 10 mg daily without recurr","exact":"lovastatin"},{"setid":"PMC2602841","drugname":"glucagon","startOffset":272,"endOffset":280,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":" IV enzyme thereby prolonging the post-prandial activity of ","suffix":"-like-peptide-1 (GLP-1). This results in increased insulin s","exact":"glucagon"},{"setid":"PMC2602841","drugname":"glucagon","startOffset":363,"endOffset":371,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":". This results in increased insulin secretion and decreased ","suffix":" production. The most common side effects of sitagliptin inc","exact":"glucagon"},{"setid":"PMC2602841","drugname":"insulin","startOffset":331,"endOffset":338,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":" glucagon-like-peptide-1 (GLP-1). This results in increased ","suffix":" secretion and decreased glucagon production. The most commo","exact":"insulin"},{"setid":"PMC2602841","drugname":"insulin","startOffset":406,"endOffset":413,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","prefix":"ions included aspirin, clopidogrel, olmesartan, carvedilol, ","suffix":", metolazone, amiodarone, bumetanide, glipizide, levothyroxi","exact":"insulin"},{"setid":"PMC2602841","drugname":"vildagliptin","startOffset":717,"endOffset":729,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":" organ of toxicity, and approval of its nearest competitor, ","suffix":", by the Federal Drug Administration (FDA) has been delayed ","exact":"vildagliptin"},{"setid":"PMC2602841","drugname":"creatinine","startOffset":309,"endOffset":319,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","prefix":"al fibrillation, and chronic kidney disease with a baseline ","suffix":" of 204 μmol/L. His medications included aspirin, clopidogre","exact":"creatinine"},{"setid":"PMC2602841","drugname":"creatinine","startOffset":1109,"endOffset":1119,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","prefix":"les in both legs. Laboratory tests revealed urea 43 mmol/L, ","suffix":" 398 μmol/L, and creatine kinase 22,000 IU/L. The patient wa","exact":"creatinine"},{"setid":"PMC2602841","drugname":"aspirin","startOffset":360,"endOffset":367,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","prefix":"baseline creatinine of 204 μmol/L. His medications included ","suffix":", clopidogrel, olmesartan, carvedilol, insulin, metolazone, ","exact":"aspirin"},{"setid":"PMC2602841","drugname":"clopidogrel","startOffset":369,"endOffset":380,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","prefix":"creatinine of 204 μmol/L. His medications included aspirin, ","suffix":", olmesartan, carvedilol, insulin, metolazone, amiodarone, b","exact":"clopidogrel"},{"setid":"PMC2602841","drugname":"carvedilol","startOffset":394,"endOffset":404,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","prefix":" His medications included aspirin, clopidogrel, olmesartan, ","suffix":", insulin, metolazone, amiodarone, bumetanide, glipizide, le","exact":"carvedilol"},{"setid":"PMC2602841","drugname":"metolazone","startOffset":415,"endOffset":425,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","prefix":"uded aspirin, clopidogrel, olmesartan, carvedilol, insulin, ","suffix":", amiodarone, bumetanide, glipizide, levothyroxine, simvasta","exact":"metolazone"},{"setid":"PMC2602841","drugname":"metolazone","startOffset":1275,"endOffset":1285,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","prefix":"olysis and acute renal failure, and olmesartan, bumetanide, ","suffix":", sitagliptin, simvastatin, and ezetimibe were all stopped. ","exact":"metolazone"},{"setid":"PMC2602841","drugname":"amiodarone","startOffset":427,"endOffset":437,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","prefix":", clopidogrel, olmesartan, carvedilol, insulin, metolazone, ","suffix":", bumetanide, glipizide, levothyroxine, simvastatin, and eze","exact":"amiodarone"},{"setid":"PMC2602841","drugname":"bumetanide","startOffset":439,"endOffset":449,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","prefix":"l, olmesartan, carvedilol, insulin, metolazone, amiodarone, ","suffix":", glipizide, levothyroxine, simvastatin, and ezetimibe. Four","exact":"bumetanide"},{"setid":"PMC2602841","drugname":"bumetanide","startOffset":1263,"endOffset":1273,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","prefix":"ith rhabdomyolysis and acute renal failure, and olmesartan, ","suffix":", metolazone, sitagliptin, simvastatin, and ezetimibe were a","exact":"bumetanide"},{"setid":"PMC2602841","drugname":"glipizide","startOffset":451,"endOffset":460,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","prefix":"n, carvedilol, insulin, metolazone, amiodarone, bumetanide, ","suffix":", levothyroxine, simvastatin, and ezetimibe. Four months pri","exact":"glipizide"},{"setid":"PMC2602841","drugname":"levothyroxine","startOffset":462,"endOffset":475,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","prefix":"ol, insulin, metolazone, amiodarone, bumetanide, glipizide, ","suffix":", simvastatin, and ezetimibe. Four months prior to presentat","exact":"levothyroxine"},{"setid":"PMC2602841","drugname":"urea","startOffset":1093,"endOffset":1097,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","prefix":"he proximal muscles in both legs. Laboratory tests revealed ","suffix":" 43 mmol/L, creatinine 398 μmol/L, and creatine kinase 22,00","exact":"urea"}],[{"setid":"PMC3477350","drugname":"rifampicin","startOffset":219,"endOffset":229,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"ived a single dose of dabigatran etexilate 150 mg on day 1, ","suffix":" 600 mg once daily on days 2-8, and single doses of dabigatr","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":279,"endOffset":289,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":" administration of dabigatran etexilate following 7 days of ","suffix":" (treatment B) decreased the geometric mean (gMean) area und","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":134,"endOffset":144,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","prefix":"y examined the effects of the CYP3A/P-glycoprotein inducer, ","suffix":", on the pharmacokinetics of dabigatran following oral admin","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":219,"endOffset":229,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"ived a single dose of dabigatran etexilate 150 mg on day 1, ","suffix":" 600 mg once daily on days 2-8, and single doses of dabigatr","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":279,"endOffset":289,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":" administration of dabigatran etexilate following 7 days of ","suffix":" (treatment B) decreased the geometric mean (gMean) area und","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":83,"endOffset":93,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","prefix":"                                          Administration of ","suffix":" for 7 days resulted in a significant reduction in the bioav","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":81,"endOffset":91,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[4]","prefix":"                                    The antibacterial agent ","suffix":" (used primarily in the treatment of tuberculosis) is a stro","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":156,"endOffset":166,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","prefix":"to determine whether, and to what extent, the P-gp inducer, ","suffix":", affects the plasma exposure of dabigatran by investigating","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":259,"endOffset":269,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","prefix":"dabigatran by investigating the effect of multiple doses of ","suffix":" 600 mg once daily on the PK parameters of dabigatran follow","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":550,"endOffset":560,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","prefix":"preted as normal activity levels of P-gp after induction by ","suffix":". The doses selected for investigation reflect standard clin","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":634,"endOffset":644,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","prefix":"lected for investigation reflect standard clinical doses of ","suffix":" and dabigatran etexilate, and were expected to allow an ade","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":798,"endOffset":808,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","prefix":"meters of dabigatran after P-gp induction. The induction by ","suffix":" was to be confirmed further by measurement of a surrogate e","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":146,"endOffset":156,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[6]","prefix":" to determine the safety and tolerability of dabigatran and ","suffix":" coadministration, and to determine the duration of the effe","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":256,"endOffset":266,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[6]","prefix":"duration of the effect of P-gp induction after cessation of ","suffix":" treatment. If an interaction between rifampicin and dabigat","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":304,"endOffset":314,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[6]","prefix":"essation of rifampicin treatment. If an interaction between ","suffix":" and dabigatran was observed, it was expected that this woul","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":302,"endOffset":312,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","prefix":"en as single doses, either alone or after multiple doses of ","suffix":", or after cessation of rifampicin. Twenty-four subjects wer","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":336,"endOffset":346,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","prefix":"r after multiple doses of rifampicin, or after cessation of ","suffix":". Twenty-four subjects were to be enrolled, with at least ei","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":260,"endOffset":270,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[2]","prefix":"al or hormonal disorders, risk of bleeding, previous use of ","suffix":" or other P-gp or CYP450 inhibitors/inducers within 4 weeks ","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":205,"endOffset":215,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","prefix":"exilate 150 mg after 7 days of washout since last intake of ","suffix":" 600 mg) and reference treatment A, and between treatment D ","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":366,"endOffset":376,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","prefix":"ilate 150 mg after 14 days washout after the last intake of ","suffix":" 600 mg) and reference treatment A.                         ","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":450,"endOffset":460,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[6]","prefix":"n in the morning after subjects had received three doses of ","suffix":" during treatment B and before administration of dabigatran ","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":167,"endOffset":177,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[2]","prefix":"n etexilate alone), the administration of the P-gp inducer, ","suffix":", over 7 days (treatment B) resulted in a significant reduct","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":157,"endOffset":167,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[4]","prefix":"tran etexilate after a 7 day washout after the last dose of ","suffix":" (treatment C, day 16), AUC","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":307,"endOffset":317,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/p[1]","prefix":" 22.0 (48.5), indicating CYP450 3A induction as a result of ","suffix":" administration. The urinary 6β-hydroxycortisol/cortisol rat","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":511,"endOffset":521,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/p[1]","prefix":"baseline by day 23, 2 weeks after the end of treatment with ","suffix":".                                                         ","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":223,"endOffset":233,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[2]","prefix":"%) subjects during treatment with dabigatran etexilate plus ","suffix":" and two (8.3%) subjects during treatment with rifampicin al","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":280,"endOffset":290,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[2]","prefix":"us rifampicin and two (8.3%) subjects during treatment with ","suffix":" alone (","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":182,"endOffset":192,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[3]","prefix":"s, with headache the most common (dabigatran, two subjects; ","suffix":", one subject; and dabigatran plus rifampicin, three subject","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":227,"endOffset":237,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[3]","prefix":" two subjects; rifampicin, one subject; and dabigatran plus ","suffix":", three subjects). No other AEs were reported during treatme","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":419,"endOffset":429,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[3]","prefix":"hyperhidrosis (one subject each) during the dabigatran plus ","suffix":" period; dizziness, nausea, oropharyngeal pain, vomiting and","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":528,"endOffset":538,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[3]","prefix":"al pain, vomiting and fatigue (one subject each) during the ","suffix":" alone period; and nausea (one subject) during the washout a","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":94,"endOffset":104,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","prefix":"                       In this study, the administration of ","suffix":" for 7 days resulted in a significant and relevant reduction","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":79,"endOffset":89,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","prefix":"                                      In the present trial, ","suffix":" administration also induced CYP3A, as shown by an elevated ","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":110,"endOffset":120,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","prefix":"       The reduction of the total dabigatran exposure after ","suffix":" pretreatment seen in this trial was of similar magnitude or","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":153,"endOffset":163,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[6]","prefix":"e absorbed mainly in the duodenum. The pronounced effect of ","suffix":" on dabigatran kinetics might, thus, be due to a remarkable ","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":295,"endOffset":305,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[6]","prefix":"duodenal P-gp expression (about a threefold increase) after ","suffix":", as reported ","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":199,"endOffset":209,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[8]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[8]","prefix":"was well tolerated when given alone and in combination with ","suffix":". The results were in line with the known safety profile of ","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":132,"endOffset":142,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","prefix":"two-thirds in dabigatran exposure due to a 1 week course of ","suffix":" has clinically relevant consequences. Patients undergoing o","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":378,"endOffset":388,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","prefix":"rapeutic concentrations of dabigatran if they have received ","suffix":" immediately before surgery. Dabigatran etexilate is also in","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":91,"endOffset":101,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","prefix":"                          In summary, the administration of ","suffix":", a P-gp inducer, for 7 days resulted in a statistically sig","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":349,"endOffset":359,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","prefix":"ealthy volunteers. Within 7 days following the cessation of ","suffix":" administration, the bioavailability returned almost to base","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":500,"endOffset":510,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","prefix":" the potential for reduced systemic exposure to dabigatran, ","suffix":" and other P-gp inducers (e.g. carbamazepine and St John's w","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":203,"endOffset":213,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[2]","prefix":"inistered as 150 mg hydroxypropyl methylcellulose capsules. ","suffix":" was administered as the commercially available Rifa® 600 mg","exact":"Rifampicin"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":173,"endOffset":183,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","prefix":"lycoprotein inducer, rifampicin, on the pharmacokinetics of ","suffix":" following oral administration of the prodrug, dabigatran et","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":173,"endOffset":183,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","prefix":"lycoprotein inducer, rifampicin, on the pharmacokinetics of ","suffix":" following oral administration of the prodrug, dabigatran et","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":230,"endOffset":240,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","prefix":"of dabigatran following oral administration of the prodrug, ","suffix":" etexilate.                                                 ","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":181,"endOffset":191,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"y in healthy volunteers. Subjects received a single dose of ","suffix":" etexilate 150 mg on day 1, rifampicin 600 mg once daily on ","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":281,"endOffset":291,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"fampicin 600 mg once daily on days 2-8, and single doses of ","suffix":" etexilate on days 9, 16 and 23.                            ","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":178,"endOffset":188,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"d all treatments. Relative to the reference (single dose of ","suffix":" etexilate alone; treatment A), administration of dabigatran","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":238,"endOffset":248,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"dabigatran etexilate alone; treatment A), administration of ","suffix":" etexilate following 7 days of rifampicin (treatment B) decr","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":167,"endOffset":177,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","prefix":"sulted in a significant reduction in the bioavailability of ","suffix":", which returned almost to baseline after 7 days washout.   ","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":198,"endOffset":208,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":"diates, BIBR 1087 SE and BIBR 951 BS, to the active moiety, ","suffix":", a direct and reversible thrombin inhibitor. Dabigatran is ","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":374,"endOffset":384,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":"id to form a pharmacologically equipotent glucuronide. Free ","suffix":" and total dabigatran (sum of free and glucuronidated dabiga","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":395,"endOffset":405,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":"logically equipotent glucuronide. Free dabigatran and total ","suffix":" (sum of free and glucuronidated dabigatran) reach peak plas","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":438,"endOffset":448,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":"gatran and total dabigatran (sum of free and glucuronidated ","suffix":") reach peak plasma concentrations after approximately 1.5 h","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":82,"endOffset":92,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","prefix":"                                   Dabigatran etexilate and ","suffix":" are not metabolized by the cytochrome P450 (CYP) system, an","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":154,"endOffset":164,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","prefix":"re not metabolized by the cytochrome P450 (CYP) system, and ","suffix":" does not affect the metabolism of other drugs that utilize ","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":199,"endOffset":209,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","prefix":"he P-gp inducer, rifampicin, affects the plasma exposure of ","suffix":" by investigating the effect of multiple doses of rifampicin","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":312,"endOffset":322,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","prefix":"ses of rifampicin 600 mg once daily on the PK parameters of ","suffix":" following a single dose of 150 mg dabigatran etexilate. The","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":357,"endOffset":367,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","prefix":" parameters of dabigatran following a single dose of 150 mg ","suffix":" etexilate. The study also evaluated the time course of a re","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":458,"endOffset":468,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","prefix":"uated the time course of a return to normal availability of ","suffix":", which could be interpreted as normal activity levels of P-","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":649,"endOffset":659,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","prefix":"stigation reflect standard clinical doses of rifampicin and ","suffix":" etexilate, and were expected to allow an adequate determina","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":748,"endOffset":758,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","prefix":" to allow an adequate determination of the PK parameters of ","suffix":" after P-gp induction. The induction by rifampicin was to be","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":131,"endOffset":141,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[6]","prefix":"objectives were to determine the safety and tolerability of ","suffix":" and rifampicin coadministration, and to determine the durat","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":319,"endOffset":329,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[6]","prefix":"ampicin treatment. If an interaction between rifampicin and ","suffix":" was observed, it was expected that this would lead to decre","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":394,"endOffset":404,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[6]","prefix":"observed, it was expected that this would lead to decreased ","suffix":" exposure.                                                  ","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":218,"endOffset":228,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","prefix":"ale subjects to investigate the relative bioavailability of ","suffix":" etexilate given as single doses, either alone or after mult","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":104,"endOffset":114,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[3]","prefix":"                 The subjects received single oral doses of ","suffix":" etexilate (150 mg), always in the morning at 08.00 h, durin","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":169,"endOffset":179,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[4]","prefix":"between days −21 and −1. Washout periods between subsequent ","suffix":" etexilate doses were included between the study days (days ","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":132,"endOffset":142,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","prefix":"parisons were performed between treatment C (single dose of ","suffix":" etexilate 150 mg after 7 days of washout since last intake ","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":291,"endOffset":301,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","prefix":"erence treatment A, and between treatment D (single dose of ","suffix":" etexilate 150 mg after 14 days washout after the last intak","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":79,"endOffset":89,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":"                                          Blood samples for ","suffix":" PK measurements were collected before (−0.5 h) and at 0.5, ","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":240,"endOffset":250,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":"24 and 34 h after administration of a single dose of 150 mg ","suffix":" etexilate in each treatment period. Plasma concentrations o","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":332,"endOffset":342,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":"atment period. Plasma concentrations of free, nonconjugated ","suffix":", total dabigatran [sum of free and conjugated dabigatran (m","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":350,"endOffset":360,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":"sma concentrations of free, nonconjugated dabigatran, total ","suffix":" [sum of free and conjugated dabigatran (measured after alka","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":389,"endOffset":399,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":"ed dabigatran, total dabigatran [sum of free and conjugated ","suffix":" (measured after alkaline cleavage of conjugates)], the prod","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":464,"endOffset":474,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":"sured after alkaline cleavage of conjugates)], the prodrug, ","suffix":" etexilate, and the intermediate metabolites, BIBR 1087 SE a","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":169,"endOffset":179,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[2]","prefix":" 2000g-4000g for 10 minutes); for the determination of free ","suffix":", 50 µl of plasma was aliquoted, diluted with 50 µl 0.2 ","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":113,"endOffset":123,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[4]","prefix":"        The lowest limit of quantification of free or total ","suffix":" was 1 ng ml","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":80,"endOffset":90,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[5]","prefix":"                                         In addition, total ","suffix":" urine concentrations were measured. The calibration range w","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":509,"endOffset":519,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[6]","prefix":" rifampicin during treatment B and before administration of ","suffix":" in each respective treatment period. Thus, morning spot uri","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":132,"endOffset":142,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[1]","prefix":"of the plasma concentration-time profiles of free and total ","suffix":" were highly comparable, as shown in ","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":98,"endOffset":108,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[2]","prefix":"                       Relative to the reference treatment (","suffix":" etexilate alone), the administration of the P-gp inducer, r","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":266,"endOffset":276,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[2]","prefix":"esulted in a significant reduction in the exposure to total ","suffix":" (67% reduction in AUC","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":91,"endOffset":101,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[4]","prefix":"                              For the single dose of 150 mg ","suffix":" etexilate after a 7 day washout after the last dose of rifa","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":87,"endOffset":97,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[6]","prefix":"                                  The PK parameters of free ","suffix":" followed the same trend as those of total dabigatran (","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":140,"endOffset":150,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[6]","prefix":"f free dabigatran followed the same trend as those of total ","suffix":" (","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":125,"endOffset":135,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[2]","prefix":" two (8.3%) subjects reported any AEs during treatment with ","suffix":" etexilate alone, four (16.7%) subjects during treatment wit","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":197,"endOffset":207,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[2]","prefix":"texilate alone, four (16.7%) subjects during treatment with ","suffix":" etexilate plus rifampicin and two (8.3%) subjects during tr","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":156,"endOffset":166,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[3]","prefix":"re nervous system disorders, with headache the most common (","suffix":", two subjects; rifampicin, one subject; and dabigatran plus","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":211,"endOffset":221,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[3]","prefix":"mon (dabigatran, two subjects; rifampicin, one subject; and ","suffix":" plus rifampicin, three subjects). No other AEs were reporte","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":305,"endOffset":315,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[3]","prefix":"subjects). No other AEs were reported during treatment with ","suffix":" alone. Other AEs reported were vertigo and hyperhidrosis (o","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":403,"endOffset":413,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[3]","prefix":"ere vertigo and hyperhidrosis (one subject each) during the ","suffix":" plus rifampicin period; dizziness, nausea, oropharyngeal pa","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":100,"endOffset":110,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":"                 Preclinical investigations have shown that ","suffix":" etexilate (but not dabigatran or its intermediate metabolit","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":130,"endOffset":140,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":"nvestigations have shown that dabigatran etexilate (but not ","suffix":" or its intermediate metabolites) is a substrate for the eff","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":290,"endOffset":300,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":"Previous investigations suggest that the bioavailability of ","suffix":" may be affected by P-gp inhibitors [","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":70,"endOffset":80,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"                                               The approved ","suffix":" etexilate dose for stroke prevention in patients with atria","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":197,"endOffset":207,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","prefix":"cant and relevant reduction in the bioavailability of total ","suffix":" (67 and 65.5% reduction in AUC","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":84,"endOffset":94,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","prefix":"                                 The reduction of the total ","suffix":" exposure after rifampicin pretreatment seen in this trial w","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":167,"endOffset":177,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[6]","prefix":"nly in the duodenum. The pronounced effect of rifampicin on ","suffix":" kinetics might, thus, be due to a remarkable increase in du","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":269,"endOffset":279,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[8]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[8]","prefix":". The results were in line with the known safety profile of ","suffix":" etexilate.                                                 ","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":86,"endOffset":96,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","prefix":"                               A reduction of two-thirds in ","suffix":" exposure due to a 1 week course of rifampicin has clinicall","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":233,"endOffset":243,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","prefix":"uences. Patients undergoing orthopaedic surgery who receive ","suffix":" etexilate for the prevention of venous thromboembolism may ","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":345,"endOffset":355,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","prefix":"romboembolism may not achieve therapeutic concentrations of ","suffix":" if they have received rifampicin immediately before surgery","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":581,"endOffset":591,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","prefix":"dose-response in stroke reduction has been demonstrated for ","suffix":" etexilate [","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":264,"endOffset":274,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","prefix":"t reduction in the bioavailability of a single oral dose of ","suffix":" etexilate in healthy volunteers. Within 7 days following th","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":488,"endOffset":498,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","prefix":"es. Owing to the potential for reduced systemic exposure to ","suffix":", rifampicin and other P-gp inducers (e.g. carbamazepine and","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":608,"endOffset":618,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","prefix":"zepine and St John's wort) are not recommended for use with ","suffix":" etexilate [","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":254,"endOffset":264,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":"ty, dabigatran, a direct and reversible thrombin inhibitor. ","suffix":" is partly conjugated with activated glucuronic acid to form","exact":"Dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":230,"endOffset":250,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","prefix":"of dabigatran following oral administration of the prodrug, ","suffix":".                                                           ","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":181,"endOffset":201,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"y in healthy volunteers. Subjects received a single dose of ","suffix":" 150 mg on day 1, rifampicin 600 mg once daily on days 2-8, ","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":281,"endOffset":301,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"fampicin 600 mg once daily on days 2-8, and single doses of ","suffix":" on days 9, 16 and 23.                                      ","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":178,"endOffset":198,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"d all treatments. Relative to the reference (single dose of ","suffix":" alone; treatment A), administration of dabigatran etexilate","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":238,"endOffset":258,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"dabigatran etexilate alone; treatment A), administration of ","suffix":" following 7 days of rifampicin (treatment B) decreased the ","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":357,"endOffset":377,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","prefix":" parameters of dabigatran following a single dose of 150 mg ","suffix":". The study also evaluated the time course of a return to no","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":649,"endOffset":669,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","prefix":"stigation reflect standard clinical doses of rifampicin and ","suffix":", and were expected to allow an adequate determination of th","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":218,"endOffset":238,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","prefix":"ale subjects to investigate the relative bioavailability of ","suffix":" given as single doses, either alone or after multiple doses","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":104,"endOffset":124,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[3]","prefix":"                 The subjects received single oral doses of ","suffix":" (150 mg), always in the morning at 08.00 h, during the foll","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":169,"endOffset":189,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[4]","prefix":"between days −21 and −1. Washout periods between subsequent ","suffix":" doses were included between the study days (days 1, 9, 16 a","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":132,"endOffset":152,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","prefix":"parisons were performed between treatment C (single dose of ","suffix":" 150 mg after 7 days of washout since last intake of rifampi","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":291,"endOffset":311,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","prefix":"erence treatment A, and between treatment D (single dose of ","suffix":" 150 mg after 14 days washout after the last intake of rifam","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":240,"endOffset":260,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":"24 and 34 h after administration of a single dose of 150 mg ","suffix":" in each treatment period. Plasma concentrations of free, no","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":464,"endOffset":484,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":"sured after alkaline cleavage of conjugates)], the prodrug, ","suffix":", and the intermediate metabolites, BIBR 1087 SE and BIBR 95","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":98,"endOffset":118,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[2]","prefix":"                       Relative to the reference treatment (","suffix":" alone), the administration of the P-gp inducer, rifampicin,","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":91,"endOffset":111,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[4]","prefix":"                              For the single dose of 150 mg ","suffix":" after a 7 day washout after the last dose of rifampicin (tr","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":125,"endOffset":145,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[2]","prefix":" two (8.3%) subjects reported any AEs during treatment with ","suffix":" alone, four (16.7%) subjects during treatment with dabigatr","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":197,"endOffset":217,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[2]","prefix":"texilate alone, four (16.7%) subjects during treatment with ","suffix":" plus rifampicin and two (8.3%) subjects during treatment wi","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":100,"endOffset":120,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":"                 Preclinical investigations have shown that ","suffix":" (but not dabigatran or its intermediate metabolites) is a s","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":70,"endOffset":90,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"                                               The approved ","suffix":" dose for stroke prevention in patients with atrial fibrilla","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":269,"endOffset":289,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[8]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[8]","prefix":". The results were in line with the known safety profile of ","suffix":".                                                     ","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":233,"endOffset":253,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","prefix":"uences. Patients undergoing orthopaedic surgery who receive ","suffix":" for the prevention of venous thromboembolism may not achiev","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":581,"endOffset":601,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","prefix":"dose-response in stroke reduction has been demonstrated for ","suffix":" [","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":264,"endOffset":284,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","prefix":"t reduction in the bioavailability of a single oral dose of ","suffix":" in healthy volunteers. Within 7 days following the cessatio","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":608,"endOffset":628,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","prefix":"zepine and St John's wort) are not recommended for use with ","suffix":" [","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":57,"endOffset":77,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":"                                                         ","suffix":" is an oral prodrug that is rapidly converted via two interm","exact":"Dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":57,"endOffset":77,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","prefix":"                                                         ","suffix":" is licensed for the prevention of venous thromboembolic eve","exact":"Dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":57,"endOffset":77,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","prefix":"                                                         ","suffix":" and dabigatran are not metabolized by the cytochrome P450 (","exact":"Dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":61,"endOffset":81,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[2]","prefix":"                                                            ","suffix":" (Pradaxa®; Boehringer Ingelheim Pharma GmbH & Co. KG) was a","exact":"Dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":57,"endOffset":77,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[6]","prefix":"                                                         ","suffix":" is assumed to be absorbed mainly in the duodenum. The prono","exact":"Dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":118,"endOffset":138,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[8]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[8]","prefix":"he overall safety profile of all treatments was favourable. ","suffix":" was well tolerated when given alone and in combination with","exact":"Dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":417,"endOffset":437,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","prefix":"f they have received rifampicin immediately before surgery. ","suffix":" is also indicated for stroke prevention in patients with at","exact":"Dabigatran etexilate"},{"setid":"PMC3477350","drugname":"pradaxa","startOffset":83,"endOffset":90,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[2]","prefix":"                                      Dabigatran etexilate (","suffix":"®; Boehringer Ingelheim Pharma GmbH & Co. KG) was administer","exact":"Pradaxa"},{"setid":"PMC3477350","drugname":"thrombin","startOffset":234,"endOffset":242,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":", to the active moiety, dabigatran, a direct and reversible ","suffix":" inhibitor. Dabigatran is partly conjugated with activated g","exact":"thrombin"},{"setid":"PMC3477350","drugname":"glucuronic acid","startOffset":301,"endOffset":316,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":"n inhibitor. Dabigatran is partly conjugated with activated ","suffix":" to form a pharmacologically equipotent glucuronide. Free da","exact":"glucuronic acid"},{"setid":"PMC3477350","drugname":"cortisol","startOffset":909,"endOffset":917,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","prefix":"nt of a surrogate end-point, the urinary 6β-hydroxycortisol/","suffix":" ratio. This ratio is thought to reflect the CYP3A activity ","exact":"cortisol"},{"setid":"PMC3477350","drugname":"cortisol","startOffset":900,"endOffset":908,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","prefix":"measurement of a surrogate end-point, the urinary 6β-hydroxy","suffix":"/cortisol ratio. This ratio is thought to reflect the CYP3A ","exact":"cortisol"},{"setid":"PMC3477350","drugname":"cortisol","startOffset":909,"endOffset":917,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","prefix":"nt of a surrogate end-point, the urinary 6β-hydroxycortisol/","suffix":" ratio. This ratio is thought to reflect the CYP3A activity ","exact":"cortisol"},{"setid":"PMC3477350","drugname":"cortisol","startOffset":75,"endOffset":83,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[6]","prefix":"                                              The 6β-hydroxy","suffix":"/cortisol ratio, an established marker of human hepatic CYP4","exact":"cortisol"},{"setid":"PMC3477350","drugname":"cortisol","startOffset":84,"endOffset":92,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[6]","prefix":"                                     The 6β-hydroxycortisol/","suffix":" ratio, an established marker of human hepatic CYP450 3A ind","exact":"cortisol"},{"setid":"PMC3477350","drugname":"cortisol","startOffset":87,"endOffset":95,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[7]","prefix":"                                  Urinary concentrations of ","suffix":" and 6β-hydroxycortisol were analysed by an HPLC-MS/MS metho","exact":"cortisol"},{"setid":"PMC3477350","drugname":"cortisol","startOffset":110,"endOffset":118,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[7]","prefix":"           Urinary concentrations of cortisol and 6β-hydroxy","suffix":" were analysed by an HPLC-MS/MS method at SGS Cephac Europe,","exact":"cortisol"},{"setid":"PMC3477350","drugname":"cortisol","startOffset":235,"endOffset":243,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[7]","prefix":"pe, St Benoît, France. The calibration curves for 6β-hydroxy","suffix":" and cortisol ranged between 1-1000 and 10-3000 ng ml","exact":"cortisol"},{"setid":"PMC3477350","drugname":"cortisol","startOffset":248,"endOffset":256,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[7]","prefix":", France. The calibration curves for 6β-hydroxycortisol and ","suffix":" ranged between 1-1000 and 10-3000 ng ml","exact":"cortisol"},{"setid":"PMC3477350","drugname":"cortisol","startOffset":104,"endOffset":112,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/p[1]","prefix":"                 Compared with day 1, the urinary 6β-hydroxy","suffix":"/cortisol ratio on day 9 was increased approximately 5.6-fol","exact":"cortisol"},{"setid":"PMC3477350","drugname":"cortisol","startOffset":113,"endOffset":121,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/p[1]","prefix":"        Compared with day 1, the urinary 6β-hydroxycortisol/","suffix":" ratio on day 9 was increased approximately 5.6-fold, from a","exact":"cortisol"},{"setid":"PMC3477350","drugname":"cortisol","startOffset":206,"endOffset":214,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/p[1]","prefix":"ased approximately 5.6-fold, from a gMean (gCV %) 6β-hydroxy","suffix":"/cortisol ratio of 3.92 (65.3) to 22.0 (48.5), indicating CY","exact":"cortisol"},{"setid":"PMC3477350","drugname":"cortisol","startOffset":215,"endOffset":223,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/p[1]","prefix":"oximately 5.6-fold, from a gMean (gCV %) 6β-hydroxycortisol/","suffix":" ratio of 3.92 (65.3) to 22.0 (48.5), indicating CYP450 3A i","exact":"cortisol"},{"setid":"PMC3477350","drugname":"cortisol","startOffset":356,"endOffset":364,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/p[1]","prefix":" result of rifampicin administration. The urinary 6β-hydroxy","suffix":"/cortisol ratio was still slightly elevated on day 16 (∼1.2-","exact":"cortisol"},{"setid":"PMC3477350","drugname":"cortisol","startOffset":365,"endOffset":373,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/p[1]","prefix":"f rifampicin administration. The urinary 6β-hydroxycortisol/","suffix":" ratio was still slightly elevated on day 16 (∼1.2-fold), bu","exact":"cortisol"},{"setid":"PMC3477350","drugname":"cortisol","startOffset":167,"endOffset":175,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","prefix":"so induced CYP3A, as shown by an elevated urinary 6β-hydroxy","suffix":"/cortisol ratio [","exact":"cortisol"},{"setid":"PMC3477350","drugname":"cortisol","startOffset":176,"endOffset":184,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","prefix":"d CYP3A, as shown by an elevated urinary 6β-hydroxycortisol/","suffix":" ratio [","exact":"cortisol"},{"setid":"PMC3477350","drugname":"edta","startOffset":95,"endOffset":99,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[2]","prefix":"                          Briefly, plasma was prepared from ","suffix":" blood (at 2000g-4000g for 10 minutes); for the determinatio","exact":"EDTA"},{"setid":"PMC3477350","drugname":"digoxin","startOffset":229,"endOffset":236,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","prefix":"agnitude or only slightly exceeded the effects reported for ","suffix":" [","exact":"digoxin"},{"setid":"PMC3477350","drugname":"digoxin","startOffset":229,"endOffset":236,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","prefix":"agnitude or only slightly exceeded the effects reported for ","suffix":" [","exact":"digoxin"},{"setid":"PMC3477350","drugname":"carbamazepine","startOffset":541,"endOffset":554,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","prefix":"ure to dabigatran, rifampicin and other P-gp inducers (e.g. ","suffix":" and St John's wort) are not recommended for use with dabiga","exact":"carbamazepine"}],[{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":283,"endOffset":294,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","prefix":"on. The aim of this study was to evaluate the potential for ","suffix":" to affect warfarin pharmacokinetics and pharmacodynamics.  ","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":197,"endOffset":208,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"le dose of racemic warfarin 25 mg alone and after 8 days of ","suffix":" 10 mg once daily. Assessments included exposure (AUC","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":283,"endOffset":294,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","prefix":"on. The aim of this study was to evaluate the potential for ","suffix":" to affect warfarin pharmacokinetics and pharmacodynamics.  ","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":197,"endOffset":208,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"le dose of racemic warfarin 25 mg alone and after 8 days of ","suffix":" 10 mg once daily. Assessments included exposure (AUC","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":83,"endOffset":94,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","prefix":"                                          Multiple doses of ","suffix":" had no clinically relevant effects on the pharmacokinetics ","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":194,"endOffset":205,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[2]","prefix":" dependence, bleeding disorders, sensitivity to warfarin or ","suffix":", or significant allergies. Subjects were also excluded if t","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":253,"endOffset":264,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","prefix":"tic and/or pharmacodynamic interaction of multiple doses of ","suffix":" with a single dose of warfarin in healthy subjects (","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":334,"endOffset":345,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","prefix":"12, 18, 24, 36, 48, 72 and 96 h postdose. Blood samples for ","suffix":" pharmacokinetic assessments were collected relative to the ","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":423,"endOffset":434,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","prefix":"ssessments were collected relative to the day 12 and day 13 ","suffix":" doses: predose (≤30 min prior), and 0.5, 1, 2, 3, 4, 6, 8, ","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":537,"endOffset":548,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","prefix":", 2, 3, 4, 6, 8, 10, 12, 18 and 24 h postdose. Steady-state ","suffix":" concentrations were determined from samples collected at tr","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":92,"endOffset":103,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":"                             The safety and tolerability of ","suffix":" and warfarin co-administration was assessed through adverse","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":97,"endOffset":108,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","prefix":"                        To assess the effect of concomitant ","suffix":" dosing on warfarin pharmacokinetics and pharmacodynamics, i","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":237,"endOffset":248,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","prefix":" within-subject pair-wise differences of day 13 (warfarin + ","suffix":") ","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":116,"endOffset":127,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[4]","prefix":"     To assess the effect of concomitant warfarin dosing on ","suffix":" pharmacokinetics, individual within-subject pair-wise diffe","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":216,"endOffset":227,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[4]","prefix":" within-subject pair-wise differences of day 13 (warfarin + ","suffix":") ","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":250,"endOffset":261,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[5]","prefix":" to detect a 6% difference in INR between day 13 (warfarin +","suffix":") and day 1 (warfarin alone), and a >90% probability that th","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":124,"endOffset":135,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","prefix":"re were no clinically relevant effects of multiple doses of ","suffix":" on the concentration-time profiles of R-and S-warfarin (","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":125,"endOffset":136,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[1]","prefix":"nistration of warfarin in the presence of multiple doses of ","suffix":" (","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":153,"endOffset":164,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/p[1]","prefix":"ct on the steady-state plasma concentration-time profile of ","suffix":" (","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":90,"endOffset":101,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":"                           In this study, multiple doses of ","suffix":" 10 mg once daily resulted in slight to modest changes in R-","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":77,"endOffset":88,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","prefix":"                                        In this study, both ","suffix":" and warfarin were administered at clinically effective dose","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":514,"endOffset":525,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","prefix":"egarding the safety profile of chronic co-administration of ","suffix":" and warfarin. Of note, clinical studies in patients with PA","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":671,"endOffset":682,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","prefix":" above, have demonstrated that chronic co-administration of ","suffix":" and warfarin does not appear to be associated with any spec","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":65,"endOffset":76,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","prefix":"                                                            ","suffix":" is an oral, propanoic acid-based endothelin receptor antago","exact":"Ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":65,"endOffset":76,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"                                                            ","suffix":" had no significant effects on the AUC","exact":"Ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":57,"endOffset":68,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","prefix":"                                                         ","suffix":" is primarily metabolized via hepatic glucuronidation [","exact":"Ambrisentan"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":168,"endOffset":176,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","prefix":"d endothelin receptor antagonist often co-administered with ","suffix":" to patients with pulmonary arterial hypertension. The aim o","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":168,"endOffset":176,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","prefix":"d endothelin receptor antagonist often co-administered with ","suffix":" to patients with pulmonary arterial hypertension. The aim o","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":305,"endOffset":313,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","prefix":"udy was to evaluate the potential for ambrisentan to affect ","suffix":" pharmacokinetics and pharmacodynamics.                     ","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":156,"endOffset":164,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"tudy, 22 healthy subjects received a single dose of racemic ","suffix":" 25 mg alone and after 8 days of ambrisentan 10 mg once dail","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":195,"endOffset":203,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","prefix":"e pharmacokinetics and pharmacodynamics of a single dose of ","suffix":". Therefore, significant dose adjustments of either drug are","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":182,"endOffset":190,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[2]","prefix":"y of alcohol dependence, bleeding disorders, sensitivity to ","suffix":" or ambrisentan, or significant allergies. Subjects were als","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":287,"endOffset":295,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","prefix":"tion of multiple doses of ambrisentan with a single dose of ","suffix":" in healthy subjects (","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":122,"endOffset":130,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","prefix":"lood samples for the pharmacokinetic assessments of R-and S-","suffix":" were collected at the following times relative to the day 1","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":202,"endOffset":210,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","prefix":"ted at the following times relative to the day 1 and day 13 ","suffix":" doses: predose (≤30 min prior), and 0.5, 1, 2, 3, 4, 6, 8, ","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":108,"endOffset":116,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":"             The safety and tolerability of ambrisentan and ","suffix":" co-administration was assessed through adverse events (AEs)","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":119,"endOffset":127,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","prefix":"  To assess the effect of concomitant ambrisentan dosing on ","suffix":" pharmacokinetics and pharmacodynamics, individual within-su","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":226,"endOffset":234,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","prefix":" individual within-subject pair-wise differences of day 13 (","suffix":" + ambrisentan) ","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":97,"endOffset":105,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[4]","prefix":"                        To assess the effect of concomitant ","suffix":" dosing on ambrisentan pharmacokinetics, individual within-s","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":205,"endOffset":213,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[4]","prefix":" individual within-subject pair-wise differences of day 13 (","suffix":" + ambrisentan) ","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":240,"endOffset":248,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[5]","prefix":">80% power to detect a 6% difference in INR between day 13 (","suffix":" +ambrisentan) and day 1 (warfarin alone), and a >90% probab","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":274,"endOffset":282,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[5]","prefix":"ce in INR between day 13 (warfarin +ambrisentan) and day 1 (","suffix":" alone), and a >90% probability that the true 95% two-sided ","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":182,"endOffset":190,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","prefix":"f ambrisentan on the concentration-time profiles of R-and S-","suffix":" (","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":79,"endOffset":87,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[1]","prefix":"                                          Administration of ","suffix":" in the presence of multiple doses of ambrisentan (","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":69,"endOffset":77,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/p[1]","prefix":"                                                    Racemic ","suffix":" had little effect on the steady-state plasma concentration-","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":167,"endOffset":175,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":" once daily resulted in slight to modest changes in R-and S-","suffix":" pharmacokinetic (AUC","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":80,"endOffset":88,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"                                     Drug interactions with ","suffix":" have been previously demonstrated for the ERAs bosentan and","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":93,"endOffset":101,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","prefix":"                        In this study, both ambrisentan and ","suffix":" were administered at clinically effective doses, and no sig","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":225,"endOffset":233,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","prefix":"cant changes in the pharmacokinetics or pharmacodynamics of ","suffix":" were observed with co-administration. However, because of t","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":530,"endOffset":538,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","prefix":"ety profile of chronic co-administration of ambrisentan and ","suffix":". Of note, clinical studies in patients with PAH, such as th","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":687,"endOffset":695,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","prefix":"onstrated that chronic co-administration of ambrisentan and ","suffix":" does not appear to be associated with any specific safety c","exact":"warfarin"},{"setid":"PMC2686069","drugname":"bosentan","startOffset":136,"endOffset":144,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"ith warfarin have been previously demonstrated for the ERAs ","suffix":" and sitaxsentan [","exact":"bosentan"},{"setid":"PMC2686069","drugname":"sitaxsentan","startOffset":149,"endOffset":160,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"have been previously demonstrated for the ERAs bosentan and ","suffix":" [","exact":"sitaxsentan"},{"setid":"PMC2686069","drugname":"caffeine","startOffset":463,"endOffset":471,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","prefix":"e nontobacco users, and agreed to discontinue the intake of ","suffix":", alcohol, grapefruit products, liver, and leafy green veget","exact":"caffeine"},{"setid":"PMC2686069","drugname":"alanine","startOffset":694,"endOffset":701,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","prefix":" within normal limits, serum aspartate aminotransferase and ","suffix":" aminotransferase concentrations <1x the upper limit of norm","exact":"alanine"}],[{"setid":"PMC3703233","drugname":"dabigatran","startOffset":396,"endOffset":406,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"fourth day, or the same treatments in the reverse sequence. ","suffix":" plasma concentration and ecarin clotting time (ECT) were me","exact":"Dabigatran"},{"setid":"PMC3703233","drugname":"dabigatran","startOffset":183,"endOffset":193,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"ion process with two compartments. The relationship between ","suffix":" concentration and ECT was implemented as a linear function.","exact":"dabigatran"},{"setid":"PMC3703233","drugname":"dabigatran","startOffset":124,"endOffset":134,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","prefix":" The model proposed effectively describes the complex PK of ","suffix":" and takes into account drug-drug interactions with P-gp act","exact":"dabigatran"},{"setid":"PMC3703233","drugname":"dabigatran","startOffset":157,"endOffset":167,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","prefix":"elop a PK/PD model to assess drug-drug interactions between ","suffix":" and P-gp modulators, using the example of clarithromycin, a","exact":"dabigatran"},{"setid":"PMC3703233","drugname":"dabigatran","startOffset":174,"endOffset":184,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"ceive in the first treatment period a single 300 mg dose of ","suffix":" etexilate (DE) and in the second treatment period 500 mg cl","exact":"dabigatran"},{"setid":"PMC3703233","drugname":"dabigatran","startOffset":183,"endOffset":193,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"ion process with two compartments. The relationship between ","suffix":" concentration and ECT was implemented as a linear function.","exact":"dabigatran"},{"setid":"PMC3703233","drugname":"dabigatran","startOffset":124,"endOffset":134,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","prefix":" The model proposed effectively describes the complex PK of ","suffix":" and takes into account drug-drug interactions with P-gp act","exact":"dabigatran"},{"setid":"PMC3703233","drugname":"dabigatran","startOffset":129,"endOffset":139,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","prefix":"h other anticoagulant drugs, such as vitamin K antagonists, ","suffix":" has a low potential for drug-drug interactions. However, it","exact":"dabigatran"},{"setid":"PMC3703233","drugname":"dabigatran","startOffset":377,"endOffset":387,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","prefix":"y, decrease or increase its bioavailability. An increase in ","suffix":" area under the concentration ","exact":"dabigatran"},{"setid":"PMC3703233","drugname":"dabigatran","startOffset":149,"endOffset":159,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","prefix":"elop a PK/PD model to assess drug-drug interactions between ","suffix":" and P-gp modulators, using clarithromycin, a strong inhibit","exact":"dabigatran"},{"setid":"PMC3703233","drugname":"dabigatran","startOffset":276,"endOffset":286,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":" administration for measurement of plasma concentrations of ","suffix":". All analyses were performed on venous blood samples collec","exact":"dabigatran"},{"setid":"PMC3703233","drugname":"dabigatran","startOffset":89,"endOffset":99,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[3]","prefix":"                                The anticoagulant effect of ","suffix":" was measured by an ecarin clotting time (ECT) assay, as des","exact":"dabigatran"},{"setid":"PMC3703233","drugname":"dabigatran","startOffset":266,"endOffset":276,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[2]","prefix":"t step consisted in identifying the structural PK model for ","suffix":" without clarithromycin. The second step comprised the estim","exact":"dabigatran"},{"setid":"PMC3703233","drugname":"dabigatran","startOffset":489,"endOffset":499,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/div[3]/p[1]","prefix":"del in order to test the presence of an interaction between ","suffix":" and clarithromycin:                                        ","exact":"dabigatran"},{"setid":"PMC3703233","drugname":"dabigatran","startOffset":128,"endOffset":138,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/p[1]","prefix":"t PK/PD model corresponded to a linear relationship between ","suffix":" concentration and its anticoagulant effect, based on the EC","exact":"dabigatran"},{"setid":"PMC3703233","drugname":"dabigatran","startOffset":151,"endOffset":161,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":"el to describe the pharmacokinetics and pharmacodynamics of ","suffix":" in healthy volunteers was a two compartment model with an a","exact":"dabigatran"},{"setid":"PMC3703233","drugname":"dabigatran","startOffset":818,"endOffset":828,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":"llow relevant characterization of the complex absorption of ","suffix":" DE ","exact":"dabigatran"},{"setid":"PMC3703233","drugname":"dabigatran","startOffset":108,"endOffset":118,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","prefix":"         In our study, clarithromycin increased exposure to ","suffix":" (AUC) by more than 50%. This increase resulted in a proport","exact":"dabigatran"},{"setid":"PMC3703233","drugname":"dabigatran","startOffset":145,"endOffset":155,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","prefix":"model effectively describes the complex pharmacokinetics of ","suffix":", allowing drug-drug interactions related to P-gp modulation","exact":"dabigatran"},{"setid":"PMC3703233","drugname":"dabigatran","startOffset":287,"endOffset":297,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","prefix":" into account. Using this model, we showed that exposure to ","suffix":" is increased by 50% in the presence of clarithromycin and i","exact":"dabigatran"},{"setid":"PMC3703233","drugname":"dabigatran","startOffset":547,"endOffset":557,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","prefix":"cient tool to investigate other drug-drug interactions with ","suffix":" concerning P-gp inhibitors, inductors or substrates.       ","exact":"dabigatran"},{"setid":"PMC3703233","drugname":"dabigatran","startOffset":396,"endOffset":406,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"fourth day, or the same treatments in the reverse sequence. ","suffix":" plasma concentration and ecarin clotting time (ECT) were me","exact":"Dabigatran"},{"setid":"PMC3703233","drugname":"dabigatran","startOffset":57,"endOffset":67,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":"                                                         ","suffix":" etexilate (DE) is an anticoagulant drug used for the preven","exact":"Dabigatran"},{"setid":"PMC3703233","drugname":"dabigatran","startOffset":61,"endOffset":71,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[2]","prefix":"                                                            ","suffix":" plasma concentrations were determined using the validated l","exact":"Dabigatran"},{"setid":"PMC3703233","drugname":"clarithromycin","startOffset":210,"endOffset":224,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","prefix":"etween dabigatran and P-gp modulators, using the example of ","suffix":", a strong inhibitor of P-gp.                               ","exact":"clarithromycin"},{"setid":"PMC3703233","drugname":"clarithromycin","startOffset":242,"endOffset":256,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"an etexilate (DE) and in the second treatment period 500 mg ","suffix":" twice daily during 3 days and then 300 mg DE plus 500 mg cl","exact":"clarithromycin"},{"setid":"PMC3703233","drugname":"clarithromycin","startOffset":314,"endOffset":328,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"in twice daily during 3 days and then 300 mg DE plus 500 mg ","suffix":" on the fourth day, or the same treatments in the reverse se","exact":"clarithromycin"},{"setid":"PMC3703233","drugname":"clarithromycin","startOffset":382,"endOffset":396,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"n the objective function. The concomitant administration of ","suffix":" induced a significant change only in DE bioavailability, wh","exact":"clarithromycin"},{"setid":"PMC3703233","drugname":"clarithromycin","startOffset":508,"endOffset":522,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"lity, which increased from 6.5% to 10.1% in the presence of ","suffix":". Clarithromycin increased peak concentration and AUC by 60.","exact":"clarithromycin"},{"setid":"PMC3703233","drugname":"clarithromycin","startOffset":220,"endOffset":234,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","prefix":"ug-drug interactions with P-gp activity modulators, such as ","suffix":".                                                           ","exact":"clarithromycin"},{"setid":"PMC3703233","drugname":"clarithromycin","startOffset":187,"endOffset":201,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","prefix":" interactions between dabigatran and P-gp modulators, using ","suffix":", a strong inhibitor of P-gp, as an example.                ","exact":"clarithromycin"},{"setid":"PMC3703233","drugname":"clarithromycin","startOffset":693,"endOffset":707,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","prefix":"ere excluded. Subjects with known hypersensitivity to DE or ","suffix":", or who had taken any medicine during the week before the s","exact":"clarithromycin"},{"setid":"PMC3703233","drugname":"clarithromycin","startOffset":179,"endOffset":193,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","prefix":"eive either first DE alone and then a combination of DE and ","suffix":", or first the combination treatment and then DE alone. The ","exact":"clarithromycin"},{"setid":"PMC3703233","drugname":"clarithromycin","startOffset":285,"endOffset":299,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[2]","prefix":" identifying the structural PK model for dabigatran without ","suffix":". The second step comprised the estimation of PK/PD paramete","exact":"clarithromycin"},{"setid":"PMC3703233","drugname":"clarithromycin","startOffset":501,"endOffset":515,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[2]","prefix":"al variability (IOV) on the full data set (with and without ","suffix":"). Finally, drug-drug interaction was investigated applying ","exact":"clarithromycin"},{"setid":"PMC3703233","drugname":"clarithromycin","startOffset":353,"endOffset":367,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/div[3]/p[1]","prefix":"nd structural parameters. The concomitant administration of ","suffix":", was included as a categorical covariate in the absorption ","exact":"clarithromycin"},{"setid":"PMC3703233","drugname":"clarithromycin","startOffset":504,"endOffset":518,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/div[3]/p[1]","prefix":" test the presence of an interaction between dabigatran and ","suffix":":                                                           ","exact":"clarithromycin"},{"setid":"PMC3703233","drugname":"clarithromycin","startOffset":83,"endOffset":97,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[1]","prefix":"                                      The administration of ","suffix":" induced a significant change only in the bioavailability of","exact":"clarithromycin"},{"setid":"PMC3703233","drugname":"clarithromycin","startOffset":71,"endOffset":85,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","prefix":"                                              In our study, ","suffix":" increased exposure to dabigatran (AUC) by more than 50%. Th","exact":"clarithromycin"},{"setid":"PMC3703233","drugname":"clarithromycin","startOffset":406,"endOffset":420,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","prefix":"rfectly the mechanism involved in the inhibition of P-gp by ","suffix":".                                                     ","exact":"clarithromycin"},{"setid":"PMC3703233","drugname":"clarithromycin","startOffset":337,"endOffset":351,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","prefix":"posure to dabigatran is increased by 50% in the presence of ","suffix":" and is characterized by substantial variability. In contras","exact":"clarithromycin"},{"setid":"PMC3703233","drugname":"clarithromycin","startOffset":129,"endOffset":143,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/p[3]","prefix":"fit plots. The grey circles represent data obtained without ","suffix":". The white circles represent data obtained with clarithromy","exact":"clarithromycin"},{"setid":"PMC3703233","drugname":"clarithromycin","startOffset":192,"endOffset":206,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/p[3]","prefix":"rithromycin. The white circles represent data obtained with ","suffix":".The solid line indicates the line of identity. The dashed l","exact":"clarithromycin"},{"setid":"PMC3703233","drugname":"clarithromycin","startOffset":524,"endOffset":538,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"eased from 6.5% to 10.1% in the presence of clarithromycin. ","suffix":" increased peak concentration and AUC by 60.2% and 49.1% res","exact":"Clarithromycin"},{"setid":"PMC3703233","drugname":"vitamin k","startOffset":106,"endOffset":115,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","prefix":"           Compared with other anticoagulant drugs, such as ","suffix":" antagonists, dabigatran has a low potential for drug-drug i","exact":"vitamin K"},{"setid":"PMC3703233","drugname":"fibrinogen","startOffset":420,"endOffset":430,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","prefix":"zed ratio, activated partial thromboplastin time (aPPT) and ","suffix":" level. Volunteers with renal insufficiency, hepatic insuffi","exact":"fibrinogen"},{"setid":"PMC3703233","drugname":"fibrinogen","startOffset":341,"endOffset":351,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","prefix":"a, median aPPT (range) was 1.04 (0.9-1.15) s, median plasma ","suffix":" concentration 2.25 (1.6-3) g l","exact":"fibrinogen"},{"setid":"PMC3703233","drugname":"citrate","startOffset":398,"endOffset":405,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":"s collected by venipuncture, using whole blood collected in ","suffix":" tubes for PD and heparinized tubes for PK analysis.        ","exact":"citrate"},{"setid":"PMC3703233","drugname":"creatinine","startOffset":122,"endOffset":132,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/div[3]/p[1]","prefix":"   Body mass index, weight, lean body weight, size, age and ","suffix":" clearance [calculated using the Modification of Diet in Ren","exact":"creatinine"},{"setid":"PMC3703233","drugname":"creatinine","startOffset":122,"endOffset":132,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/div[3]/p[1]","prefix":"   Body mass index, weight, lean body weight, size, age and ","suffix":" clearance [calculated using the Modification of Diet in Ren","exact":"creatinine"},{"setid":"PMC3703233","drugname":"creatinine","startOffset":147,"endOffset":157,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[3]","prefix":"ariates tested (weight, body mass index, body surface area, ","suffix":" clearance) was associated with a significant decrease in th","exact":"creatinine"}],[{"setid":"PMC3900249","drugname":"amiodarone","startOffset":298,"endOffset":308,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"ange in warfarin dose requirement. To evaluate the roles of ","suffix":" and its circulating metabolites in this highly variable inh","exact":"amiodarone"},{"setid":"PMC3900249","drugname":"amiodarone","startOffset":205,"endOffset":215,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"coagulation therapy showed that the addition/elimination of ","suffix":" resulted in a 6-65% change in warfarin dose requirement. To","exact":"amiodarone"},{"setid":"PMC3900249","drugname":"amiodarone","startOffset":298,"endOffset":308,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"ange in warfarin dose requirement. To evaluate the roles of ","suffix":" and its circulating metabolites in this highly variable inh","exact":"amiodarone"},{"setid":"PMC3900249","drugname":"amiodarone","startOffset":243,"endOffset":253,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[5]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[5]","prefix":" dose change required to maintain an INR of 2.0 - 3.0 after ","suffix":" was added or discontinued in a cohort of patients undergoin","exact":"amiodarone"},{"setid":"PMC3900249","drugname":"amiodarone","startOffset":338,"endOffset":348,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","prefix":"in which an out-of-range INR was attributed to the warfarin-","suffix":" drug interaction were identified. These incidents were asso","exact":"amiodarone"},{"setid":"PMC3900249","drugname":"amiodarone","startOffset":442,"endOffset":452,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","prefix":" These incidents were associated with 163 episodes in which ","suffix":" was added or discontinued in patients taking warfarin, or i","exact":"amiodarone"},{"setid":"PMC3900249","drugname":"amiodarone","startOffset":524,"endOffset":534,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","prefix":"r discontinued in patients taking warfarin, or in which the ","suffix":" dose was changed. Of these 163 episodes, 90 were excluded f","exact":"amiodarone"},{"setid":"PMC3900249","drugname":"amiodarone","startOffset":668,"endOffset":678,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","prefix":"ue to either unstable warfarin therapy prior to addition of ","suffix":" (n=40), an interaction due to change in amiodarone dose (n=","exact":"amiodarone"},{"setid":"PMC3900249","drugname":"amiodarone","startOffset":719,"endOffset":729,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","prefix":"ition of amiodarone (n=40), an interaction due to change in ","suffix":" dose (n=27); warfarin and amiodarone having been initiated ","exact":"amiodarone"},{"setid":"PMC3900249","drugname":"amiodarone","startOffset":756,"endOffset":766,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","prefix":"ction due to change in amiodarone dose (n=27); warfarin and ","suffix":" having been initiated concurrently (n=14), the duration of ","exact":"amiodarone"},{"setid":"PMC3900249","drugname":"amiodarone","startOffset":846,"endOffset":856,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","prefix":"ed concurrently (n=14), the duration of concurrent warfarin/","suffix":" therapy being less than 1 month (n=6) or no records availab","exact":"amiodarone"},{"setid":"PMC3900249","drugname":"amiodarone","startOffset":345,"endOffset":355,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/div[2]/p[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/div[2]/p[1]","prefix":"ing us with blood samples from patients undergoing warfarin/","suffix":" therapy. This work was supported by the National Institutes","exact":"amiodarone"},{"setid":"PMC3900249","drugname":"amiodarone","startOffset":57,"endOffset":67,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"                                                         ","suffix":" (AMIO) was originally introduced as an anti-anginal drug ov","exact":"Amiodarone"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":246,"endOffset":254,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"ion/elimination of amiodarone resulted in a 6-65% change in ","suffix":" dose requirement. To evaluate the roles of amiodarone and i","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":246,"endOffset":254,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"ion/elimination of amiodarone resulted in a 6-65% change in ","suffix":" dose requirement. To evaluate the roles of amiodarone and i","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":199,"endOffset":207,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"F). Stroke is a major concern in patients with AF and since ","suffix":" is the preferred treatment for stroke prevention, AMIO is t","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":303,"endOffset":311,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"ke prevention, AMIO is therefore often co-administered with ","suffix":" (","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":173,"endOffset":181,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":"rated that AMIO inhibits the clearance of both (S)- and (R)-","suffix":" (","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":175,"endOffset":183,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[5]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[5]","prefix":"spective study was performed to determine mean and range of ","suffix":" dose change required to maintain an INR of 2.0 - 3.0 after ","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":322,"endOffset":330,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[5]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[5]","prefix":"d or discontinued in a cohort of patients undergoing stable ","suffix":" therapy. Next, stabilized plasma concentrations, [I], of AM","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":460,"endOffset":468,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[5]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[5]","prefix":"e of its circulating metabolites were determined in several ","suffix":" patients undergoing combination therapy. In order to measur","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":239,"endOffset":247,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","prefix":"ers of our analysis for an out of range INR attributed to a ","suffix":"-AMIO drug interaction which occurred upon either addition o","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":367,"endOffset":375,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","prefix":"r elimination of AMIO therapy to patients undergoing stable ","suffix":" treatment. Results of the analysis are described in ","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":169,"endOffset":177,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[2]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[2]","prefix":"mpounds were carried out in the presence of either 4 μM (S)-","suffix":", for studies in HLM, or 2 μg/mL rac-warfarin (approximate p","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":214,"endOffset":222,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[2]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[2]","prefix":"ither 4 μM (S)-warfarin, for studies in HLM, or 2 μg/mL rac-","suffix":" (approximate physiological concentration), for studies in h","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":61,"endOffset":69,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","prefix":"                                                        The ","suffix":"-AMIO interaction is known to be due to metabolic inhibition","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":183,"endOffset":191,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","prefix":"bition of the P450 enzymes responsible for the clearance of ","suffix":", mainly CYP2C9 (","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":106,"endOffset":114,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[6]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[6]","prefix":"           The overall change in intrinsic clearance of (S)-","suffix":" caused by the drug interaction with AMIO can be predicted a","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":165,"endOffset":173,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[7]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[7]","prefix":"ntration vs time curve (AUC) is therefore predicted for (S)-","suffix":" clearance based on the sum of the [I]/K","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":101,"endOffset":109,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[8]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[8]","prefix":"                The actual increase in the mean AUC for (S)-","suffix":" caused by the drug interaction with AMIO has been reported ","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":204,"endOffset":212,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[8]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[8]","prefix":"h AMIO has been reported to range from 27 to 110% in single ","suffix":" dose studies carried out in small groups (n = 5 or 6) of he","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":216,"endOffset":224,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","prefix":"patient anticoagulation management for 3129 patients taking ","suffix":". During this 6 year period, a total of 230 incidents in whi","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":329,"endOffset":337,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","prefix":"ncidents in which an out-of-range INR was attributed to the ","suffix":"-amiodarone drug interaction were identified. These incident","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":498,"endOffset":506,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","prefix":"ich amiodarone was added or discontinued in patients taking ","suffix":", or in which the amiodarone dose was changed. Of these 163 ","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":630,"endOffset":638,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","prefix":"odes, 90 were excluded from analysis due to either unstable ","suffix":" therapy prior to addition of amiodarone (n=40), an interact","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":743,"endOffset":751,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","prefix":"0), an interaction due to change in amiodarone dose (n=27); ","suffix":" and amiodarone having been initiated concurrently (n=14), t","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":837,"endOffset":845,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","prefix":"n initiated concurrently (n=14), the duration of concurrent ","suffix":"/amiodarone therapy being less than 1 month (n=6) or no reco","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":90,"endOffset":98,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[1]","prefix":"                               Three patients stabilized on ","suffix":" who were to be initiated on concomitant AMIO therapy were r","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":529,"endOffset":537,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[1]","prefix":" patients resulted in a 33, 40 or 71% reduction in required ","suffix":" dose. All patients gave informed consent for the study whic","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":93,"endOffset":101,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[2]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[2]","prefix":"                            HLMs were preincubated with (S)-","suffix":", inhibitor and buffer at 37°C and 70 rpm in a water bath fo","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":528,"endOffset":536,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[2]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[2]","prefix":"rpm for 5 min. Supernatants were then analyzed for 7-hydroxy","suffix":" content by HPLC using fluorescence detection. A time course","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":662,"endOffset":670,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[2]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[2]","prefix":" revealed that, under the experimental conditions, 7-hydroxy","suffix":" production was essentially linear out to 30 minutes.       ","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":336,"endOffset":344,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/div[2]/p[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/div[2]/p[1]","prefix":"in providing us with blood samples from patients undergoing ","suffix":"/amiodarone therapy. This work was supported by the National","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":295,"endOffset":303,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[2]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[2]","prefix":" physiological concentration), for studies in human plasma. ","suffix":" was found not to affect metabolite protein binding in eithe","exact":"Warfarin"}],[{"setid":"PMC1459289","drugname":"nelfinavir","startOffset":57,"endOffset":67,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"                                                         ","suffix":" (NFV) is an HIV protease inhibitor (PI) that has demonstrat","exact":"Nelfinavir"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":551,"endOffset":562,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"n inhibitor of CYP3A4 but an inducer of other CYP isoforms. ","suffix":" metabolism is complex, utilizing both oxidative and conjuga","exact":"Pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":57,"endOffset":68,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"                                                         ","suffix":" has become the preferred statin because of its lack of sign","exact":"Pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":118,"endOffset":129,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"he mechanism by which these drugs reduce plasma exposure to ","suffix":" is unknown, but this drug-drug interaction is of concern be","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":210,"endOffset":221,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":" drug-drug interaction is of concern because a reduction in ","suffix":" plasma concentration may adversely affect the drug's abilit","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":785,"endOffset":796,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"ines the hypothesis that NFV would have a similar effect on ","suffix":" pharmacokinetics as ritonavir/saquinavir.                  ","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":279,"endOffset":290,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":" examine the effect of efavirenz on the pharmacokinetics of ","suffix":", atorvastatin, and simvastatin and the effect of NFV on the","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":371,"endOffset":382,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":"imvastatin and the effect of NFV on the pharmacokinetics of ","suffix":". The efavirenz-statin interactions were recently published ","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":88,"endOffset":99,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","prefix":"                                 Subjects self-administered ","suffix":" 40 mg daily in the morning for the first 3 days and on the ","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":170,"endOffset":181,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","prefix":"y in the morning for the first 3 days and on the fourth day ","suffix":" was administered under observation. Blood samples were obta","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":346,"endOffset":357,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","prefix":"5, 1, 2, 3, 4, 6, 8, 12, and 24 h after administration, for ","suffix":" pharmacokinetics. On days 4 through 12, subjects took NFV 1","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":508,"endOffset":519,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","prefix":"On days 13 through 15, subjects continued NFV and restarted ","suffix":" with the morning dose of NFV. On day 16, pravastatin and NF","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":561,"endOffset":572,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","prefix":"tarted pravastatin with the morning dose of NFV. On day 16, ","suffix":" and NFV doses were administered under observation and sampl","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":664,"endOffset":675,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","prefix":" under observation and samples were collected over 24 h for ","suffix":" pharmacokinetics. Fasting serum total cholesterol, triglyce","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":73,"endOffset":84,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[1]","prefix":"                                                Samples for ","suffix":" plasma concentrations were analyzed by Advion Biosciences I","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":90,"endOffset":101,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","prefix":"                               The primary endpoint was the ","suffix":" AUC from 0 to 24 h before and after coadministration of NFV","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":113,"endOffset":124,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","prefix":"    Plots of time-specific geometric mean concentrations of ","suffix":" with and without NFV are shown in ","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":199,"endOffset":210,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"abolism by P4503A4 and results from studies suggesting that ","suffix":" is safe and tolerable in patients taking potent antiretrovi","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":80,"endOffset":91,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"                                     The mechanism by which ","suffix":" concentrations are reduced is not known. The metabolism of ","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":151,"endOffset":162,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":" concentrations are reduced is not known. The metabolism of ","suffix":" is complex. Induction of non-CYP3A4 oxidation or glucuronid","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":266,"endOffset":277,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"on or glucuronidation may result in more rapid clearance of ","suffix":". In addition, hepatic transporter OATP1B1 may participate i","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":77,"endOffset":88,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"                                        Clinical studies of ","suffix":" for the treatment of HIV-associated dyslipidemia have shown","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":202,"endOffset":213,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":" shown mixed results. For example, in a randomized trial of ","suffix":" versus fenofibrate for combined HIV-associated dyslipidemia","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":312,"endOffset":323,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"sociated dyslipidemia, only 36% of subjects receiving 40 mg ","suffix":" daily met the LDL goal (median 20% decrease) and 18% met th","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":69,"endOffset":80,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"                                                In summary, ","suffix":" remains the statin of choice in HIV-infected persons taking","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":273,"endOffset":284,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"in and atorvastatin. The observed near 50% reduction in the ","suffix":" median AUC and a trend toward less reduction in LDL when co","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":395,"endOffset":406,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"L when coadministered with NFV suggest that higher doses of ","suffix":" may need to be prescribed to achieve optimal lipid-lowering","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":521,"endOffset":532,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"ering activity. It remains unclear what the optimal dose of ","suffix":" is to achieve maximal lipid-lowering activity safely in HIV","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":726,"endOffset":737,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"hat greater improvements in lipid levels may be observed if ","suffix":" doses are adjusted in the setting of agents that are known ","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":921,"endOffset":932,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"g the safety, tolerability, and efficacy of higher doses of ","suffix":" are warranted.                                             ","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":86,"endOffset":97,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/p[1]","prefix":"                               Participating ACTG A5108 NFV-","suffix":" investigators and sites: J. Norris, S. Valle (Stanford Univ","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"simvastatin","startOffset":310,"endOffset":321,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":"z on the pharmacokinetics of pravastatin, atorvastatin, and ","suffix":" and the effect of NFV on the pharmacokinetics of pravastati","exact":"simvastatin"},{"setid":"PMC1459289","drugname":"simvastatin","startOffset":204,"endOffset":215,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"iretroviral therapy, given its safety profile compared with ","suffix":" and atorvastatin. The observed near 50% reduction in the pr","exact":"simvastatin"},{"setid":"PMC1459289","drugname":"ritonavir","startOffset":404,"endOffset":413,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":" PI drugs in clinical use that is not usually combined with ","suffix":", but NFV has a similar effect on the CYP enzymes as ritonav","exact":"ritonavir"},{"setid":"PMC1459289","drugname":"ritonavir","startOffset":466,"endOffset":475,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"tonavir, but NFV has a similar effect on the CYP enzymes as ","suffix":" in that it is an inhibitor of CYP3A4 but an inducer of othe","exact":"ritonavir"},{"setid":"PMC1459289","drugname":"ritonavir","startOffset":817,"endOffset":826,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"ld have a similar effect on pravastatin pharmacokinetics as ","suffix":"/saquinavir.                                                ","exact":"ritonavir"},{"setid":"PMC1459289","drugname":"saquinavir","startOffset":827,"endOffset":837,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"similar effect on pravastatin pharmacokinetics as ritonavir/","suffix":".                                                     ","exact":"saquinavir"},{"setid":"PMC1459289","drugname":"atorvastatin","startOffset":292,"endOffset":304,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":"effect of efavirenz on the pharmacokinetics of pravastatin, ","suffix":", and simvastatin and the effect of NFV on the pharmacokinet","exact":"atorvastatin"},{"setid":"PMC1459289","drugname":"atorvastatin","startOffset":220,"endOffset":232,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"apy, given its safety profile compared with simvastatin and ","suffix":". The observed near 50% reduction in the pravastatin median ","exact":"atorvastatin"},{"setid":"PMC1459289","drugname":"efavirenz","startOffset":242,"endOffset":251,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":"study. The primary objectives were to examine the effect of ","suffix":" on the pharmacokinetics of pravastatin, atorvastatin, and s","exact":"efavirenz"},{"setid":"PMC1459289","drugname":"efavirenz","startOffset":388,"endOffset":397,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":"e effect of NFV on the pharmacokinetics of pravastatin. The ","suffix":"-statin interactions were recently published [","exact":"efavirenz"},{"setid":"PMC1459289","drugname":"cholesterol","startOffset":298,"endOffset":309,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"tion may adversely affect the drug's ability to lower serum ","suffix":" effectively. NFV is one of the few PI drugs in clinical use","exact":"cholesterol"},{"setid":"PMC1459289","drugname":"cholesterol","startOffset":714,"endOffset":725,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","prefix":" 24 h for pravastatin pharmacokinetics. Fasting serum total ","suffix":", triglycerides, and high density lipoprotein concentrations","exact":"cholesterol"},{"setid":"PMC1459289","drugname":"cholesterol","startOffset":298,"endOffset":309,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"tion may adversely affect the drug's ability to lower serum ","suffix":" effectively. NFV is one of the few PI drugs in clinical use","exact":"cholesterol"},{"setid":"PMC1459289","drugname":"cholesterol","startOffset":714,"endOffset":725,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","prefix":" 24 h for pravastatin pharmacokinetics. Fasting serum total ","suffix":", triglycerides, and high density lipoprotein concentrations","exact":"cholesterol"},{"setid":"PMC1459289","drugname":"alanine","startOffset":542,"endOffset":549,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","prefix":"wo had grade 2 gastrointestinal complaints, one had grade 3 ","suffix":" aminotransferase and grade 2 aspartate aminotransferase on ","exact":"alanine"},{"setid":"PMC1459289","drugname":"fenofibrate","startOffset":221,"endOffset":232,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"s. For example, in a randomized trial of pravastatin versus ","suffix":" for combined HIV-associated dyslipidemia, only 36% of subje","exact":"fenofibrate"}],[{"setid":"PMC3681953","drugname":"simvastatin","startOffset":769,"endOffset":780,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"0.166, 0.036 to 0.185, and 0.014 to 0.044 for atorvastatin, ","suffix":", and the combined statin analysis, respectively.           ","exact":"simvastatin"},{"setid":"PMC3681953","drugname":"simvastatin","startOffset":210,"endOffset":221,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[7]","prefix":"ys only a secondary role in the metabolism of atorvastatin, ","suffix":", and lovastatin. Nonetheless, our current investigation int","exact":"simvastatin"},{"setid":"PMC3681953","drugname":"simvastatin","startOffset":366,"endOffset":377,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","prefix":"Median, first quartile, and third quartile of atorvastatin, ","suffix":", and lovastatin dose were determined for each combined geno","exact":"simvastatin"},{"setid":"PMC3681953","drugname":"simvastatin","startOffset":656,"endOffset":667,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","prefix":". Potency differences were accounted for by normalizing the ","suffix":" and lovastatin doses to atorvastatin-equivalent doses (i.e.","exact":"simvastatin"},{"setid":"PMC3681953","drugname":"simvastatin","startOffset":729,"endOffset":740,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","prefix":"nd lovastatin doses to atorvastatin-equivalent doses (i.e., ","suffix":" and lovastatin have 83% and 58% the potency, respectively, ","exact":"simvastatin"},{"setid":"PMC3681953","drugname":"lovastatin","startOffset":227,"endOffset":237,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[7]","prefix":"ry role in the metabolism of atorvastatin, simvastatin, and ","suffix":". Nonetheless, our current investigation intends to use the ","exact":"lovastatin"},{"setid":"PMC3681953","drugname":"lovastatin","startOffset":383,"endOffset":393,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","prefix":"rtile, and third quartile of atorvastatin, simvastatin, and ","suffix":" dose were determined for each combined genotype group. As u","exact":"lovastatin"},{"setid":"PMC3681953","drugname":"lovastatin","startOffset":672,"endOffset":682,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","prefix":"ences were accounted for by normalizing the simvastatin and ","suffix":" doses to atorvastatin-equivalent doses (i.e., simvastatin a","exact":"lovastatin"},{"setid":"PMC3681953","drugname":"lovastatin","startOffset":745,"endOffset":755,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","prefix":"ses to atorvastatin-equivalent doses (i.e., simvastatin and ","suffix":" have 83% and 58% the potency, respectively, of atorvastatin","exact":"lovastatin"},{"setid":"PMC3681953","drugname":"atorvastatin","startOffset":755,"endOffset":767,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"from 0.129 to 0.166, 0.036 to 0.185, and 0.014 to 0.044 for ","suffix":", simvastatin, and the combined statin analysis, respectivel","exact":"atorvastatin"},{"setid":"PMC3681953","drugname":"atorvastatin","startOffset":311,"endOffset":323,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"CYP3A5 were determined to be responsible for 85% and 15% of ","suffix":" metabolism, respectively, in a reported ","exact":"atorvastatin"},{"setid":"PMC3681953","drugname":"atorvastatin","startOffset":755,"endOffset":767,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"from 0.129 to 0.166, 0.036 to 0.185, and 0.014 to 0.044 for ","suffix":", simvastatin, and the combined statin analysis, respectivel","exact":"atorvastatin"},{"setid":"PMC3681953","drugname":"atorvastatin","startOffset":311,"endOffset":323,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"CYP3A5 were determined to be responsible for 85% and 15% of ","suffix":" metabolism, respectively, in a reported ","exact":"atorvastatin"},{"setid":"PMC3681953","drugname":"atorvastatin","startOffset":196,"endOffset":208,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[7]","prefix":"3A5 likely plays only a secondary role in the metabolism of ","suffix":", simvastatin, and lovastatin. Nonetheless, our current inve","exact":"atorvastatin"},{"setid":"PMC3681953","drugname":"atorvastatin","startOffset":352,"endOffset":364,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","prefix":"notype group. Median, first quartile, and third quartile of ","suffix":", simvastatin, and lovastatin dose were determined for each ","exact":"atorvastatin"},{"setid":"PMC3681953","drugname":"atorvastatin","startOffset":692,"endOffset":704,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","prefix":" for by normalizing the simvastatin and lovastatin doses to ","suffix":"-equivalent doses (i.e., simvastatin and lovastatin have 83%","exact":"atorvastatin"},{"setid":"PMC3681953","drugname":"atorvastatin","startOffset":803,"endOffset":815,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","prefix":"d lovastatin have 83% and 58% the potency, respectively, of ","suffix":" [","exact":"atorvastatin"}],[{"setid":"PMC2722908","drugname":"warfarin","startOffset":396,"endOffset":404,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","prefix":"eloped and used an algorithm for estimating the appropriate ","suffix":" dose that is based on both clinical and genetic data from a","exact":"warfarin"},{"setid":"PMC2722908","drugname":"warfarin","startOffset":439,"endOffset":447,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"culating the percentage of patients whose predicted dose of ","suffix":" was within 20% of the actual stable therapeutic dose; we al","exact":"warfarin"},{"setid":"PMC2722908","drugname":"warfarin","startOffset":196,"endOffset":204,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"tified larger proportions of patients who required 21 mg of ","suffix":" or less per week and of those who required 49 mg or more pe","exact":"warfarin"},{"setid":"PMC2722908","drugname":"warfarin","startOffset":151,"endOffset":159,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","prefix":"ic algorithm for estimating the appropriate initial dose of ","suffix":" produces recommendations that are significantly closer to t","exact":"warfarin"},{"setid":"PMC2722908","drugname":"warfarin","startOffset":424,"endOffset":432,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","prefix":" the 46.2% of the population that required 21 mg or less of ","suffix":" per week or 49 mg or more per week for therapeutic anticoag","exact":"warfarin"},{"setid":"PMC2722908","drugname":"warfarin","startOffset":57,"endOffset":65,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"                                                         ","suffix":" is the most widely used oral anticoagulant agent worldwide;","exact":"Warfarin"},{"setid":"PMC2722908","drugname":"warfarin","startOffset":79,"endOffset":87,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","prefix":"                                          The International ","suffix":" Pharmacogenetics Consortium comprises 21 research groups fr","exact":"Warfarin"},{"setid":"PMC2722908","drugname":"warfarin","startOffset":90,"endOffset":98,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[10]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[10]/p[1]","prefix":"                           The members of the International ","suffix":" Pharmacogenetics Consortium are as follows (alphabetical li","exact":"Warfarin"},{"setid":"PMC2722908","drugname":"warfarin","startOffset":151,"endOffset":159,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","prefix":"patients plays an important role in determining the dose of ","suffix":" that should be used when oral anticoagulation is initiated,","exact":"warfarin"},{"setid":"PMC2722908","drugname":"warfarin","startOffset":396,"endOffset":404,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","prefix":"eloped and used an algorithm for estimating the appropriate ","suffix":" dose that is based on both clinical and genetic data from a","exact":"warfarin"},{"setid":"PMC2722908","drugname":"warfarin","startOffset":439,"endOffset":447,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"culating the percentage of patients whose predicted dose of ","suffix":" was within 20% of the actual stable therapeutic dose; we al","exact":"warfarin"},{"setid":"PMC2722908","drugname":"warfarin","startOffset":196,"endOffset":204,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"tified larger proportions of patients who required 21 mg of ","suffix":" or less per week and of those who required 49 mg or more pe","exact":"warfarin"},{"setid":"PMC2722908","drugname":"warfarin","startOffset":151,"endOffset":159,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","prefix":"ic algorithm for estimating the appropriate initial dose of ","suffix":" produces recommendations that are significantly closer to t","exact":"warfarin"},{"setid":"PMC2722908","drugname":"warfarin","startOffset":424,"endOffset":432,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","prefix":" the 46.2% of the population that required 21 mg or less of ","suffix":" per week or 49 mg or more per week for therapeutic anticoag","exact":"warfarin"},{"setid":"PMC2722908","drugname":"warfarin","startOffset":289,"endOffset":297,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","prefix":"tic data for a total of 5700 patients who were treated with ","suffix":". These data were curated (i.e., collected, formatted, and s","exact":"warfarin"},{"setid":"PMC2722908","drugname":"warfarin","startOffset":141,"endOffset":149,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","prefix":" clinical factors that have previously been associated with ","suffix":" therapy and that were available from the information receiv","exact":"warfarin"},{"setid":"PMC2722908","drugname":"warfarin","startOffset":327,"endOffset":335,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","prefix":" on demographic characteristics, the primary indication for ","suffix":" treatment, the stable therapeutic dose of warfarin, the tre","exact":"warfarin"},{"setid":"PMC2722908","drugname":"warfarin","startOffset":378,"endOffset":386,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","prefix":"tion for warfarin treatment, the stable therapeutic dose of ","suffix":", the treatment INR (the INR achieved with a stable warfarin","exact":"warfarin"},{"setid":"PMC2722908","drugname":"warfarin","startOffset":438,"endOffset":446,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","prefix":"warfarin, the treatment INR (the INR achieved with a stable ","suffix":" dose), the target INR (the desired INR), the use of concomi","exact":"warfarin"},{"setid":"PMC2722908","drugname":"warfarin","startOffset":194,"endOffset":202,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[1]","prefix":"site, for a total of 4043 patients who had a stable dose of ","suffix":" and a target INR of 2 to 3) as the \"derivation cohort\" for ","exact":"warfarin"},{"setid":"PMC2722908","drugname":"warfarin","startOffset":4,"endOffset":12,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]/a[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]/a[3]","prefix":"www.","suffix":"dosing.org","exact":"warfarin"},{"setid":"PMC2722908","drugname":"warfarin","startOffset":169,"endOffset":177,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"significantly better predictions of the appropriate dose of ","suffix":" than either the clinical algorithm or a fixed-dose approach","exact":"warfarin"},{"setid":"PMC2722908","drugname":"warfarin","startOffset":352,"endOffset":360,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"proaches were noted among patients whose stable therapeutic ","suffix":" doses were 21 mg or less per week and among those whose sta","exact":"warfarin"},{"setid":"PMC2722908","drugname":"warfarin","startOffset":134,"endOffset":142,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":" not address the issue of whether a precise initial dose of ","suffix":" translates into improved clinical end points, such as a red","exact":"warfarin"},{"setid":"PMC2722908","drugname":"warfarin","startOffset":147,"endOffset":155,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":" of pharmacogenetic dose prediction as compared with actual ","suffix":" dose (Section 8 in ","exact":"warfarin"},{"setid":"PMC2722908","drugname":"warfarin","startOffset":178,"endOffset":186,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"patients, we developed a pharmacogenetic dose algorithm for ","suffix":" that uses genotypes from two genes (","exact":"warfarin"},{"setid":"PMC2722908","drugname":"warfarin","startOffset":695,"endOffset":703,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/div[2]/p[2]","prefix":"polymorphisms in CYP4F2 with the stable therapeutic dose of ","suffix":" (a patent that has been licensed by the Marshfield Clinic t","exact":"warfarin"},{"setid":"PMC2722908","drugname":"vitamin k","startOffset":224,"endOffset":233,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"clude potentially important factors such as smoking status, ","suffix":" intake, or alcohol consumption, as well as other genetic fa","exact":"vitamin K"},{"setid":"PMC2722908","drugname":"lasso","startOffset":858,"endOffset":863,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[1]","prefix":"te adaptive regression splines, least-angle regression, and ","suffix":", in addition to ordinary linear regression. Logarithmic and","exact":"Lasso"}],[{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":100,"endOffset":111,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"                         Subjects received rosuvastatin and ","suffix":" orally: day 1, rosuvastatin 10 mg single dose; days 6 to 9,","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":172,"endOffset":183,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"orally: day 1, rosuvastatin 10 mg single dose; days 6 to 9, ","suffix":" 75 mg once daily; day 10, eltrombopag 75 mg once daily and ","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":210,"endOffset":221,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"le dose; days 6 to 9, eltrombopag 75 mg once daily; day 10, ","suffix":" 75 mg once daily and rosuvastatin 10 mg single dose. Advers","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":86,"endOffset":97,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"                                       Co-administration of ","suffix":" with rosuvastatin increased geometric mean (90% confidence ","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":95,"endOffset":106,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","prefix":"                              Concomitant administration of ","suffix":" with rosuvastatin was associated with increased rosuvastati","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":274,"endOffset":285,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","prefix":"ductase inhibitors may be reduced by the concomitant use of ","suffix":". In subjects taking eltrombopag, a reduced dose of HMG Co-A","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":306,"endOffset":317,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","prefix":"d by the concomitant use of eltrombopag. In subjects taking ","suffix":", a reduced dose of HMG Co-A reductase inhibitors may be nee","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":81,"endOffset":92,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","prefix":"                                    In preclinical studies, ","suffix":" inhibited the organic anion transporting polypeptide 1B1 (O","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":293,"endOffset":304,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","prefix":"itten, informed consent. Subjects received rosuvastatin and ","suffix":" orally in the following sequence: day 1, rosuvastatin 10 mg","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":399,"endOffset":410,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","prefix":"day 1, rosuvastatin 10 mg single dose; day 6 through day 9, ","suffix":" 75 mg once daily; day 10, eltrombopag 75 mg once daily and ","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":437,"endOffset":448,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","prefix":" day 6 through day 9, eltrombopag 75 mg once daily; day 10, ","suffix":" 75 mg once daily and rosuvastatin 10 mg single dose. This s","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":81,"endOffset":92,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[6]","prefix":"                                        Steady-state plasma ","suffix":" ","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":86,"endOffset":97,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[7]","prefix":"                                   To assess the effects of ","suffix":" on rosuvastatin PK, log transformed plasma rosuvastatin AUC","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":82,"endOffset":93,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[2]","prefix":"                                       Co-administration of ","suffix":" with rosuvastatin increased plasma rosuvastatin AUC(0,∞) by","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":118,"endOffset":129,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[4]","prefix":"   For the overall population, the geometric mean of plasma ","suffix":" ","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":94,"endOffset":105,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[8]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[8]","prefix":"                       The impact of rosuvastatin on plasma ","suffix":" PK was not formally assessed. However, eltrombopag trough c","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":145,"endOffset":156,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[8]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[8]","prefix":"n plasma eltrombopag PK was not formally assessed. However, ","suffix":" trough concentrations collected prior to co-administration ","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":363,"endOffset":374,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[8]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[8]","prefix":"ation of a single dose of rosuvastatin. In addition, plasma ","suffix":" exposure for the 75 mg once daily regimen (in combination w","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":511,"endOffset":522,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[8]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[8]","prefix":" of rosuvastatin) was generally as expected based on plasma ","suffix":" exposures observed in other eltrombopag studies [","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":551,"endOffset":562,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[8]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[8]","prefix":"ted based on plasma eltrombopag exposures observed in other ","suffix":" studies [","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":64,"endOffset":75,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","prefix":"                                                     Plasma ","suffix":" exposures collected in the presence of rosuvastatin were si","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":275,"endOffset":286,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","prefix":"tudies that have shown approximately two-fold higher plasma ","suffix":" exposures in Asian ","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":102,"endOffset":113,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","prefix":"               In conclusion, concomitant administration of ","suffix":" with rosuvastatin was associated with increased rosuvastati","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":281,"endOffset":292,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","prefix":"ductase inhibitors may be reduced by the concomitant use of ","suffix":". In subjects taking eltrombopag, a reduced dose of HMG Co-A","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":313,"endOffset":324,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","prefix":"d by the concomitant use of eltrombopag. In subjects taking ","suffix":", a reduced dose of HMG Co-A reductase inhibitors may be nee","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":65,"endOffset":76,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","prefix":"                                                            ","suffix":", an oral, nonpeptide thrombopoietin receptor agonist, inhib","exact":"Eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":57,"endOffset":68,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":"                                                         ","suffix":" (GlaxoSmithKline) is an oral, nonpeptide thrombopoietin rec","exact":"Eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":205,"endOffset":216,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","prefix":" 1B1 (OATP1B1) and breast cancer resistance protein (BCRP). ","suffix":" was also identified as a BCRP substrate ","exact":"Eltrombopag"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":83,"endOffset":95,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"                                          Subjects received ","suffix":" and eltrombopag orally: day 1, rosuvastatin 10 mg single do","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":127,"endOffset":139,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"bjects received rosuvastatin and eltrombopag orally: day 1, ","suffix":" 10 mg single dose; days 6 to 9, eltrombopag 75 mg once dail","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":243,"endOffset":255,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":" 75 mg once daily; day 10, eltrombopag 75 mg once daily and ","suffix":" 10 mg single dose. Adverse event assessments were performed","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":103,"endOffset":115,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"                      Co-administration of eltrombopag with ","suffix":" increased geometric mean (90% confidence interval) plasma r","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":174,"endOffset":186,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"n increased geometric mean (90% confidence interval) plasma ","suffix":" AUC(0,∞) by 55% (42%, 69%) and ","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":112,"endOffset":124,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","prefix":"             Concomitant administration of eltrombopag with ","suffix":" was associated with increased rosuvastatin exposure. The th","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":155,"endOffset":167,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","prefix":"eltrombopag with rosuvastatin was associated with increased ","suffix":" exposure. The therapeutic index of HMG Co-A reductase inhib","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":276,"endOffset":288,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","prefix":"jects provided written, informed consent. Subjects received ","suffix":" and eltrombopag orally in the following sequence: day 1, ro","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":346,"endOffset":358,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","prefix":"in and eltrombopag orally in the following sequence: day 1, ","suffix":" 10 mg single dose; day 6 through day 9, eltrombopag 75 mg o","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":470,"endOffset":482,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","prefix":" 75 mg once daily; day 10, eltrombopag 75 mg once daily and ","suffix":" 10 mg single dose. This study was designed and monitored in","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":499,"endOffset":511,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[4]","prefix":"6, 8, 12, 24, 36, 48, 60, 72, 84 and 96 h after single dose ","suffix":" administration on days 1 and 10. A blood sample was obtaine","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":123,"endOffset":135,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[4]","prefix":"asma PK samples collected on days 1 and 10 were assayed for ","suffix":" using a validated analytical method based on solid phase ex","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":391,"endOffset":403,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[4]","prefix":"liquot of plasma, the lower limit of quantification for the ","suffix":" assay was 0.2 ng ml","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":101,"endOffset":113,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[7]","prefix":"                    To assess the effects of eltrombopag on ","suffix":" PK, log transformed plasma rosuvastatin AUC(0,∞) and ","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":141,"endOffset":153,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[7]","prefix":"s of eltrombopag on rosuvastatin PK, log transformed plasma ","suffix":" AUC(0,∞) and ","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":124,"endOffset":136,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[8]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[8]","prefix":"tivariate analyses of the relationship between day 1 plasma ","suffix":" AUC(0,∞) and ","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":99,"endOffset":111,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[2]","prefix":"                      Co-administration of eltrombopag with ","suffix":" increased plasma rosuvastatin AUC(0,∞) by 55% and ","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":129,"endOffset":141,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[2]","prefix":"istration of eltrombopag with rosuvastatin increased plasma ","suffix":" AUC(0,∞) by 55% and ","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":138,"endOffset":150,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[3]","prefix":"bined genotype scores (approach 3) of 2-3 had higher plasma ","suffix":" exposures than subjects with scores of 0-1, and there was a","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":240,"endOffset":252,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[3]","prefix":"scores of 0-1, and there was also a trend for higher plasma ","suffix":" exposures for subjects in category 4 (approach 2). However,","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":438,"endOffset":450,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[3]","prefix":"ions regarding the relationship between genotype and plasma ","suffix":" exposure. Plasma rosuvastatin AUC(0,∞) ","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":468,"endOffset":480,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[3]","prefix":"p between genotype and plasma rosuvastatin exposure. Plasma ","suffix":" AUC(0,∞) ","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":110,"endOffset":122,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"       Because it was known that Asian subjects have higher ","suffix":" exposures than non-Asian subjects [","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":112,"endOffset":124,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","prefix":"     The finding of statistically significant higher plasma ","suffix":" exposures in female subjects has not been reported in the l","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":71,"endOffset":83,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[8]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[8]","prefix":"                                              The impact of ","suffix":" on plasma eltrombopag PK was not formally assessed. However","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":219,"endOffset":231,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[8]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[8]","prefix":"ough concentrations collected prior to co-administration of ","suffix":" were similar to trough concentrations collected 24 h after ","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":329,"endOffset":341,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[8]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[8]","prefix":" collected 24 h after co-administration of a single dose of ","suffix":". In addition, plasma eltrombopag exposure for the 75 mg onc","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":455,"endOffset":467,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[8]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[8]","prefix":"mg once daily regimen (in combination with a single dose of ","suffix":") was generally as expected based on plasma eltrombopag expo","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":115,"endOffset":127,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","prefix":"  Plasma eltrombopag exposures collected in the presence of ","suffix":" were similar between Asian and non-Asian subjects. This is ","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":119,"endOffset":131,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","prefix":" conclusion, concomitant administration of eltrombopag with ","suffix":" was associated with increased rosuvastatin exposure. The th","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":162,"endOffset":174,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","prefix":"eltrombopag with rosuvastatin was associated with increased ","suffix":" exposure. The therapeutic index of HMG Co-A reductase inhib","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":57,"endOffset":69,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","prefix":"                                                         ","suffix":" has known transporter-mediated drug interactions, such as i","exact":"Rosuvastatin"},{"setid":"PMC3162661","drugname":"gemfibrozil","startOffset":149,"endOffset":160,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","prefix":"er-mediated drug interactions, such as its interaction with ","suffix":" and cyclosporin [","exact":"gemfibrozil"},{"setid":"PMC3162661","drugname":"cyclosporin","startOffset":165,"endOffset":176,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","prefix":" interactions, such as its interaction with gemfibrozil and ","suffix":" [","exact":"cyclosporin"}],[{"setid":"PMC90851","drugname":"cholesterol","startOffset":163,"endOffset":174,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"-CoA) reductase inhibitors are effective agents in lowering ","suffix":" and triglycerides and are being used by human immunodeficie","exact":"cholesterol"},{"setid":"PMC90851","drugname":"cholesterol","startOffset":207,"endOffset":218,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[11]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[11]/p[1]","prefix":"evaluated. Metabolic laboratory parameters, including total ","suffix":", low-density lipoproteins (LDL), triglycerides, glucose, in","exact":"cholesterol"},{"setid":"PMC90851","drugname":"cholesterol","startOffset":69,"endOffset":80,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","prefix":"                                                    Fasting ","suffix":" and LDL levels were significantly reduced in both arms on d","exact":"cholesterol"},{"setid":"PMC90851","drugname":"cholesterol","startOffset":516,"endOffset":527,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"rations in the liver. It was interesting to observe similar ","suffix":"-lowering effects of atorvastatin and simvastatin in the pre","exact":"cholesterol"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":725,"endOffset":735,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"e study was performed to determine the interactions between ","suffix":", a protease inhibitor, and two HMG-CoA reductase inhibitors","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":1004,"endOffset":1014,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"atin (20 mg once a day) for the first 14 days of the study. ","suffix":" (1,250 mg twice a day) was added on days 15 to 28. Pharmaco","exact":"Nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":1163,"endOffset":1173,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"med on days 14 and 28. The study drugs were well tolerated. ","suffix":" increased the steady-state area under the plasma concentrat","exact":"Nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":725,"endOffset":735,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"e study was performed to determine the interactions between ","suffix":", a protease inhibitor, and two HMG-CoA reductase inhibitors","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":690,"endOffset":700,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":"itor. It is therefore important to study the interaction of ","suffix":" and HMG-CoA reductase inhibitors. Two HMG-CoA reductase inh","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":185,"endOffset":195,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","prefix":" study to determine the pharmacokinetic interaction between ","suffix":" and atorvastatin or nelfinavir and simvastatin in healthy v","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":216,"endOffset":226,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","prefix":"okinetic interaction between nelfinavir and atorvastatin or ","suffix":" and simvastatin in healthy volunteers. Thirty-two subjects ","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":232,"endOffset":242,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[1]","prefix":" In period 2, subjects received simvastatin (20 mg QD) plus ","suffix":" (1,250 mg BID) for an additional 14 days (days 15 to 28). A","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":321,"endOffset":331,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[1]","prefix":" an additional 14 days (days 15 to 28). All simvastatin and ","suffix":" doses were taken with food.                                ","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":121,"endOffset":131,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[8]/p[1]","prefix":"Trough samples (7 ml) were collected prior to initiation of ","suffix":" on day 14 and prior to dosing on days 20 and 25. Serial blo","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":79,"endOffset":89,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[9]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[9]/p[1]","prefix":"                                          Concentrations of ","suffix":" and its active metabolite AG1402, previous named M8 (","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":304,"endOffset":314,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","prefix":". One Caucasian male in treatment group 1 (atorvastatin and ","suffix":") developed a rash, requested withdrawal from the study, and","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":624,"endOffset":634,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","prefix":"en days 20 to 25 in period 2. Mean trough concentrations of ","suffix":" on days 15, 20, 25, and 28 were 0 (0), 2.4 (1.9), 3.0 (2.3)","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":756,"endOffset":766,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","prefix":"and 3.4 (2.0) ng-eq/ml, indicating that the steady state of ","suffix":" was reached between days 20 and 35.                        ","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":150,"endOffset":160,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[2]","prefix":"ime profiles of atorvastatin in the absence and presence of ","suffix":" are presented in Fig. ","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":149,"endOffset":159,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[3]","prefix":"time profiles of simvastatin in the absence and presence of ","suffix":" are presented in Fig. ","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":372,"endOffset":382,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","prefix":"onsidered treatment-related adverse events, most related to ","suffix":" treatment. The most frequently reported adverse event was d","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":529,"endOffset":539,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"ons. In this study, we investigated the interaction between ","suffix":" and two HMG-CoA reductase inhibitors, simvastatin and atorv","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":127,"endOffset":137,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"s of this study indicate that administration of 1,250 mg of ","suffix":" BID increases the steady-state simvastatin equivalent conce","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":81,"endOffset":91,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"                                    The interaction between ","suffix":" and simvastatin or atorvastatin is likely due mainly to the","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":176,"endOffset":186,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"astatin is likely due mainly to the inhibition of CYP3A4 by ","suffix":" since the in vitro and in vivo drug metabolism of these com","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":298,"endOffset":308,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"hese compounds is well established. Inhibition of CYP3A4 by ","suffix":" could occur at the gastrointestinal wall, which would have ","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":403,"endOffset":413,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"rvastatin and simvastatin caused by the coadministration of ","suffix":" may not reflect the change in drug concentrations in the li","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":608,"endOffset":618,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"atorvastatin and simvastatin in the presence and absence of ","suffix":" (Table ","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":295,"endOffset":305,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"hronic coadministration of atorvastatin or simvastatin with ","suffix":" in HIV-positive patients. The greater-than-500% increase in","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":415,"endOffset":425,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"ncrease in the simvastatin concentration in the presence of ","suffix":" was quite extensive and may increase the risk of skeletal m","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":572,"endOffset":582,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":" is recommended that simvastatin not be coadministered with ","suffix":". Nelfinavir had a more moderate effect on atorvastatin conc","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":849,"endOffset":859,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"tion to achieve the desired effect when coadministered with ","suffix":".                                                     ","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":91,"endOffset":101,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[7]","prefix":"                          In conclusion, a clinical dose of ","suffix":" (1,250 mg BID) increased systemic exposure to simvastatin a","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":445,"endOffset":455,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":"h Conf. Retrovir. Opportunistic Infect., abstr LB 6, 2000). ","suffix":", like the other protease inhibitors, is an inhibitor of CYP","exact":"Nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":582,"endOffset":592,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":"though it is not as strong a CYP3A4 inhibitor as ritonavir. ","suffix":" is a widely prescribed protease inhibitor. It is therefore ","exact":"Nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":1004,"endOffset":1014,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"atin (20 mg once a day) for the first 14 days of the study. ","suffix":" (1,250 mg twice a day) was added on days 15 to 28. Pharmaco","exact":"Nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":1163,"endOffset":1173,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"med on days 14 and 28. The study drugs were well tolerated. ","suffix":" increased the steady-state area under the plasma concentrat","exact":"Nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":445,"endOffset":455,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":"h Conf. Retrovir. Opportunistic Infect., abstr LB 6, 2000). ","suffix":", like the other protease inhibitors, is an inhibitor of CYP","exact":"Nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":582,"endOffset":592,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":"though it is not as strong a CYP3A4 inhibitor as ritonavir. ","suffix":" is a widely prescribed protease inhibitor. It is therefore ","exact":"Nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":61,"endOffset":71,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","prefix":"                                                            ","suffix":" in combination with atorvastatin or simvastatin was well to","exact":"Nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":584,"endOffset":594,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"ded that simvastatin not be coadministered with nelfinavir. ","suffix":" had a more moderate effect on atorvastatin concentrations. ","exact":"Nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":251,"endOffset":261,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[7]","prefix":"ecommended for long-term coadministration with simvastatin. ","suffix":" also increased systemic exposure to atorvastatin moderately","exact":"Nelfinavir"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":797,"endOffset":809,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"a protease inhibitor, and two HMG-CoA reductase inhibitors, ","suffix":" and simvastatin, in healthy volunteers. Thirty-two healthy ","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":797,"endOffset":809,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"a protease inhibitor, and two HMG-CoA reductase inhibitors, ","suffix":" and simvastatin, in healthy volunteers. Thirty-two healthy ","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":894,"endOffset":906,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"thy volunteers. Thirty-two healthy subjects received either ","suffix":" calcium (10 mg once a day) or simvastatin (20 mg once a day","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":313,"endOffset":325,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":"been shown to increase the concentration of simvastatin and ","suffix":" (C. Fichtenbaum, J. Gerber, S. Rosenkranz et al., Abstr. 7t","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":200,"endOffset":212,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","prefix":"mine the pharmacokinetic interaction between nelfinavir and ","suffix":" or nelfinavir and simvastatin in healthy volunteers. Thirty","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":94,"endOffset":106,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[10]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[10]/p[1]","prefix":"                           Plasma samples were analyzed for ","suffix":" equivalent concentrations (as the total of atorvastatin aci","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":150,"endOffset":162,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[10]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[10]/p[1]","prefix":"for atorvastatin equivalent concentrations (as the total of ","suffix":" acid and its active metabolites) or simvastatin equivalent ","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":287,"endOffset":299,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","prefix":"nd three females). One Caucasian male in treatment group 1 (","suffix":" and nelfinavir) developed a rash, requested withdrawal from","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":472,"endOffset":484,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","prefix":"ic analysis. The mean (standard deviation [SD]) ages of the ","suffix":" and simvastatin groups were 31.5 (5.0) and 38.3 (9.7) years","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":594,"endOffset":606,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","prefix":"9.7) years, respectively. The mean (SD) body weights of the ","suffix":" and simvastatin groups were 74 (12) and 72 (9) kg, respecti","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":78,"endOffset":90,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","prefix":"                                           Mean (SD) trough ","suffix":" equivalent concentrations on days 1, 5, 10, 14, 20, 25, and","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":493,"endOffset":505,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","prefix":" ng-eq/ml. These results indicated that the steady state of ","suffix":" and simvastatin was reached on day 5 in period 1 and betwee","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":106,"endOffset":118,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[2]","prefix":"               The mean (SD) concentration-time profiles of ","suffix":" in the absence and presence of nelfinavir are presented in ","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":92,"endOffset":104,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","prefix":"                             Nelfinavir in combination with ","suffix":" or simvastatin was well tolerated in this study. There were","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":594,"endOffset":606,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"navir and two HMG-CoA reductase inhibitors, simvastatin and ","suffix":", because of the potential for drug interaction and the pote","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":733,"endOffset":745,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"f the coadministration of these drugs. Both simvastatin and ","suffix":" are extensively metabolized by humans, and a number of acti","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":906,"endOffset":918,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":" The active metabolites account for most of the activity of ","suffix":" and simvastatin. The enzyme inhibition assay used in this s","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":250,"endOffset":262,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"t concentrations extensively and increases the steady-state ","suffix":" equivalent concentrations moderately. The geometric mean AU","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":111,"endOffset":123,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"      The interaction between nelfinavir and simvastatin or ","suffix":" is likely due mainly to the inhibition of CYP3A4 by nelfina","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":425,"endOffset":437,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"ve a major effect on the bioavailability of simvastatin and ","suffix":", and/or at the liver, which would have an effect on the bio","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":550,"endOffset":562,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"the bioavailability and elimination rate of simvastatin and ","suffix":". In addition, a number of in vitro (","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":340,"endOffset":352,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"tion period. The increase in the systemic concentrations of ","suffix":" and simvastatin caused by the coadministration of nelfinavi","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":548,"endOffset":560,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"eresting to observe similar cholesterol-lowering effects of ","suffix":" and simvastatin in the presence and absence of nelfinavir (","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":262,"endOffset":274,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"are difficult to extrapolate to chronic coadministration of ","suffix":" or simvastatin with nelfinavir in HIV-positive patients. Th","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":625,"endOffset":637,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"d with nelfinavir. Nelfinavir had a more moderate effect on ","suffix":" concentrations. The recommended doses of atorvastatin are 1","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":679,"endOffset":691,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"ct on atorvastatin concentrations. The recommended doses of ","suffix":" are 10 to 80 mg/day. Thus, the 10-mg dose of atorvastatin s","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":737,"endOffset":749,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"f atorvastatin are 10 to 80 mg/day. Thus, the 10-mg dose of ","suffix":" should be started and titrated with caution to achieve the ","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":298,"endOffset":310,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[7]","prefix":"simvastatin. Nelfinavir also increased systemic exposure to ","suffix":" moderately and should be coadministered with atorvastatin w","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":356,"endOffset":368,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[7]","prefix":"o atorvastatin moderately and should be coadministered with ","suffix":" with caution.                                              ","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":796,"endOffset":808,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":"wo HMG-CoA reductase inhibitors were chosen for this study. ","suffix":" was studied because it is the most prescribed HMG-CoA reduc","exact":"Atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":796,"endOffset":808,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":"wo HMG-CoA reductase inhibitors were chosen for this study. ","suffix":" was studied because it is the most prescribed HMG-CoA reduc","exact":"Atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":175,"endOffset":187,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/div[2]/p[1]","prefix":"r excellent statistical analysis of the data and the Pfizer ","suffix":" Team for valuable suggestions for the study.               ","exact":"Atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin calcium","startOffset":894,"endOffset":914,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"thy volunteers. Thirty-two healthy subjects received either ","suffix":" (10 mg once a day) or simvastatin (20 mg once a day) for th","exact":"atorvastatin calcium"},{"setid":"PMC90851","drugname":"atorvastatin calcium","startOffset":894,"endOffset":914,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"thy volunteers. Thirty-two healthy subjects received either ","suffix":" (10 mg once a day) or simvastatin (20 mg once a day) for th","exact":"atorvastatin calcium"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":814,"endOffset":825,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"tor, and two HMG-CoA reductase inhibitors, atorvastatin and ","suffix":", in healthy volunteers. Thirty-two healthy subjects receive","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":937,"endOffset":948,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":" received either atorvastatin calcium (10 mg once a day) or ","suffix":" (20 mg once a day) for the first 14 days of the study. Nelf","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":231,"endOffset":242,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","prefix":"ction between nelfinavir and atorvastatin or nelfinavir and ","suffix":" in healthy volunteers. Thirty-two subjects were enrolled in","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":199,"endOffset":210,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[10]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[10]/p[1]","prefix":"e total of atorvastatin acid and its active metabolites) or ","suffix":" equivalent concentrations (as the total of simvastatin acid","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":254,"endOffset":265,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[10]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[10]/p[1]","prefix":") or simvastatin equivalent concentrations (as the total of ","suffix":" acid and its active metabolites) by a validated enzyme inhi","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":108,"endOffset":119,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","prefix":"             Nelfinavir in combination with atorvastatin or ","suffix":" was well tolerated in this study. There were no serious adv","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":278,"endOffset":289,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":" extrapolate to chronic coadministration of atorvastatin or ","suffix":" with nelfinavir in HIV-positive patients. The greater-than-","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":814,"endOffset":825,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"tor, and two HMG-CoA reductase inhibitors, atorvastatin and ","suffix":", in healthy volunteers. Thirty-two healthy subjects receive","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":937,"endOffset":948,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":" received either atorvastatin calcium (10 mg once a day) or ","suffix":" (20 mg once a day) for the first 14 days of the study. Nelf","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":297,"endOffset":308,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":"s ritonavir has been shown to increase the concentration of ","suffix":" and atorvastatin (C. Fichtenbaum, J. Gerber, S. Rosenkranz ","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":888,"endOffset":899,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":" it is the most prescribed HMG-CoA reductase inhibitor, and ","suffix":" was studied because it is particularly susceptible to CYP3A","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":231,"endOffset":242,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","prefix":"ction between nelfinavir and atorvastatin or nelfinavir and ","suffix":" in healthy volunteers. Thirty-two subjects were enrolled in","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":92,"endOffset":103,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[1]","prefix":"                             In period 1, subjects received ","suffix":" (Zocor; 20 mg QD) in the morning for the first 14 days of t","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":204,"endOffset":215,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[1]","prefix":" first 14 days of the study. In period 2, subjects received ","suffix":" (20 mg QD) plus nelfinavir (1,250 mg BID) for an additional","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":305,"endOffset":316,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[1]","prefix":",250 mg BID) for an additional 14 days (days 15 to 28). All ","suffix":" and nelfinavir doses were taken with food.                 ","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":199,"endOffset":210,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[10]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[10]/p[1]","prefix":"e total of atorvastatin acid and its active metabolites) or ","suffix":" equivalent concentrations (as the total of simvastatin acid","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":254,"endOffset":265,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[10]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[10]/p[1]","prefix":") or simvastatin equivalent concentrations (as the total of ","suffix":" acid and its active metabolites) by a validated enzyme inhi","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":489,"endOffset":500,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","prefix":"mean (standard deviation [SD]) ages of the atorvastatin and ","suffix":" groups were 31.5 (5.0) and 38.3 (9.7) years, respectively. ","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":611,"endOffset":622,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","prefix":"ctively. The mean (SD) body weights of the atorvastatin and ","suffix":" groups were 74 (12) and 72 (9) kg, respectively.           ","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":278,"endOffset":289,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","prefix":".2), and 3.3 (3.3) ng-eq/ml, respectively. Mean (SD) trough ","suffix":" equivalent concentrations on days 1, 5, 10, 14, 20, 25, and","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":510,"endOffset":521,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","prefix":"results indicated that the steady state of atorvastatin and ","suffix":" was reached on day 5 in period 1 and between days 20 to 25 ","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":106,"endOffset":117,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[3]","prefix":"               The mean (SD) concentration-time profiles of ","suffix":" in the absence and presence of nelfinavir are presented in ","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":108,"endOffset":119,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","prefix":"             Nelfinavir in combination with atorvastatin or ","suffix":" was well tolerated in this study. There were no serious adv","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":578,"endOffset":589,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"on between nelfinavir and two HMG-CoA reductase inhibitors, ","suffix":" and atorvastatin, because of the potential for drug interac","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":717,"endOffset":728,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":" the potential of the coadministration of these drugs. Both ","suffix":" and atorvastatin are extensively metabolized by humans, and","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":923,"endOffset":934,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"olites account for most of the activity of atorvastatin and ","suffix":". The enzyme inhibition assay used in this study measured th","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":169,"endOffset":180,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"on of 1,250 mg of nelfinavir BID increases the steady-state ","suffix":" equivalent concentrations extensively and increases the ste","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":96,"endOffset":107,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"                     The interaction between nelfinavir and ","suffix":" or atorvastatin is likely due mainly to the inhibition of C","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":409,"endOffset":420,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":", which would have a major effect on the bioavailability of ","suffix":" and atorvastatin, and/or at the liver, which would have an ","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":534,"endOffset":545,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"ve an effect on the bioavailability and elimination rate of ","suffix":" and atorvastatin. In addition, a number of in vitro (","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":357,"endOffset":368,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"increase in the systemic concentrations of atorvastatin and ","suffix":" caused by the coadministration of nelfinavir may not reflec","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":565,"endOffset":576,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"ve similar cholesterol-lowering effects of atorvastatin and ","suffix":" in the presence and absence of nelfinavir (Table ","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":278,"endOffset":289,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":" extrapolate to chronic coadministration of atorvastatin or ","suffix":" with nelfinavir in HIV-positive patients. The greater-than-","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":370,"endOffset":381,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"IV-positive patients. The greater-than-500% increase in the ","suffix":" concentration in the presence of nelfinavir was quite exten","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":533,"endOffset":544,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"f skeletal muscle damage. Therefore, it is recommended that ","suffix":" not be coadministered with nelfinavir. Nelfinavir had a mor","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":148,"endOffset":159,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[7]","prefix":"of nelfinavir (1,250 mg BID) increased systemic exposure to ","suffix":" approximately 500% and is not recommended for long-term coa","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":238,"endOffset":249,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[7]","prefix":" and is not recommended for long-term coadministration with ","suffix":". Nelfinavir also increased systemic exposure to atorvastati","exact":"simvastatin"},{"setid":"PMC90851","drugname":"zocor","startOffset":105,"endOffset":110,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[1]","prefix":"                In period 1, subjects received simvastatin (","suffix":"; 20 mg QD) in the morning for the first 14 days of the stud","exact":"Zocor"},{"setid":"PMC90851","drugname":"itraconazole","startOffset":237,"endOffset":249,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"uctase inhibitors with CYP3A4 inhibitors/substrates such as ","suffix":" (","exact":"itraconazole"},{"setid":"PMC90851","drugname":"itraconazole","startOffset":237,"endOffset":249,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"uctase inhibitors with CYP3A4 inhibitors/substrates such as ","suffix":" (","exact":"itraconazole"},{"setid":"PMC90851","drugname":"saquinavir","startOffset":223,"endOffset":233,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":"itors of CYP3A4. The dual protease inhibitor combination of ","suffix":" plus ritonavir has been shown to increase the concentration","exact":"saquinavir"},{"setid":"PMC90851","drugname":"ritonavir","startOffset":239,"endOffset":248,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":" The dual protease inhibitor combination of saquinavir plus ","suffix":" has been shown to increase the concentration of simvastatin","exact":"ritonavir"},{"setid":"PMC90851","drugname":"ritonavir","startOffset":571,"endOffset":580,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":" CYP3A4, although it is not as strong a CYP3A4 inhibitor as ","suffix":". Nelfinavir is a widely prescribed protease inhibitor. It i","exact":"ritonavir"},{"setid":"PMC90851","drugname":"retrovir","startOffset":393,"endOffset":401,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":"htenbaum, J. Gerber, S. Rosenkranz et al., Abstr. 7th Conf. ","suffix":". Opportunistic Infect., abstr LB 6, 2000). Nelfinavir, like","exact":"Retrovir"},{"setid":"PMC90851","drugname":"insulin","startOffset":276,"endOffset":283,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[11]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[11]/p[1]","prefix":"ol, low-density lipoproteins (LDL), triglycerides, glucose, ","suffix":", and C-peptide, were determined after an overnight fast on ","exact":"insulin"},{"setid":"PMC90851","drugname":"insulin","startOffset":276,"endOffset":283,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[11]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[11]/p[1]","prefix":"ol, low-density lipoproteins (LDL), triglycerides, glucose, ","suffix":", and C-peptide, were determined after an overnight fast on ","exact":"insulin"},{"setid":"PMC90851","drugname":"benadryl","startOffset":666,"endOffset":674,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","prefix":" 23 and withdrew from the study. Subject 3 was treated with ","suffix":" and prednisone orally plus Kenalog intramuscularly. The ras","exact":"Benadryl"},{"setid":"PMC90851","drugname":"prednisone","startOffset":679,"endOffset":689,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","prefix":"rew from the study. Subject 3 was treated with Benadryl and ","suffix":" orally plus Kenalog intramuscularly. The rash resolved afte","exact":"prednisone"},{"setid":"PMC90851","drugname":"kenalog","startOffset":702,"endOffset":709,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","prefix":"ject 3 was treated with Benadryl and prednisone orally plus ","suffix":" intramuscularly. The rash resolved after 13 days. Subject 1","exact":"Kenalog"},{"setid":"PMC90851","drugname":"tylenol","startOffset":834,"endOffset":841,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","prefix":"erienced a severe migraine headache, which was treated with ","suffix":" and resolved after 2 days. Seven subjects received medicati","exact":"Tylenol"}],[{"setid":"PMC3187007","drugname":"telaprevir","startOffset":348,"endOffset":358,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"atitis C. This study was conducted to examine the effect of ","suffix":" on atorvastatin and amlodipine pharmacokinetics (PK). This ","exact":"telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":608,"endOffset":618,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"mlodipine and 20 mg atorvastatin was administered on day 1. ","suffix":" was taken with food as a 750-mg dose every 8 h from day 11 ","exact":"Telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":844,"endOffset":854,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"lasma samples were collected for determination of the PK of ","suffix":", amlodipine, atorvastatin, ","exact":"telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":348,"endOffset":358,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"atitis C. This study was conducted to examine the effect of ","suffix":" on atorvastatin and amlodipine pharmacokinetics (PK). This ","exact":"telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":844,"endOffset":854,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"lasma samples were collected for determination of the PK of ","suffix":", amlodipine, atorvastatin, ","exact":"telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":274,"endOffset":284,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":"was designed to evaluate the drug-drug interactions between ","suffix":" and amlodipine and atorvastatin in healthy volunteers.     ","exact":"telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":131,"endOffset":141,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","prefix":" phase 1, open-label, single-center, nonrandomized study of ","suffix":" in combination with Caduet tablets containing 5 mg of amlod","exact":"telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":392,"endOffset":402,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","prefix":"-atorvastatin alone on day 1, followed by a washout period, ","suffix":" at a dose of 750 mg every 8 h (q8h) on days 11 through 26, ","exact":"telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":393,"endOffset":403,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/p[1]","prefix":"dministered alone and when administered in combination with ","suffix":". Clinical chemistry and hematology were assessed predose an","exact":"telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":130,"endOffset":140,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":"steady-state pharmacokinetic parameters were calculated for ","suffix":" on day 17 after coadministration with a single dose of amlo","exact":"telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":208,"endOffset":218,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[1]","prefix":"he study due to an adverse event (herpes zoster) during the ","suffix":"-alone period. This was considered possibly related to treat","exact":"telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":489,"endOffset":499,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[1]","prefix":"exception was moderate diarrhea in one volunteer during the ","suffix":"-amlodipine-atorvastatin combination period.                ","exact":"telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":608,"endOffset":618,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[2]","prefix":"atorvastatin-alone period, in 2 volunteers [10%] during the ","suffix":"-alone period, and in 1 volunteer [5%] during the telaprevir","exact":"telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":668,"endOffset":678,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[2]","prefix":"telaprevir-alone period, and in 1 volunteer [5%] during the ","suffix":"-amlodipine-atorvastatin combination period); dizziness (occ","exact":"telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":777,"endOffset":787,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[2]","prefix":"riod); dizziness (occurred in 2 volunteers [10%] during the ","suffix":"-alone period, and in 3 volunteers [15%] during the telaprev","exact":"telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":839,"endOffset":849,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[2]","prefix":"laprevir-alone period, and in 3 volunteers [15%] during the ","suffix":"-amlodipine-atorvastatin combination period); diarrhea (occu","exact":"telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":1013,"endOffset":1023,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[2]","prefix":"3 periods); nausea (occurred in 1 volunteer [5%] during the ","suffix":"-alone period and in 2 volunteers [11%] during the telaprevi","exact":"telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":1074,"endOffset":1084,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[2]","prefix":"elaprevir-alone period and in 2 volunteers [11%] during the ","suffix":"-amlodipine-atorvastatin combination period). Rash has been ","exact":"telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":1169,"endOffset":1179,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[2]","prefix":"combination period). Rash has been previously reported with ","suffix":" administration (","exact":"telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":93,"endOffset":103,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"                        Potential drug-drug interactions of ","suffix":" with amlodipine and atorvastatin were investigated in healt","exact":"telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":253,"endOffset":263,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":" PK of these drugs with and without the coadministration of ","suffix":". A formulation containing a combination of amlodipine and a","exact":"telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":99,"endOffset":109,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"                  A clinical drug-drug interaction study of ","suffix":" and midazolam showed that telaprevir increased the AUC of o","exact":"telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":136,"endOffset":146,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"g interaction study of telaprevir and midazolam showed that ","suffix":" increased the AUC of oral midazolam almost 9-fold (","exact":"telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":102,"endOffset":112,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"               Results from the present study indicate that ","suffix":" significantly inhibited the metabolism of both amlodipine a","exact":"telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":71,"endOffset":81,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"                                              The effect of ","suffix":" on atorvastatin disposition was more pronounced. Atorvastat","exact":"telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":86,"endOffset":96,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"                               Upon the coadministration of ","suffix":" with a single dose of amlodipine-atorvastatin, the atorvast","exact":"telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":82,"endOffset":92,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"                                   With coadministration of ","suffix":", the mean (SD) apparent clearance decreased from 685 (272) ","exact":"telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":67,"endOffset":77,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[8]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[8]","prefix":"                                                  The PK of ","suffix":" were evaluated after coadministration at steady state with ","exact":"telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":99,"endOffset":109,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[9]","prefix":"                  The coadministration of multiple doses of ","suffix":" with one dose of amlodipine and atorvastatin administered i","exact":"telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":548,"endOffset":558,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[9]","prefix":"ported in other clinical trials after the administration of ","suffix":" alone (","exact":"telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":108,"endOffset":118,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[10]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[10]","prefix":"         In summary, the results of this study suggest that ","suffix":" significantly increased exposure to amlodipine and atorvast","exact":"telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":61,"endOffset":71,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"                                                            ","suffix":" is a hepatitis C virus protease inhibitor that is both a su","exact":"Telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":608,"endOffset":618,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"mlodipine and 20 mg atorvastatin was administered on day 1. ","suffix":" was taken with food as a 750-mg dose every 8 h from day 11 ","exact":"Telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":57,"endOffset":67,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"                                                         ","suffix":" is an orally administered inhibitor of the nonstructural 3/","exact":"Telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":57,"endOffset":67,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":"                                                         ","suffix":" inhibits CYP3A-mediated metabolism at therapeutic concentra","exact":"Telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":61,"endOffset":71,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[1]","prefix":"                                                            ","suffix":" (375-mg tablets, Patheon, Mississauga, Ontario, Canada) was","exact":"Telaprevir"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":166,"endOffset":176,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"hibitor that is both a substrate and an inhibitor of CYP3A. ","suffix":" and atorvastatin are both substrates of CYP3A and are among","exact":"Amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":379,"endOffset":389,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"ted to examine the effect of telaprevir on atorvastatin and ","suffix":" pharmacokinetics (PK). This was an open-label, single seque","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":547,"endOffset":557,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"healthy male and female volunteers. A coformulation of 5 mg ","suffix":" and 20 mg atorvastatin was administered on day 1. Telaprevi","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":717,"endOffset":727,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"very 8 h from day 11 until day 26, and a single dose of the ","suffix":"-atorvastatin combination was readministered on day 17. Plas","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":856,"endOffset":866,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"s were collected for determination of the PK of telaprevir, ","suffix":", atorvastatin, ","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":379,"endOffset":389,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"ted to examine the effect of telaprevir on atorvastatin and ","suffix":" pharmacokinetics (PK). This was an open-label, single seque","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":547,"endOffset":557,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"healthy male and female volunteers. A coformulation of 5 mg ","suffix":" and 20 mg atorvastatin was administered on day 1. Telaprevi","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":717,"endOffset":727,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"very 8 h from day 11 until day 26, and a single dose of the ","suffix":"-atorvastatin combination was readministered on day 17. Plas","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":856,"endOffset":866,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"s were collected for determination of the PK of telaprevir, ","suffix":", atorvastatin, ","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":289,"endOffset":299,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":" evaluate the drug-drug interactions between telaprevir and ","suffix":" and atorvastatin in healthy volunteers.                    ","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":196,"endOffset":206,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","prefix":"revir in combination with Caduet tablets containing 5 mg of ","suffix":" and 20 mg of atorvastatin (amlodipine-atorvastatin). Volunt","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":234,"endOffset":244,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","prefix":"ts containing 5 mg of amlodipine and 20 mg of atorvastatin (","suffix":"-atorvastatin). Volunteers received the following treatment:","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":322,"endOffset":332,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","prefix":"lunteers received the following treatment: a single dose of ","suffix":"-atorvastatin alone on day 1, followed by a washout period, ","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":484,"endOffset":494,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","prefix":"very 8 h (q8h) on days 11 through 26, with a single dose of ","suffix":"-atorvastatin on day 17. Outpatient visits occurred at the s","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":139,"endOffset":149,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[2]","prefix":"tatin (25-mg fixed dose combination tablets containing 5 mg ","suffix":" and 20 mg atorvastatin; Pfizer Incorporated, New York, NY) ","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":125,"endOffset":135,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","prefix":"macokinetic evaluations were based on the concentrations of ","suffix":", atorvastatin, ","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":68,"endOffset":78,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","prefix":"                                                     Plasma ","suffix":", atorvastatin, ","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":313,"endOffset":323,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[3]","prefix":" (Indianapolis, IN). Analytes and their internal standards (","suffix":"-d4 maleic acid, atorvastatin-d5 sodium salt, ","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":303,"endOffset":313,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/p[1]","prefix":") were assessed predose and at 8, 10, and 24 h postdose for ","suffix":"-atorvastatin when administered alone and when administered ","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":77,"endOffset":87,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","prefix":"                                            The mean plasma ","suffix":" concentration-time profile is shown in ","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":196,"endOffset":206,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":"evir on day 17 after coadministration with a single dose of ","suffix":"-atorvastatin. The mean (SD) ","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":500,"endOffset":510,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[1]","prefix":"as moderate diarrhea in one volunteer during the telaprevir-","suffix":"-atorvastatin combination period.                           ","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":537,"endOffset":547,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[2]","prefix":"ncluded headache (occurred in 5 volunteers [24%] during the ","suffix":"-atorvastatin-alone period, in 2 volunteers [10%] during the","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":679,"endOffset":689,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[2]","prefix":"alone period, and in 1 volunteer [5%] during the telaprevir-","suffix":"-atorvastatin combination period); dizziness (occurred in 2 ","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":850,"endOffset":860,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[2]","prefix":"one period, and in 3 volunteers [15%] during the telaprevir-","suffix":"-atorvastatin combination period); diarrhea (occurred in 1 v","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":1085,"endOffset":1095,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[2]","prefix":"lone period and in 2 volunteers [11%] during the telaprevir-","suffix":"-atorvastatin combination period). Rash has been previously ","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":109,"endOffset":119,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"        Potential drug-drug interactions of telaprevir with ","suffix":" and atorvastatin were investigated in healthy volunteers by","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":307,"endOffset":317,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"on of telaprevir. A formulation containing a combination of ","suffix":" and atorvastatin (Caduet) was used in this study for dosing","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":426,"endOffset":436,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":" for dosing convenience. No significant interaction between ","suffix":" and atorvastatin was expected.                             ","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":160,"endOffset":170,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"t telaprevir significantly inhibited the metabolism of both ","suffix":" and atorvastatin. The bioavailability of amlodipine has bee","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":212,"endOffset":222,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"of both amlodipine and atorvastatin. The bioavailability of ","suffix":" has been reported to be ∼60% (","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":119,"endOffset":129,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"on the coadministration of telaprevir with a single dose of ","suffix":"-atorvastatin, the atorvastatin AUC","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":154,"endOffset":164,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[8]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[8]","prefix":"fter coadministration at steady state with a single dose of ","suffix":"-atorvastatin. The ","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":127,"endOffset":137,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[9]","prefix":"nistration of multiple doses of telaprevir with one dose of ","suffix":" and atorvastatin administered in 2 periods was well tolerat","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":155,"endOffset":165,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[10]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[10]","prefix":"suggest that telaprevir significantly increased exposure to ","suffix":" and atorvastatin (","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":166,"endOffset":176,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"hibitor that is both a substrate and an inhibitor of CYP3A. ","suffix":" and atorvastatin are both substrates of CYP3A and are among","exact":"Amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":57,"endOffset":67,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"                                                         ","suffix":" is a dihydropyridine calcium channel antagonist used to tre","exact":"Amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":61,"endOffset":71,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[2]","prefix":"                                                            ","suffix":"-atorvastatin (25-mg fixed dose combination tablets containi","exact":"Amlodipine"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":181,"endOffset":193,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":" both a substrate and an inhibitor of CYP3A. Amlodipine and ","suffix":" are both substrates of CYP3A and are among the drugs most f","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":362,"endOffset":374,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":" study was conducted to examine the effect of telaprevir on ","suffix":" and amlodipine pharmacokinetics (PK). This was an open-labe","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":568,"endOffset":580,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"le volunteers. A coformulation of 5 mg amlodipine and 20 mg ","suffix":" was administered on day 1. Telaprevir was taken with food a","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":728,"endOffset":740,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"om day 11 until day 26, and a single dose of the amlodipine-","suffix":" combination was readministered on day 17. Plasma samples we","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":868,"endOffset":880,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"cted for determination of the PK of telaprevir, amlodipine, ","suffix":", ","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":181,"endOffset":193,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":" both a substrate and an inhibitor of CYP3A. Amlodipine and ","suffix":" are both substrates of CYP3A and are among the drugs most f","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":362,"endOffset":374,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":" study was conducted to examine the effect of telaprevir on ","suffix":" and amlodipine pharmacokinetics (PK). This was an open-labe","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":568,"endOffset":580,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"le volunteers. A coformulation of 5 mg amlodipine and 20 mg ","suffix":" was administered on day 1. Telaprevir was taken with food a","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":728,"endOffset":740,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"om day 11 until day 26, and a single dose of the amlodipine-","suffix":" combination was readministered on day 17. Plasma samples we","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":868,"endOffset":880,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"cted for determination of the PK of telaprevir, amlodipine, ","suffix":", ","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":304,"endOffset":316,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":"rug-drug interactions between telaprevir and amlodipine and ","suffix":" in healthy volunteers.                                     ","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":220,"endOffset":232,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","prefix":"h Caduet tablets containing 5 mg of amlodipine and 20 mg of ","suffix":" (amlodipine-atorvastatin). Volunteers received the followin","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":245,"endOffset":257,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","prefix":"ng 5 mg of amlodipine and 20 mg of atorvastatin (amlodipine-","suffix":"). Volunteers received the following treatment: a single dos","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":333,"endOffset":345,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","prefix":"ceived the following treatment: a single dose of amlodipine-","suffix":" alone on day 1, followed by a washout period, telaprevir at","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":495,"endOffset":507,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","prefix":"8h) on days 11 through 26, with a single dose of amlodipine-","suffix":" on day 17. Outpatient visits occurred at the screening visi","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":72,"endOffset":84,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[2]","prefix":"                                                 Amlodipine-","suffix":" (25-mg fixed dose combination tablets containing 5 mg amlod","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":160,"endOffset":172,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[2]","prefix":"se combination tablets containing 5 mg amlodipine and 20 mg ","suffix":"; Pfizer Incorporated, New York, NY) was administered orally","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":137,"endOffset":149,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","prefix":"evaluations were based on the concentrations of amlodipine, ","suffix":", ","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":80,"endOffset":92,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","prefix":"                                         Plasma amlodipine, ","suffix":", ","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":340,"endOffset":352,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[3]","prefix":"es and their internal standards (amlodipine-d4 maleic acid, ","suffix":"-d5 sodium salt, ","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":314,"endOffset":326,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/p[1]","prefix":"ssed predose and at 8, 10, and 24 h postdose for amlodipine-","suffix":" when administered alone and when administered in combinatio","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":77,"endOffset":89,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","prefix":"                                            The mean plasma ","suffix":" concentration-time profile obtained is shown in ","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":207,"endOffset":219,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":" 17 after coadministration with a single dose of amlodipine-","suffix":". The mean (SD) ","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":511,"endOffset":523,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[1]","prefix":" diarrhea in one volunteer during the telaprevir-amlodipine-","suffix":" combination period.                                        ","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":548,"endOffset":560,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[2]","prefix":"dache (occurred in 5 volunteers [24%] during the amlodipine-","suffix":"-alone period, in 2 volunteers [10%] during the telaprevir-a","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":690,"endOffset":702,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[2]","prefix":"d, and in 1 volunteer [5%] during the telaprevir-amlodipine-","suffix":" combination period); dizziness (occurred in 2 volunteers [1","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":861,"endOffset":873,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[2]","prefix":" and in 3 volunteers [15%] during the telaprevir-amlodipine-","suffix":" combination period); diarrhea (occurred in 1 volunteer [5%]","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":1096,"endOffset":1108,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[2]","prefix":" and in 2 volunteers [11%] during the telaprevir-amlodipine-","suffix":" combination period). Rash has been previously reported with","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":124,"endOffset":136,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"al drug-drug interactions of telaprevir with amlodipine and ","suffix":" were investigated in healthy volunteers by comparing the PK","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":322,"endOffset":334,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"r. A formulation containing a combination of amlodipine and ","suffix":" (Caduet) was used in this study for dosing convenience. No ","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":441,"endOffset":453,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"venience. No significant interaction between amlodipine and ","suffix":" was expected.                                              ","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":175,"endOffset":187,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"gnificantly inhibited the metabolism of both amlodipine and ","suffix":". The bioavailability of amlodipine has been reported to be ","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":85,"endOffset":97,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"                                The effect of telaprevir on ","suffix":" disposition was more pronounced. Atorvastatin is given in t","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":130,"endOffset":142,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"ministration of telaprevir with a single dose of amlodipine-","suffix":", the atorvastatin AUC","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":148,"endOffset":160,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"laprevir with a single dose of amlodipine-atorvastatin, the ","suffix":" AUC","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":165,"endOffset":177,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[8]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[8]","prefix":"nistration at steady state with a single dose of amlodipine-","suffix":". The ","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":142,"endOffset":154,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[9]","prefix":"ultiple doses of telaprevir with one dose of amlodipine and ","suffix":" administered in 2 periods was well tolerated. There were no","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":170,"endOffset":182,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[10]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[10]","prefix":"laprevir significantly increased exposure to amlodipine and ","suffix":" (","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":189,"endOffset":201,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":" high blood pressure and angina or coronary artery disease. ","suffix":" is a hydroxymethyl glutaryl coenzyme A (HMG-CoA) reductase ","exact":"Atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":189,"endOffset":201,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":" high blood pressure and angina or coronary artery disease. ","suffix":" is a hydroxymethyl glutaryl coenzyme A (HMG-CoA) reductase ","exact":"Atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":131,"endOffset":143,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"telaprevir on atorvastatin disposition was more pronounced. ","suffix":" is given in the acid form, and its ","exact":"Atorvastatin"},{"setid":"PMC3187007","drugname":"cholesterol","startOffset":290,"endOffset":301,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"coenzyme A (HMG-CoA) reductase inhibitor used to lower high ","suffix":" levels and reduce the risk of heart attack and stroke. Thes","exact":"cholesterol"},{"setid":"PMC3187007","drugname":"caduet","startOffset":472,"endOffset":478,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"with CHC and are commercially available as a coformulation (","suffix":"; Pfizer) (","exact":"Caduet"},{"setid":"PMC3187007","drugname":"caduet","startOffset":162,"endOffset":168,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","prefix":"nter, nonrandomized study of telaprevir in combination with ","suffix":" tablets containing 5 mg of amlodipine and 20 mg of atorvast","exact":"Caduet"},{"setid":"PMC3187007","drugname":"caduet","startOffset":472,"endOffset":478,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"with CHC and are commercially available as a coformulation (","suffix":"; Pfizer) (","exact":"Caduet"},{"setid":"PMC3187007","drugname":"caduet","startOffset":162,"endOffset":168,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","prefix":"nter, nonrandomized study of telaprevir in combination with ","suffix":" tablets containing 5 mg of amlodipine and 20 mg of atorvast","exact":"Caduet"},{"setid":"PMC3187007","drugname":"caduet","startOffset":336,"endOffset":342,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"on containing a combination of amlodipine and atorvastatin (","suffix":") was used in this study for dosing convenience. No signific","exact":"Caduet"},{"setid":"PMC3187007","drugname":"caduet","startOffset":472,"endOffset":478,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"with CHC and are commercially available as a coformulation (","suffix":"; Pfizer) (","exact":"Caduet"},{"setid":"PMC3187007","drugname":"caduet","startOffset":162,"endOffset":168,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","prefix":"nter, nonrandomized study of telaprevir in combination with ","suffix":" tablets containing 5 mg of amlodipine and 20 mg of atorvast","exact":"Caduet"},{"setid":"PMC3187007","drugname":"caduet","startOffset":336,"endOffset":342,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"on containing a combination of amlodipine and atorvastatin (","suffix":") was used in this study for dosing convenience. No signific","exact":"Caduet"},{"setid":"PMC3187007","drugname":"midazolam","startOffset":114,"endOffset":123,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"   A clinical drug-drug interaction study of telaprevir and ","suffix":" showed that telaprevir increased the AUC of oral midazolam ","exact":"midazolam"},{"setid":"PMC3187007","drugname":"midazolam","startOffset":173,"endOffset":182,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":" midazolam showed that telaprevir increased the AUC of oral ","suffix":" almost 9-fold (","exact":"midazolam"}],[{"setid":"PMC3195022","drugname":"fluconazole","startOffset":391,"endOffset":402,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"-way crossover study investigated the effect of concomitant ","suffix":" on voriconazole pharmacokinetics in 10 subjects: 8 extensiv","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":588,"endOffset":599,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"sted of 4-day voriconazole-only and 5-day voriconazole-plus-","suffix":" treatments, separated by a 14-day washout. Voriconazole pha","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":918,"endOffset":929,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"drug interaction should antifungal therapy be switched from ","suffix":" to voriconazole, following various simulated lag times for ","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":1036,"endOffset":1047,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"ag times for the switch. In CYP2C19 extensive metabolizers, ","suffix":" increased the maximum plasma concentration and the area und","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":1279,"endOffset":1290,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":", however, voriconazole pharmacokinetics were unaffected by ","suffix":". The simulations based on pharmacokinetic modeling predicte","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":1427,"endOffset":1438,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"azole was started 6, 12, 24, or 36 h after the last dose of ","suffix":", the voriconazole AUC ratios (sequential therapy versus vor","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":1628,"endOffset":1639,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"14, respectively. This suggests that the remaining systemic ","suffix":" would result in a marked drug interaction with voriconazole","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":1795,"endOffset":1806,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"s were observed during coadministration, concomitant use of ","suffix":" and voriconazole is not recommended. Frequent monitoring fo","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":123,"endOffset":134,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":" clinical practice, antifungal therapy may be switched from ","suffix":" to voriconazole; such sequential use poses the potential fo","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":391,"endOffset":402,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"-way crossover study investigated the effect of concomitant ","suffix":" on voriconazole pharmacokinetics in 10 subjects: 8 extensiv","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":588,"endOffset":599,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"sted of 4-day voriconazole-only and 5-day voriconazole-plus-","suffix":" treatments, separated by a 14-day washout. Voriconazole pha","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":918,"endOffset":929,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"drug interaction should antifungal therapy be switched from ","suffix":" to voriconazole, following various simulated lag times for ","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":1036,"endOffset":1047,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"ag times for the switch. In CYP2C19 extensive metabolizers, ","suffix":" increased the maximum plasma concentration and the area und","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":1279,"endOffset":1290,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":", however, voriconazole pharmacokinetics were unaffected by ","suffix":". The simulations based on pharmacokinetic modeling predicte","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":1427,"endOffset":1438,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"azole was started 6, 12, 24, or 36 h after the last dose of ","suffix":", the voriconazole AUC ratios (sequential therapy versus vor","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":1628,"endOffset":1639,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"14, respectively. This suggests that the remaining systemic ","suffix":" would result in a marked drug interaction with voriconazole","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":1795,"endOffset":1806,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"s were observed during coadministration, concomitant use of ","suffix":" and voriconazole is not recommended. Frequent monitoring fo","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":1960,"endOffset":1971,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"nts is advisable if voriconazole is used sequentially after ","suffix":".                                                         ","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":74,"endOffset":85,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"                                           Voriconazole and ","suffix":" have similar mechanisms of action, and use of the combinati","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":155,"endOffset":166,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[4]","prefix":"e pharmacokinetics of voriconazole when coadministered with ","suffix":" to assess the maximal impact of fluconazole-mediated CYP2C1","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":199,"endOffset":210,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[4]","prefix":"ministered with fluconazole to assess the maximal impact of ","suffix":"-mediated CYP2C19 inhibition on voriconazole levels. A physi","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":490,"endOffset":501,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[4]","prefix":"zole therapy is initiated after various lag times following ","suffix":" discontinuation.                                           ","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":190,"endOffset":201,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","prefix":"zole-only treatment and a 5-day period of voriconazole-plus-","suffix":" combination treatment, separated by a 14-day washout phase.","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":823,"endOffset":834,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","prefix":"ion of both agents. During the combination treatment phase, ","suffix":" was administered immediately after the voriconazole dose.  ","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":65,"endOffset":76,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","prefix":"                                                        For ","suffix":", standard inputs available within Simcyp were utilized. The","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":317,"endOffset":328,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[3]","prefix":"e, dosing interval, and dosing duration of voriconazole and ","suffix":" in the simulation were identical to those used in the clini","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":573,"endOffset":584,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[3]","prefix":"es of 200 mg each), or voriconazole was coadministered with ","suffix":" (first fluconazole dose of 400 mg and subsequent doses of 2","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":592,"endOffset":603,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[3]","prefix":" or voriconazole was coadministered with fluconazole (first ","suffix":" dose of 400 mg and subsequent doses of 200 mg each every 24","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":702,"endOffset":713,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[3]","prefix":" 200 mg each every 24 h). For simulating sequential dosing, ","suffix":" dosing remained the same, while voriconazole administration","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":843,"endOffset":854,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[3]","prefix":"ated at times of 6, 12, and 24 h following the last dose of ","suffix":".                                                         ","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":181,"endOffset":192,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","prefix":") received voriconazole alone followed by voriconazole plus ","suffix":", and five (mean age, 24 years; age range, 22 to 27 years) r","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":278,"endOffset":289,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","prefix":"ears; age range, 22 to 27 years) received voriconazole plus ","suffix":" followed by voriconazole alone. The mean weights in the two","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":81,"endOffset":92,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[2]","prefix":"                                        Coadministration of ","suffix":" had a different effect on voriconazole pharmacokinetics in ","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":251,"endOffset":262,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[2]","prefix":"ons of voriconazole were increased when coadministered with ","suffix":" compared with voriconazole alone, while in PMs, the concent","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":81,"endOffset":92,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[3]","prefix":"                                        Coadministration of ","suffix":" reduced the intersubject variability of voriconazole ","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":183,"endOffset":194,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","prefix":" sequential dosing of voriconazole following termination of ","suffix":" therapy. The doses of both drugs remained the same as in th","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":407,"endOffset":418,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","prefix":"time intervals (6, 12, 24, and 36 h) after the last dose of ","suffix":". Accordingly, fluconazole was given at a dose of 400 mg on ","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":433,"endOffset":444,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","prefix":" and 36 h) after the last dose of fluconazole. Accordingly, ","suffix":" was given at a dose of 400 mg on day 1, followed by 200 mg ","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":135,"endOffset":146,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"s clinical study suggest that concomitant administration of ","suffix":" and voriconazole significantly increases plasma voriconazol","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":349,"endOffset":360,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"armacokinetics of voriconazole appeared to be unaffected by ","suffix":" in that population. This observation is not surprising, sin","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":1137,"endOffset":1148,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"mulations of sequential use suggested that the influence of ","suffix":" on systemic levels of voriconazole would persist for at lea","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":1239,"endOffset":1250,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"zole would persist for at least 24 h after the last dose of ","suffix":".                                                     ","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":249,"endOffset":260,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"etics was reduced when voriconazole was coadministered with ","suffix":" compared with the variability in pharmacokinetics when vori","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":415,"endOffset":426,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"is presumably occurred because the inhibition of CYP2C19 by ","suffix":" caused EM subjects to behave in a similar fashion to PM sub","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":583,"endOffset":594,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"the systemic exposure to voriconazole when given along with ","suffix":" observed in EMs did not exceed that observed in PMs. In cli","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":814,"endOffset":825,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"of these results, it is tempting to deduce that concomitant ","suffix":" could be used as a booster to achieve therapeutic levels of","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":1200,"endOffset":1211,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"equire additional consideration. First, the optimum dose of ","suffix":" needed to boost voriconazole levels is currently unknown. S","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":1278,"endOffset":1289,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":" to boost voriconazole levels is currently unknown. Second, ","suffix":" alters the shape of the concentration-time curve and marked","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":154,"endOffset":165,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"erns were noted during coadministration of voriconazole and ","suffix":" in healthy volunteers in the present study. However, elevat","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":135,"endOffset":146,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":" results of this study show that concomitantly administered ","suffix":" significantly increases plasma levels of voriconazole. Ther","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":232,"endOffset":243,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"lasma levels of voriconazole. Therefore, concomitant use of ","suffix":" and voriconazole is not recommended until it has been furth","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":452,"endOffset":463,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"nts is advisable if voriconazole is used sequentially after ","suffix":", especially when voriconazole is initiated within 24 h of t","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":531,"endOffset":542,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"ally when voriconazole is initiated within 24 h of the last ","suffix":" dose.                                                     ","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":57,"endOffset":68,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":"                                                         ","suffix":" is a potent CYP2C19 inhibitor (","exact":"Fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":577,"endOffset":588,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","prefix":"ery 12 h on days 2 and 3 and a single 200-mg dose on day 4. ","suffix":" was administered as a single loading dose of 400 mg orally ","exact":"Fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":57,"endOffset":68,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"                                                         ","suffix":" is categorized as a potent inhibitor of CYP2C9 and CPY2C19,","exact":"Fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":172,"endOffset":183,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"2C9 and CPY2C19, as well as a moderate inhibitor of CYP3A4. ","suffix":"'s effect on voriconazole pharmacokinetics is probably due t","exact":"Fluconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":138,"endOffset":150,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"ice, antifungal therapy may be switched from fluconazole to ","suffix":"; such sequential use poses the potential for drug interacti","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":274,"endOffset":286,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"ue to cytochrome P450 2C19 (CYP2C19)-mediated inhibition of ","suffix":" metabolism. This open-label, randomized, two-way crossover ","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":406,"endOffset":418,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"study investigated the effect of concomitant fluconazole on ","suffix":" pharmacokinetics in 10 subjects: 8 extensive metabolizers a","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":542,"endOffset":554,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":" poor metabolizers of CYP2C19. The study consisted of 4-day ","suffix":"-only and 5-day voriconazole-plus-fluconazole treatments, se","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":570,"endOffset":582,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"9. The study consisted of 4-day voriconazole-only and 5-day ","suffix":"-plus-fluconazole treatments, separated by a 14-day washout.","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":643,"endOffset":655,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"plus-fluconazole treatments, separated by a 14-day washout. ","suffix":" pharmacokinetics were determined by noncompartmental analys","exact":"Voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":933,"endOffset":945,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"n should antifungal therapy be switched from fluconazole to ","suffix":", following various simulated lag times for the switch. In C","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":1155,"endOffset":1167,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"the area under the plasma concentration-time curve (AUC) of ","suffix":" by 57% and 178%, respectively. In poor metabolizers, howeve","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":133,"endOffset":145,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[3]","prefix":"tion of fluconazole reduced the intersubject variability of ","suffix":" ","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":1230,"endOffset":1242,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":" 57% and 178%, respectively. In poor metabolizers, however, ","suffix":" pharmacokinetics were unaffected by fluconazole. The simula","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":1360,"endOffset":1372,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"lations based on pharmacokinetic modeling predicted that if ","suffix":" was started 6, 12, 24, or 36 h after the last dose of fluco","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":1444,"endOffset":1456,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":" 6, 12, 24, or 36 h after the last dose of fluconazole, the ","suffix":" AUC ratios (sequential therapy versus voriconazole only) af","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":1495,"endOffset":1507,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"ole, the voriconazole AUC ratios (sequential therapy versus ","suffix":" only) after the first dose would be 1.51, 1.41, 1.28, and 1","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":1687,"endOffset":1699,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":" fluconazole would result in a marked drug interaction with ","suffix":" for ≥24 h. Although no safety issues were observed during c","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":1811,"endOffset":1823,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"during coadministration, concomitant use of fluconazole and ","suffix":" is not recommended. Frequent monitoring for voriconazole-re","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":1868,"endOffset":1880,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"nd voriconazole is not recommended. Frequent monitoring for ","suffix":"-related adverse events is advisable if voriconazole is used","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":138,"endOffset":150,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"ice, antifungal therapy may be switched from fluconazole to ","suffix":"; such sequential use poses the potential for drug interacti","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":274,"endOffset":286,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"ue to cytochrome P450 2C19 (CYP2C19)-mediated inhibition of ","suffix":" metabolism. This open-label, randomized, two-way crossover ","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":406,"endOffset":418,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"study investigated the effect of concomitant fluconazole on ","suffix":" pharmacokinetics in 10 subjects: 8 extensive metabolizers a","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":542,"endOffset":554,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":" poor metabolizers of CYP2C19. The study consisted of 4-day ","suffix":"-only and 5-day voriconazole-plus-fluconazole treatments, se","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":570,"endOffset":582,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"9. The study consisted of 4-day voriconazole-only and 5-day ","suffix":"-plus-fluconazole treatments, separated by a 14-day washout.","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":933,"endOffset":945,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"n should antifungal therapy be switched from fluconazole to ","suffix":", following various simulated lag times for the switch. In C","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":1155,"endOffset":1167,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"the area under the plasma concentration-time curve (AUC) of ","suffix":" by 57% and 178%, respectively. In poor metabolizers, howeve","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":1230,"endOffset":1242,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":" 57% and 178%, respectively. In poor metabolizers, however, ","suffix":" pharmacokinetics were unaffected by fluconazole. The simula","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":1360,"endOffset":1372,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"lations based on pharmacokinetic modeling predicted that if ","suffix":" was started 6, 12, 24, or 36 h after the last dose of fluco","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":1444,"endOffset":1456,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":" 6, 12, 24, or 36 h after the last dose of fluconazole, the ","suffix":" AUC ratios (sequential therapy versus voriconazole only) af","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":1495,"endOffset":1507,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"ole, the voriconazole AUC ratios (sequential therapy versus ","suffix":" only) after the first dose would be 1.51, 1.41, 1.28, and 1","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":1687,"endOffset":1699,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":" fluconazole would result in a marked drug interaction with ","suffix":" for ≥24 h. Although no safety issues were observed during c","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":1811,"endOffset":1823,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"during coadministration, concomitant use of fluconazole and ","suffix":" is not recommended. Frequent monitoring for voriconazole-re","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":1868,"endOffset":1880,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"nd voriconazole is not recommended. Frequent monitoring for ","suffix":"-related adverse events is advisable if voriconazole is used","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":1920,"endOffset":1932,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"ing for voriconazole-related adverse events is advisable if ","suffix":" is used sequentially after fluconazole.                    ","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":105,"endOffset":117,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"            The pharmacokinetics of the triazole antifungal ","suffix":" have been widely studied (","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":117,"endOffset":129,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[4]","prefix":"To examine these issues, we studied the pharmacokinetics of ","suffix":" when coadministered with fluconazole to assess the maximal ","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":242,"endOffset":254,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[4]","prefix":"aximal impact of fluconazole-mediated CYP2C19 inhibition on ","suffix":" levels. A physiologically based pharmacokinetic (PBPK) mode","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":422,"endOffset":434,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[4]","prefix":"xtent/magnitude of the drug interaction in situations where ","suffix":" therapy is initiated after various lag times following fluc","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":122,"endOffset":134,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","prefix":"he study was divided into two treatments, a 4-day period of ","suffix":"-only treatment and a 5-day period of voriconazole-plus-fluc","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":172,"endOffset":184,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","prefix":"period of voriconazole-only treatment and a 5-day period of ","suffix":"-plus-fluconazole combination treatment, separated by a 14-d","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":874,"endOffset":886,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","prefix":"t phase, fluconazole was administered immediately after the ","suffix":" dose.                                                      ","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":87,"endOffset":99,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","prefix":"                                  Serial plasma samples for ","suffix":" pharmacokinetics were collected predosing and at 1, 2, 3, 4","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":251,"endOffset":263,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","prefix":"48 h after dosing on day 4. Plasma samples were assayed for ","suffix":" by a previously validated method using automated solid-phas","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":92,"endOffset":104,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[1]","prefix":"                             Pharmacokinetic parameters for ","suffix":" calculated on day 4 of each treatment period were used as e","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":310,"endOffset":322,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","prefix":"Simcyp Ltd., Sheffield, United Kingdom). A Simcyp model for ","suffix":" was developed using the physicochemical properties, ","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":300,"endOffset":312,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[3]","prefix":"th sexes. The dose, dosing interval, and dosing duration of ","suffix":" and fluconazole in the simulation were identical to those u","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":412,"endOffset":424,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[3]","prefix":"identical to those used in the clinical study. Accordingly, ","suffix":" alone was dosed every 12 h for 4 days (first two doses of 4","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":536,"endOffset":548,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[3]","prefix":"ses of 400 mg and subsequent five doses of 200 mg each), or ","suffix":" was coadministered with fluconazole (first fluconazole dose","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":746,"endOffset":758,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[3]","prefix":"uential dosing, fluconazole dosing remained the same, while ","suffix":" administration was initiated at times of 6, 12, and 24 h fo","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":132,"endOffset":144,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","prefix":"ts (mean age, 29 years; age range, 24 to 43 years) received ","suffix":" alone followed by voriconazole plus fluconazole, and five (","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":163,"endOffset":175,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","prefix":"ge, 24 to 43 years) received voriconazole alone followed by ","suffix":" plus fluconazole, and five (mean age, 24 years; age range, ","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":260,"endOffset":272,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","prefix":"ve (mean age, 24 years; age range, 22 to 27 years) received ","suffix":" plus fluconazole followed by voriconazole alone. The mean w","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":302,"endOffset":314,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","prefix":"7 years) received voriconazole plus fluconazole followed by ","suffix":" alone. The mean weights in the two groups were 70 kg (range","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":119,"endOffset":131,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[2]","prefix":"  Coadministration of fluconazole had a different effect on ","suffix":" pharmacokinetics in EMs and PMs. In EMs, plasma concentrati","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":198,"endOffset":210,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[2]","prefix":"cokinetics in EMs and PMs. In EMs, plasma concentrations of ","suffix":" were increased when coadministered with fluconazole compare","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":277,"endOffset":289,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[2]","prefix":"ncreased when coadministered with fluconazole compared with ","suffix":" alone, while in PMs, the concentration-time profiles were s","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":133,"endOffset":145,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[3]","prefix":"tion of fluconazole reduced the intersubject variability of ","suffix":" ","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":145,"endOffset":157,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","prefix":" carried out to evaluate the effect of sequential dosing of ","suffix":" following termination of fluconazole therapy. The doses of ","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":296,"endOffset":308,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","prefix":" the same as in the clinical study, with the exception that ","suffix":" was initiated sequentially at various time intervals (6, 12","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":535,"endOffset":547,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","prefix":"on day 1, followed by 200 mg every 24 h on days 2 to 5, and ","suffix":" was initiated sequentially at doses of 400 mg every 12 h on","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":151,"endOffset":163,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":" suggest that concomitant administration of fluconazole and ","suffix":" significantly increases plasma voriconazole concentrations ","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":195,"endOffset":207,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"fluconazole and voriconazole significantly increases plasma ","suffix":" concentrations in CYP2C19 EMs. Although the sample size was","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":307,"endOffset":319,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":" the sample size was small for PMs, the pharmacokinetics of ","suffix":" appeared to be unaffected by fluconazole in that population","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":1171,"endOffset":1183,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"ted that the influence of fluconazole on systemic levels of ","suffix":" would persist for at least 24 h after the last dose of fluc","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":196,"endOffset":208,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":" as a moderate inhibitor of CYP3A4. Fluconazole's effect on ","suffix":" pharmacokinetics is probably due to its inhibition of CPY2C","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":278,"endOffset":290,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"inetics is probably due to its inhibition of CPY2C19, since ","suffix":" metabolism is mainly mediated by CYP2C19, followed by CYP3A","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":165,"endOffset":177,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"an volunteers, the considerable intersubject variability in ","suffix":" pharmacokinetics was reduced when voriconazole was coadmini","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":212,"endOffset":224,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"riability in voriconazole pharmacokinetics was reduced when ","suffix":" was coadministered with fluconazole compared with the varia","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":316,"endOffset":328,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"zole compared with the variability in pharmacokinetics when ","suffix":" was administered alone. This presumably occurred because th","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":548,"endOffset":560,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"cts in this respect. Nevertheless, the systemic exposure to ","suffix":" when given along with fluconazole observed in EMs did not e","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":670,"endOffset":682,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":" did not exceed that observed in PMs. In clinical practice, ","suffix":" is administered to both EMs and PMs at an identical dose. O","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":886,"endOffset":898,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"could be used as a booster to achieve therapeutic levels of ","suffix":" with doses lower than those currently recommended, to allow","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":970,"endOffset":982,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"lower than those currently recommended, to allow once-daily ","suffix":" dosing, or to reduce the intersubject variability in vorico","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":1036,"endOffset":1048,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"nazole dosing, or to reduce the intersubject variability in ","suffix":" pharmacokinetics. Although this approach seems attractive, ","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":1228,"endOffset":1240,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"ion. First, the optimum dose of fluconazole needed to boost ","suffix":" levels is currently unknown. Second, fluconazole alters the","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":1362,"endOffset":1374,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"hape of the concentration-time curve and markedly increases ","suffix":" trough concentrations, which have been linked to a higher i","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":1446,"endOffset":1458,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"entrations, which have been linked to a higher incidence of ","suffix":"-associated toxicity (","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":137,"endOffset":149,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"icant safety concerns were noted during coadministration of ","suffix":" and fluconazole in healthy volunteers in the present study.","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":228,"endOffset":240,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":" healthy volunteers in the present study. However, elevated ","suffix":" plasma levels are associated with an increased likelihood o","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":188,"endOffset":200,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"stered fluconazole significantly increases plasma levels of ","suffix":". Therefore, concomitant use of fluconazole and voriconazole","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":248,"endOffset":260,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"voriconazole. Therefore, concomitant use of fluconazole and ","suffix":" is not recommended until it has been further evaluated in c","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":360,"endOffset":372,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"rther evaluated in clinical trials. Frequent monitoring for ","suffix":"-related adverse events is advisable if voriconazole is used","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":412,"endOffset":424,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"ing for voriconazole-related adverse events is advisable if ","suffix":" is used sequentially after fluconazole, especially when vor","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":481,"endOffset":493,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"ole is used sequentially after fluconazole, especially when ","suffix":" is initiated within 24 h of the last fluconazole dose.     ","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":643,"endOffset":655,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"plus-fluconazole treatments, separated by a 14-day washout. ","suffix":" pharmacokinetics were determined by noncompartmental analys","exact":"Voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":57,"endOffset":69,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"                                                         ","suffix":" and fluconazole have similar mechanisms of action, and use ","exact":"Voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":403,"endOffset":415,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","prefix":" All treatments were administered orally in a fasted state. ","suffix":" was given as a loading dose of 400 mg orally twice daily (e","exact":"Voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":61,"endOffset":73,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[2]","prefix":"                                                            ","suffix":" pharmacokinetic parameters were determined by noncompartmen","exact":"Voriconazole"},{"setid":"PMC3195022","drugname":"advantage","startOffset":190,"endOffset":199,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"f the combination of both drugs does not appear to offer an ","suffix":" over use of the single agents (","exact":"advantage"}],[{"setid":"PMC1156914","drugname":"olanzapine","startOffset":413,"endOffset":423,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":" polypharmacy, and 13.9 days without antipsychotic therapy. ","suffix":"-initiated patients were significantly more likely to be on ","exact":"Olanzapine"},{"setid":"PMC1156914","drugname":"olanzapine","startOffset":685,"endOffset":695,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"he number of monotherapy days was significantly greater for ","suffix":" than quetiapine (p < .001), but not for olanzapine versus r","exact":"olanzapine"},{"setid":"PMC1156914","drugname":"olanzapine","startOffset":736,"endOffset":746,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"ater for olanzapine than quetiapine (p < .001), but not for ","suffix":" versus risperidone, or for risperidone versus quetiapine-in","exact":"olanzapine"},{"setid":"PMC1156914","drugname":"olanzapine","startOffset":286,"endOffset":296,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"n patients (N = 796) who were initiated during the study on ","suffix":" (N = 405), quetiapine (N = 115), or risperidone (N = 276). ","exact":"olanzapine"},{"setid":"PMC1156914","drugname":"olanzapine","startOffset":685,"endOffset":695,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"he number of monotherapy days was significantly greater for ","suffix":" than quetiapine (p < .001), but not for olanzapine versus r","exact":"olanzapine"},{"setid":"PMC1156914","drugname":"olanzapine","startOffset":736,"endOffset":746,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"ater for olanzapine than quetiapine (p < .001), but not for ","suffix":" versus risperidone, or for risperidone versus quetiapine-in","exact":"olanzapine"},{"setid":"PMC1156914","drugname":"olanzapine","startOffset":448,"endOffset":458,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[8]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[8]","prefix":"tients initiated on commonly used atypical antipsychotics - ","suffix":", quetiapine, or risperidone - and compared their rates and ","exact":"olanzapine"},{"setid":"PMC1156914","drugname":"olanzapine","startOffset":192,"endOffset":202,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[5]","prefix":"ted on one of three commonly used atypical antipsychotics - ","suffix":", quetiapine, or risperidone, in regular oral formulation. P","exact":"olanzapine"},{"setid":"PMC1156914","drugname":"olanzapine","startOffset":183,"endOffset":193,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[3]","prefix":"utcome measures for initiating treatment group comparisons (","suffix":", quetiapine, or risperidone): (a) the percentage of patient","exact":"olanzapine"},{"setid":"PMC1156914","drugname":"olanzapine","startOffset":99,"endOffset":109,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":"                      A significantly greater percentage of ","suffix":"-treated patients were on antipsychotic monotherapy during t","exact":"olanzapine"},{"setid":"PMC1156914","drugname":"olanzapine","startOffset":142,"endOffset":152,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[3]","prefix":"ber of monotherapy days on the initiating antipsychotic for ","suffix":", quetiapine, and risperidone are presented in Table ","exact":"olanzapine"},{"setid":"PMC1156914","drugname":"olanzapine","startOffset":191,"endOffset":201,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"the time of initiation on the studied atypical medications (","suffix":", quetiapine, and risperidone). These monotherapy-initiated ","exact":"olanzapine"},{"setid":"PMC1156914","drugname":"olanzapine","startOffset":230,"endOffset":240,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"d atypical antipsychotic medications. Patients initiated on ","suffix":" were significantly more likely to be on monotherapy compare","exact":"olanzapine"},{"setid":"PMC1156914","drugname":"olanzapine","startOffset":505,"endOffset":515,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"gs appear consistent with several previous studies in which ","suffix":"-treated patients were found to have significantly higher ra","exact":"olanzapine"},{"setid":"PMC1156914","drugname":"olanzapine","startOffset":278,"endOffset":288,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[9]","prefix":"or of the sponsor's antipsychotic medication (in this case, ","suffix":"). Although we cannot completely rule out this possibility, ","exact":"olanzapine"},{"setid":"PMC1156914","drugname":"olanzapine","startOffset":229,"endOffset":239,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":"he 1-year period compared to risperidone and to quetiapine. ","suffix":"-treated patients were 2.08 times more likely to be on monot","exact":"Olanzapine"},{"setid":"PMC1156914","drugname":"quetiapine","startOffset":308,"endOffset":318,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"ho were initiated during the study on olanzapine (N = 405), ","suffix":" (N = 115), or risperidone (N = 276). The percentage of pati","exact":"quetiapine"},{"setid":"PMC1156914","drugname":"quetiapine","startOffset":793,"endOffset":803,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"or olanzapine versus risperidone, or for risperidone versus ","suffix":"-initiated patients.                                        ","exact":"quetiapine"},{"setid":"PMC1156914","drugname":"quetiapine","startOffset":460,"endOffset":470,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[8]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[8]","prefix":"ated on commonly used atypical antipsychotics - olanzapine, ","suffix":", or risperidone - and compared their rates and duration of ","exact":"quetiapine"},{"setid":"PMC1156914","drugname":"quetiapine","startOffset":204,"endOffset":214,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[5]","prefix":"f three commonly used atypical antipsychotics - olanzapine, ","suffix":", or risperidone, in regular oral formulation. Participants ","exact":"quetiapine"},{"setid":"PMC1156914","drugname":"quetiapine","startOffset":195,"endOffset":205,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[3]","prefix":"res for initiating treatment group comparisons (olanzapine, ","suffix":", or risperidone): (a) the percentage of patients on antipsy","exact":"quetiapine"},{"setid":"PMC1156914","drugname":"quetiapine","startOffset":541,"endOffset":551,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":", 1.01-1.84, p = .043). Differences between risperidone and ","suffix":" initiators showed a trend toward significance (OR = 1.53, 9","exact":"quetiapine"},{"setid":"PMC1156914","drugname":"quetiapine","startOffset":154,"endOffset":164,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[3]","prefix":"herapy days on the initiating antipsychotic for olanzapine, ","suffix":", and risperidone are presented in Table ","exact":"quetiapine"},{"setid":"PMC1156914","drugname":"quetiapine","startOffset":203,"endOffset":213,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"initiation on the studied atypical medications (olanzapine, ","suffix":", and risperidone). These monotherapy-initiated patients con","exact":"quetiapine"},{"setid":"PMC1156914","drugname":"quetiapine","startOffset":481,"endOffset":491,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[8]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[8]","prefix":"is also important because some antipsychotics, particularly ","suffix":" in low doses, may have been used to treat insomnia rather t","exact":"quetiapine"},{"setid":"PMC1156914","drugname":"quetiapine","startOffset":601,"endOffset":611,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"-year post initiation compared to risperidone (p = .043) or ","suffix":" (p = .002). The number of monotherapy days was significantl","exact":"quetiapine"},{"setid":"PMC1156914","drugname":"quetiapine","startOffset":793,"endOffset":803,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"or olanzapine versus risperidone, or for risperidone versus ","suffix":"-initiated patients.                                        ","exact":"quetiapine"},{"setid":"PMC1156914","drugname":"quetiapine","startOffset":701,"endOffset":711,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"otherapy days was significantly greater for olanzapine than ","suffix":" (p < .001), but not for olanzapine versus risperidone, or f","exact":"quetiapine"},{"setid":"PMC1156914","drugname":"quetiapine","startOffset":308,"endOffset":318,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"ho were initiated during the study on olanzapine (N = 405), ","suffix":" (N = 115), or risperidone (N = 276). The percentage of pati","exact":"quetiapine"},{"setid":"PMC1156914","drugname":"quetiapine","startOffset":601,"endOffset":611,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"-year post initiation compared to risperidone (p = .043) or ","suffix":" (p = .002). The number of monotherapy days was significantl","exact":"quetiapine"},{"setid":"PMC1156914","drugname":"quetiapine","startOffset":701,"endOffset":711,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"otherapy days was significantly greater for olanzapine than ","suffix":" (p < .001), but not for olanzapine versus risperidone, or f","exact":"quetiapine"},{"setid":"PMC1156914","drugname":"quetiapine","startOffset":793,"endOffset":803,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"or olanzapine versus risperidone, or for risperidone versus ","suffix":"-initiated patients.                                        ","exact":"quetiapine"},{"setid":"PMC1156914","drugname":"quetiapine","startOffset":460,"endOffset":470,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[8]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[8]","prefix":"ated on commonly used atypical antipsychotics - olanzapine, ","suffix":", or risperidone - and compared their rates and duration of ","exact":"quetiapine"},{"setid":"PMC1156914","drugname":"quetiapine","startOffset":204,"endOffset":214,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[5]","prefix":"f three commonly used atypical antipsychotics - olanzapine, ","suffix":", or risperidone, in regular oral formulation. Participants ","exact":"quetiapine"},{"setid":"PMC1156914","drugname":"quetiapine","startOffset":195,"endOffset":205,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[3]","prefix":"res for initiating treatment group comparisons (olanzapine, ","suffix":", or risperidone): (a) the percentage of patients on antipsy","exact":"quetiapine"},{"setid":"PMC1156914","drugname":"quetiapine","startOffset":217,"endOffset":227,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":"apy during the 1-year period compared to risperidone and to ","suffix":". Olanzapine-treated patients were 2.08 times more likely to","exact":"quetiapine"},{"setid":"PMC1156914","drugname":"quetiapine","startOffset":311,"endOffset":321,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":"ients were 2.08 times more likely to be on monotherapy than ","suffix":" (Odds Ratio (OR) = 2.08, 95% Confidence Interval (CI), 1.30","exact":"quetiapine"},{"setid":"PMC1156914","drugname":"quetiapine","startOffset":541,"endOffset":551,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":", 1.01-1.84, p = .043). Differences between risperidone and ","suffix":" initiators showed a trend toward significance (OR = 1.53, 9","exact":"quetiapine"},{"setid":"PMC1156914","drugname":"quetiapine","startOffset":154,"endOffset":164,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[3]","prefix":"herapy days on the initiating antipsychotic for olanzapine, ","suffix":", and risperidone are presented in Table ","exact":"quetiapine"},{"setid":"PMC1156914","drugname":"quetiapine","startOffset":203,"endOffset":213,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"initiation on the studied atypical medications (olanzapine, ","suffix":", and risperidone). These monotherapy-initiated patients con","exact":"quetiapine"},{"setid":"PMC1156914","drugname":"quetiapine","startOffset":305,"endOffset":315,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":" significantly more likely to be on monotherapy compared to ","suffix":" (rate and duration) or risperidone-initiated patients (rate","exact":"quetiapine"},{"setid":"PMC1156914","drugname":"quetiapine","startOffset":481,"endOffset":491,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[8]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[8]","prefix":"is also important because some antipsychotics, particularly ","suffix":" in low doses, may have been used to treat insomnia rather t","exact":"quetiapine"},{"setid":"PMC1156914","drugname":"quetiapine","startOffset":638,"endOffset":648,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[8]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[8]","prefix":"phrenia. Although some have speculated that higher doses of ","suffix":" produce better outcome, the available data [","exact":"quetiapine"},{"setid":"PMC1156914","drugname":"risperidone","startOffset":333,"endOffset":344,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"the study on olanzapine (N = 405), quetiapine (N = 115), or ","suffix":" (N = 276). The percentage of patients with monotherapy on t","exact":"risperidone"},{"setid":"PMC1156914","drugname":"risperidone","startOffset":774,"endOffset":785,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":" < .001), but not for olanzapine versus risperidone, or for ","suffix":" versus quetiapine-initiated patients.                      ","exact":"risperidone"},{"setid":"PMC1156914","drugname":"risperidone","startOffset":475,"endOffset":486,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[8]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[8]","prefix":"y used atypical antipsychotics - olanzapine, quetiapine, or ","suffix":" - and compared their rates and duration of monotherapy duri","exact":"risperidone"},{"setid":"PMC1156914","drugname":"risperidone","startOffset":219,"endOffset":230,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[5]","prefix":"y used atypical antipsychotics - olanzapine, quetiapine, or ","suffix":", in regular oral formulation. Participants were defined as ","exact":"risperidone"},{"setid":"PMC1156914","drugname":"risperidone","startOffset":210,"endOffset":221,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[3]","prefix":"ing treatment group comparisons (olanzapine, quetiapine, or ","suffix":"): (a) the percentage of patients on antipsychotic monothera","exact":"risperidone"},{"setid":"PMC1156914","drugname":"risperidone","startOffset":575,"endOffset":586,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"antipsychotic during the 1-year post initiation compared to ","suffix":" (p = .043) or quetiapine (p = .002). The number of monother","exact":"risperidone"},{"setid":"PMC1156914","drugname":"risperidone","startOffset":754,"endOffset":765,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"e than quetiapine (p < .001), but not for olanzapine versus ","suffix":", or for risperidone versus quetiapine-initiated patients.  ","exact":"risperidone"},{"setid":"PMC1156914","drugname":"risperidone","startOffset":333,"endOffset":344,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"the study on olanzapine (N = 405), quetiapine (N = 115), or ","suffix":" (N = 276). The percentage of patients with monotherapy on t","exact":"risperidone"},{"setid":"PMC1156914","drugname":"risperidone","startOffset":575,"endOffset":586,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"antipsychotic during the 1-year post initiation compared to ","suffix":" (p = .043) or quetiapine (p = .002). The number of monother","exact":"risperidone"},{"setid":"PMC1156914","drugname":"risperidone","startOffset":754,"endOffset":765,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"e than quetiapine (p < .001), but not for olanzapine versus ","suffix":", or for risperidone versus quetiapine-initiated patients.  ","exact":"risperidone"},{"setid":"PMC1156914","drugname":"risperidone","startOffset":774,"endOffset":785,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":" < .001), but not for olanzapine versus risperidone, or for ","suffix":" versus quetiapine-initiated patients.                      ","exact":"risperidone"},{"setid":"PMC1156914","drugname":"risperidone","startOffset":475,"endOffset":486,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[8]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[8]","prefix":"y used atypical antipsychotics - olanzapine, quetiapine, or ","suffix":" - and compared their rates and duration of monotherapy duri","exact":"risperidone"},{"setid":"PMC1156914","drugname":"risperidone","startOffset":219,"endOffset":230,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[5]","prefix":"y used atypical antipsychotics - olanzapine, quetiapine, or ","suffix":", in regular oral formulation. Participants were defined as ","exact":"risperidone"},{"setid":"PMC1156914","drugname":"risperidone","startOffset":210,"endOffset":221,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[3]","prefix":"ing treatment group comparisons (olanzapine, quetiapine, or ","suffix":"): (a) the percentage of patients on antipsychotic monothera","exact":"risperidone"},{"setid":"PMC1156914","drugname":"risperidone","startOffset":198,"endOffset":209,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":"ipsychotic monotherapy during the 1-year period compared to ","suffix":" and to quetiapine. Olanzapine-treated patients were 2.08 ti","exact":"risperidone"},{"setid":"PMC1156914","drugname":"risperidone","startOffset":452,"endOffset":463,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":".002), and 1.36 times more likely to be on monotherapy than ","suffix":" (OR = 1.36, 95%CI, 1.01-1.84, p = .043). Differences betwee","exact":"risperidone"},{"setid":"PMC1156914","drugname":"risperidone","startOffset":525,"endOffset":536,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":"OR = 1.36, 95%CI, 1.01-1.84, p = .043). Differences between ","suffix":" and quetiapine initiators showed a trend toward significanc","exact":"risperidone"},{"setid":"PMC1156914","drugname":"risperidone","startOffset":170,"endOffset":181,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[3]","prefix":"he initiating antipsychotic for olanzapine, quetiapine, and ","suffix":" are presented in Table ","exact":"risperidone"},{"setid":"PMC1156914","drugname":"risperidone","startOffset":219,"endOffset":230,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"e studied atypical medications (olanzapine, quetiapine, and ","suffix":"). These monotherapy-initiated patients continued on monothe","exact":"risperidone"},{"setid":"PMC1156914","drugname":"risperidone","startOffset":339,"endOffset":350,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"n monotherapy compared to quetiapine (rate and duration) or ","suffix":"-initiated patients (rate only) during the 1-year post treat","exact":"risperidone"},{"setid":"PMC1156914","drugname":"risperidone","startOffset":605,"endOffset":616,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"o have significantly higher rate of monotherapy compared to ","suffix":" [","exact":"risperidone"}],[{"setid":"PMC1490169","drugname":"warfarin","startOffset":152,"endOffset":160,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","prefix":"ount for a significant proportion of overanticoagulation in ","suffix":" users. However, little is known about the incidence or degr","exact":"warfarin"},{"setid":"PMC1490169","drugname":"warfarin","startOffset":110,"endOffset":118,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"               Retrospective cohort study of patients using ","suffix":" who initiated an antibiotic (azithromycin, levofloxacin, or","exact":"warfarin"},{"setid":"PMC1490169","drugname":"warfarin","startOffset":73,"endOffset":81,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"                                            The benefits of ","suffix":" are well established but offset by the risk of major hemorr","exact":"warfarin"},{"setid":"PMC1490169","drugname":"warfarin","startOffset":123,"endOffset":131,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":"ducted a retrospective cohort study of patients with stable ","suffix":" doses and INRs who received a prescription for terazosin, a","exact":"warfarin"},{"setid":"PMC1490169","drugname":"warfarin","startOffset":430,"endOffset":438,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":"osen as our control because of its lack of interaction with ","suffix":".","exact":"warfarin"},{"setid":"PMC1490169","drugname":"warfarin","startOffset":435,"endOffset":443,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"years old. There were no differences in the indications for ","suffix":" use (","exact":"warfarin"},{"setid":"PMC1490169","drugname":"warfarin","startOffset":111,"endOffset":119,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"      A graded increase in both the incidence and degree of ","suffix":" interaction from terazosin to azithromycin to levofloxacin ","exact":"warfarin"},{"setid":"PMC1490169","drugname":"warfarin","startOffset":199,"endOffset":207,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":"azithromycin, levofloxacin, or TMP/SMX was added to chronic ","suffix":" therapy in patients who were acutely ill. Prior studies are","exact":"warfarin"},{"setid":"PMC1490169","drugname":"warfarin","startOffset":117,"endOffset":125,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","prefix":"It is well known that sulfa-based antibiotics interact with ","suffix":", but the incidence has not been adequately studied.","exact":"warfarin"},{"setid":"PMC1490169","drugname":"warfarin","startOffset":144,"endOffset":152,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","prefix":"gths. We eliminated patients who did not have both a stable ","suffix":" dose and a stable level of anticoagulant intensity and limi","exact":"warfarin"},{"setid":"PMC1490169","drugname":"warfarin","startOffset":1014,"endOffset":1022,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","prefix":"ty to our findings. Terazosin is known not to interact with ","suffix":", while TMP/SMX has a well-described interaction.","exact":"warfarin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":148,"endOffset":160,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"udy of patients using warfarin who initiated an antibiotic (","suffix":", levofloxacin, or trimethoprim/sulfamethoxazole (TMP/SMX)) ","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":122,"endOffset":134,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","prefix":"   The mean change in INR was −0.15 for terazosin, 0.51 for ","suffix":", 0.85 for levofloxacin, and 1.76 for TMP/SMX. These mean IN","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":356,"endOffset":368,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","prefix":"dence of supratherapeutic INR was 5% for terazosin, 31% for ","suffix":", 33% for levofloxacin, and 69% for TMP/SMX. The incidence o","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":478,"endOffset":490,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","prefix":"ncidence of absolute INR >4.0 was 0% for terazosin, 16% for ","suffix":", 19% for levofloxacin, and 44% for TMP/SMX.                ","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":114,"endOffset":126,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[6]/p[1]","prefix":"           Among acutely ill outpatients, oral antibiotics (","suffix":", levofloxacin, and TMP/SMX) increase the incidence and degr","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":315,"endOffset":327,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"MX in 120 patients. Initially 43, 35, 41, and 24 terazosin, ","suffix":", levofloxacin, and TMP/SMX patients, respectively, were inc","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":120,"endOffset":132,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/p[1]","prefix":"ng acutely ill outpatients, the use of the oral antibiotics ","suffix":", levofloxacin, and TMP/SMX increases both the incidence and","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":148,"endOffset":160,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"udy of patients using warfarin who initiated an antibiotic (","suffix":", levofloxacin, or trimethoprim/sulfamethoxazole (TMP/SMX)) ","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":122,"endOffset":134,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","prefix":"   The mean change in INR was −0.15 for terazosin, 0.51 for ","suffix":", 0.85 for levofloxacin, and 1.76 for TMP/SMX. These mean IN","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":356,"endOffset":368,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","prefix":"dence of supratherapeutic INR was 5% for terazosin, 31% for ","suffix":", 33% for levofloxacin, and 69% for TMP/SMX. The incidence o","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":478,"endOffset":490,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","prefix":"ncidence of absolute INR >4.0 was 0% for terazosin, 16% for ","suffix":", 19% for levofloxacin, and 44% for TMP/SMX.                ","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":114,"endOffset":126,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[6]/p[1]","prefix":"           Among acutely ill outpatients, oral antibiotics (","suffix":", levofloxacin, and TMP/SMX) increase the incidence and degr","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":190,"endOffset":202,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":"n doses and INRs who received a prescription for terazosin, ","suffix":", levofloxacin, or TMP/SMX for clinical indications between ","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":142,"endOffset":154,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"ptions for terazosin in 333 patients, 273 prescriptions for ","suffix":" in 158 patients, 370 prescriptions for levofloxacin in 258 ","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":315,"endOffset":327,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"MX in 120 patients. Initially 43, 35, 41, and 24 terazosin, ","suffix":", levofloxacin, and TMP/SMX patients, respectively, were inc","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":722,"endOffset":734,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":" patients had INRs drawn between days 15 and 30. Thirty-two ","suffix":", 27 levofloxacin, and 16 TMP/SMX patients were included in ","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":245,"endOffset":257,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"ysis. The median time to follow-up was 17.5 (terazosin), 7 (","suffix":"), 6 (levofloxacin), and 6 (TMP/SMX) days. Men constituted 9","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":150,"endOffset":162,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"idence and degree of warfarin interaction from terazosin to ","suffix":" to levofloxacin to TMP/SMX was found (","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":139,"endOffset":151,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":"icant increase in the incidence of overanticoagulation when ","suffix":", levofloxacin, or TMP/SMX was added to chronic warfarin the","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":157,"endOffset":169,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"d no significant differences in INR after the initiation of ","suffix":" for clinical indications compared with terazosin","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":713,"endOffset":725,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","prefix":"ease. Chronic renal disease was seen more frequently in the ","suffix":" and levofloxacin groups than the TMP/SMX and terazosin grou","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":120,"endOffset":132,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/p[1]","prefix":"ng acutely ill outpatients, the use of the oral antibiotics ","suffix":", levofloxacin, and TMP/SMX increases both the incidence and","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":162,"endOffset":174,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"s using warfarin who initiated an antibiotic (azithromycin, ","suffix":", or trimethoprim/sulfamethoxazole (TMP/SMX)) or terazosin f","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":145,"endOffset":157,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","prefix":"NR was −0.15 for terazosin, 0.51 for azithromycin, 0.85 for ","suffix":", and 1.76 for TMP/SMX. These mean INR changes in the antibi","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":378,"endOffset":390,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","prefix":"tic INR was 5% for terazosin, 31% for azithromycin, 33% for ","suffix":", and 69% for TMP/SMX. The incidence of absolute INR >4.0 wa","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":500,"endOffset":512,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","prefix":"NR >4.0 was 0% for terazosin, 16% for azithromycin, 19% for ","suffix":", and 44% for TMP/SMX.                                      ","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":128,"endOffset":140,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[6]/p[1]","prefix":"ng acutely ill outpatients, oral antibiotics (azithromycin, ","suffix":", and TMP/SMX) increase the incidence and degree of overanti","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":329,"endOffset":341,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"ents. Initially 43, 35, 41, and 24 terazosin, azithromycin, ","suffix":", and TMP/SMX patients, respectively, were included and brou","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":134,"endOffset":146,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/p[1]","prefix":" outpatients, the use of the oral antibiotics azithromycin, ","suffix":", and TMP/SMX increases both the incidence and degree of ove","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":162,"endOffset":174,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"s using warfarin who initiated an antibiotic (azithromycin, ","suffix":", or trimethoprim/sulfamethoxazole (TMP/SMX)) or terazosin f","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":145,"endOffset":157,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","prefix":"NR was −0.15 for terazosin, 0.51 for azithromycin, 0.85 for ","suffix":", and 1.76 for TMP/SMX. These mean INR changes in the antibi","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":378,"endOffset":390,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","prefix":"tic INR was 5% for terazosin, 31% for azithromycin, 33% for ","suffix":", and 69% for TMP/SMX. The incidence of absolute INR >4.0 wa","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":500,"endOffset":512,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","prefix":"NR >4.0 was 0% for terazosin, 16% for azithromycin, 19% for ","suffix":", and 44% for TMP/SMX.                                      ","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":128,"endOffset":140,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[6]/p[1]","prefix":"ng acutely ill outpatients, oral antibiotics (azithromycin, ","suffix":", and TMP/SMX) increase the incidence and degree of overanti","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":204,"endOffset":216,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":"Rs who received a prescription for terazosin, azithromycin, ","suffix":", or TMP/SMX for clinical indications between January 1998 a","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":194,"endOffset":206,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"ons for azithromycin in 158 patients, 370 prescriptions for ","suffix":" in 258 patients, and 151 prescriptions for TMP/SMX in 120 p","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":329,"endOffset":341,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"ents. Initially 43, 35, 41, and 24 terazosin, azithromycin, ","suffix":", and TMP/SMX patients, respectively, were included and brou","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":739,"endOffset":751,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"s drawn between days 15 and 30. Thirty-two azithromycin, 27 ","suffix":", and 16 TMP/SMX patients were included in the trial (","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":263,"endOffset":275,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"ime to follow-up was 17.5 (terazosin), 7 (azithromycin), 6 (","suffix":"), and 6 (TMP/SMX) days. Men constituted 97% of all patients","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":166,"endOffset":178,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"e of warfarin interaction from terazosin to azithromycin to ","suffix":" to TMP/SMX was found (","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":153,"endOffset":165,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":" in the incidence of overanticoagulation when azithromycin, ","suffix":", or TMP/SMX was added to chronic warfarin therapy in patien","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":730,"endOffset":742,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","prefix":"al disease was seen more frequently in the azithromycin and ","suffix":" groups than the TMP/SMX and terazosin groups; however, the ","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":134,"endOffset":146,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/p[1]","prefix":" outpatients, the use of the oral antibiotics azithromycin, ","suffix":", and TMP/SMX increases both the incidence and degree of ove","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"trimethoprim","startOffset":179,"endOffset":191,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"who initiated an antibiotic (azithromycin, levofloxacin, or ","suffix":"/sulfamethoxazole (TMP/SMX)) or terazosin for clinical indic","exact":"trimethoprim"},{"setid":"PMC1490169","drugname":"trimethoprim","startOffset":179,"endOffset":191,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"who initiated an antibiotic (azithromycin, levofloxacin, or ","suffix":"/sulfamethoxazole (TMP/SMX)) or terazosin for clinical indic","exact":"trimethoprim"},{"setid":"PMC1490169","drugname":"sulfamethoxazole","startOffset":192,"endOffset":208,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":" an antibiotic (azithromycin, levofloxacin, or trimethoprim/","suffix":" (TMP/SMX)) or terazosin for clinical indications between Ja","exact":"sulfamethoxazole"},{"setid":"PMC1490169","drugname":"sulfamethoxazole","startOffset":192,"endOffset":208,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":" an antibiotic (azithromycin, levofloxacin, or trimethoprim/","suffix":" (TMP/SMX)) or terazosin for clinical indications between Ja","exact":"sulfamethoxazole"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":223,"endOffset":232,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"evofloxacin, or trimethoprim/sulfamethoxazole (TMP/SMX)) or ","suffix":" for clinical indications between January 1998 and December ","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":102,"endOffset":111,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","prefix":"                       The mean change in INR was −0.15 for ","suffix":", 0.51 for azithromycin, 0.85 for levofloxacin, and 1.76 for","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":271,"endOffset":280,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","prefix":"antibiotic groups were all statistically different from the ","suffix":" group. The incidence of supratherapeutic INR was 5% for ter","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":337,"endOffset":346,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","prefix":"sin group. The incidence of supratherapeutic INR was 5% for ","suffix":", 31% for azithromycin, 33% for levofloxacin, and 69% for TM","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":459,"endOffset":468,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","prefix":" for TMP/SMX. The incidence of absolute INR >4.0 was 0% for ","suffix":", 16% for azithromycin, 19% for levofloxacin, and 44% for TM","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":179,"endOffset":188,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":"ble warfarin doses and INRs who received a prescription for ","suffix":", azithromycin, levofloxacin, or TMP/SMX for clinical indica","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":354,"endOffset":363,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":"t a university-affiliated Veteran's Affairs Medical Center. ","suffix":" was chosen as our control because of its lack of interactio","exact":"Terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":223,"endOffset":232,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"evofloxacin, or trimethoprim/sulfamethoxazole (TMP/SMX)) or ","suffix":" for clinical indications between January 1998 and December ","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":102,"endOffset":111,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","prefix":"                       The mean change in INR was −0.15 for ","suffix":", 0.51 for azithromycin, 0.85 for levofloxacin, and 1.76 for","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":271,"endOffset":280,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","prefix":"antibiotic groups were all statistically different from the ","suffix":" group. The incidence of supratherapeutic INR was 5% for ter","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":337,"endOffset":346,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","prefix":"sin group. The incidence of supratherapeutic INR was 5% for ","suffix":", 31% for azithromycin, 33% for levofloxacin, and 69% for TM","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":459,"endOffset":468,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","prefix":" for TMP/SMX. The incidence of absolute INR >4.0 was 0% for ","suffix":", 16% for azithromycin, 19% for levofloxacin, and 44% for TM","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":179,"endOffset":188,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":"ble warfarin doses and INRs who received a prescription for ","suffix":", azithromycin, levofloxacin, or TMP/SMX for clinical indica","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":93,"endOffset":102,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"                        We identified 333 prescriptions for ","suffix":" in 333 patients, 273 prescriptions for azithromycin in 158 ","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":304,"endOffset":313,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"s for TMP/SMX in 120 patients. Initially 43, 35, 41, and 24 ","suffix":", azithromycin, levofloxacin, and TMP/SMX patients, respecti","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":587,"endOffset":596,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"all exclusions were made as indicated. Nine patients in the ","suffix":" group had follow-up INRs on or before day 15 and an additio","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":102,"endOffset":111,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"               There were no differences in outcomes in the ","suffix":" data analyzed at day 15 or 30, so the latter was used in al","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":230,"endOffset":239,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"ll further analysis. The median time to follow-up was 17.5 (","suffix":"), 7 (azithromycin), 6 (levofloxacin), and 6 (TMP/SMX) days.","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":137,"endOffset":146,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":" both the incidence and degree of warfarin interaction from ","suffix":" to azithromycin to levofloxacin to TMP/SMX was found (","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":209,"endOffset":218,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"tion of azithromycin for clinical indications compared with ","suffix":"","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":771,"endOffset":780,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","prefix":"e azithromycin and levofloxacin groups than the TMP/SMX and ","suffix":" groups; however, the significance of this is unknown but is","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":896,"endOffset":905,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","prefix":"t is likely to be minimal. Finally, we utilized a negative (","suffix":") and positive (TMP/SMX) control to confer validity to our f","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":223,"endOffset":232,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"evofloxacin, or trimethoprim/sulfamethoxazole (TMP/SMX)) or ","suffix":" for clinical indications between January 1998 and December ","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":102,"endOffset":111,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","prefix":"                       The mean change in INR was −0.15 for ","suffix":", 0.51 for azithromycin, 0.85 for levofloxacin, and 1.76 for","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":271,"endOffset":280,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","prefix":"antibiotic groups were all statistically different from the ","suffix":" group. The incidence of supratherapeutic INR was 5% for ter","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":337,"endOffset":346,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","prefix":"sin group. The incidence of supratherapeutic INR was 5% for ","suffix":", 31% for azithromycin, 33% for levofloxacin, and 69% for TM","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":459,"endOffset":468,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","prefix":" for TMP/SMX. The incidence of absolute INR >4.0 was 0% for ","suffix":", 16% for azithromycin, 19% for levofloxacin, and 44% for TM","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":179,"endOffset":188,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":"ble warfarin doses and INRs who received a prescription for ","suffix":", azithromycin, levofloxacin, or TMP/SMX for clinical indica","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":93,"endOffset":102,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"                        We identified 333 prescriptions for ","suffix":" in 333 patients, 273 prescriptions for azithromycin in 158 ","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":304,"endOffset":313,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"s for TMP/SMX in 120 patients. Initially 43, 35, 41, and 24 ","suffix":", azithromycin, levofloxacin, and TMP/SMX patients, respecti","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":587,"endOffset":596,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"all exclusions were made as indicated. Nine patients in the ","suffix":" group had follow-up INRs on or before day 15 and an additio","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":102,"endOffset":111,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"               There were no differences in outcomes in the ","suffix":" data analyzed at day 15 or 30, so the latter was used in al","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":230,"endOffset":239,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"ll further analysis. The median time to follow-up was 17.5 (","suffix":"), 7 (azithromycin), 6 (levofloxacin), and 6 (TMP/SMX) days.","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":137,"endOffset":146,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":" both the incidence and degree of warfarin interaction from ","suffix":" to azithromycin to levofloxacin to TMP/SMX was found (","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":209,"endOffset":218,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"tion of azithromycin for clinical indications compared with ","suffix":"","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":771,"endOffset":780,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","prefix":"e azithromycin and levofloxacin groups than the TMP/SMX and ","suffix":" groups; however, the significance of this is unknown but is","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":896,"endOffset":905,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","prefix":"t is likely to be minimal. Finally, we utilized a negative (","suffix":") and positive (TMP/SMX) control to confer validity to our f","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":354,"endOffset":363,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":"t a university-affiliated Veteran's Affairs Medical Center. ","suffix":" was chosen as our control because of its lack of interactio","exact":"Terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":974,"endOffset":983,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","prefix":"itive (TMP/SMX) control to confer validity to our findings. ","suffix":" is known not to interact with warfarin, while TMP/SMX has a","exact":"Terazosin"}],[{"setid":"PMC3091944","drugname":"warfarin","startOffset":226,"endOffset":234,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"sm, and other thromboembolic events. But, successful use of ","suffix":" has been challenged by its large inter-individual variation","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":307,"endOffset":315,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"llenged by its large inter-individual variation in required ","suffix":" dose and narrow therapeutic index.(","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":118,"endOffset":126,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":"arfarin is a racemic mixture of S- and R- enatiomers with S-","suffix":" being 2-5 times more potent and conferring the majority of ","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":63,"endOffset":71,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[4]","prefix":"                                                      Since ","suffix":" is classified as a BDDCS Class 2 drug(","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":124,"endOffset":132,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","prefix":"the presence of 100 μM rifampin, the uptake of 1 μM racemic ","suffix":" was decreased by 23% in rat hepatocytes (p < 0.05; ","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":109,"endOffset":117,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[2]/p[1]","prefix":"                The concentration-time profiles of 7-hydroxy","suffix":" (S-warfarin metabolite) and 10-hydroxywarfarin (R-warfarin ","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":121,"endOffset":129,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[2]/p[1]","prefix":"    The concentration-time profiles of 7-hydroxywarfarin (S-","suffix":" metabolite) and 10-hydroxywarfarin (R-warfarin metabolite) ","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":156,"endOffset":164,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[2]/p[1]","prefix":" of 7-hydroxywarfarin (S-warfarin metabolite) and 10-hydroxy","suffix":" (R-warfarin metabolite) after a single oral dose of 7.5 mg ","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":168,"endOffset":176,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[2]/p[1]","prefix":"ywarfarin (S-warfarin metabolite) and 10-hydroxywarfarin (R-","suffix":" metabolite) after a single oral dose of 7.5 mg warfarin alo","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":224,"endOffset":232,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[2]/p[1]","prefix":" (R-warfarin metabolite) after a single oral dose of 7.5 mg ","suffix":" alone or with a single intravenous dose of rifampin are sho","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":94,"endOffset":102,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[4]/p[1]","prefix":"                               A single 7.5 mg dose of oral ","suffix":" caused a small, transient increase in INR from baseline dur","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":224,"endOffset":232,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","prefix":"of the widely-used, narrow therapeutic index, anticoagulant ","suffix":". The results of our clinical study demonstrated that co-adm","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":244,"endOffset":252,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[5]","prefix":" polymorphisms in the human genome that may be important in ","suffix":" dose selection. In these GWAS studies, no common variants i","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":421,"endOffset":429,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[5]","prefix":"ransporters were found to be significant in determining the ","suffix":" dose requirements of patients.(","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":167,"endOffset":175,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[7]","prefix":"eared to be delayed since early in the time course S- and R-","suffix":" concentration-time curves, AUC","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":81,"endOffset":89,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[8]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[8]","prefix":"                                    We purposely selected a ","suffix":" dose for this study (7.5mg) that would provide adequate dru","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":385,"endOffset":393,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[8]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[8]","prefix":" volunteer study that also used a single 7.5mg dose of oral ","suffix":".(","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":132,"endOffset":140,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[9]","prefix":"our single dose clinical study of the effect of rifampin on ","suffix":" pharmacokinetics in healthy volunteers suggeststhat hepatic","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":291,"endOffset":299,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/p[2]","prefix":"in was chosen to maximize OATP inhibition and any effect on ","suffix":" uptake Rifampin is a known inhibitor of the 3 major human O","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":170,"endOffset":178,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[2]/p[2]","prefix":"surements were collected at the following times relative to ","suffix":" dosing: predose, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 ","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":477,"endOffset":485,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[2]/p[2]","prefix":"r INR determination at 0, 12, 24, 48, 72 and 96 hours after ","suffix":" dosing.                                                    ","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":105,"endOffset":113,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[3]/p[1]","prefix":"                    Pharmacokinetic parameters for R- and S-","suffix":" and their major metabolites were estimated from plasma conc","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":91,"endOffset":99,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[5]/p[1]","prefix":"                                  Using previously reported ","suffix":" pharmacokinetic data in healthy volunteers(","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":96,"endOffset":104,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[6]/p[1]","prefix":"                             The concentrations of S- and R-","suffix":" and their main metabolites were measured using high pressur","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":104,"endOffset":112,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[6]/p[2]","prefix":"                     The samples and standards for S- and R-","suffix":" (Sigma-Aldrich, St. Louis, MO) were prepared by liquid-liqu","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":95,"endOffset":103,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[6]/p[3]","prefix":"                              The samples and standards for ","suffix":" metabolites were prepared by liquid-liquid extraction of 10","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":105,"endOffset":113,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[6]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[6]/p[4]","prefix":"                    Chromatographic conditions for S- and R-","suffix":" were as described by Naidong and colleagues(","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":84,"endOffset":92,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[6]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[6]/p[5]","prefix":"                                         Chromatography for ","suffix":" metabolites was performed on an Agilent Eclipse XDB C18 col","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":90,"endOffset":98,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[6]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[6]/p[6]","prefix":"                                   The methods for S- and R-","suffix":" were validated from 1.5 to 300 ng/ml. The 1 h and 2 h sampl","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":259,"endOffset":267,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[6]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[6]/p[6]","prefix":"ations within the validated range. The methods for 7-hydroxy","suffix":" and 10-hydroxywarfarin were validated from 1.5 to 150 ng/ml","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":282,"endOffset":290,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[6]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[6]/p[6]","prefix":"ated range. The methods for 7-hydroxywarfarin and 10-hydroxy","suffix":" were validated from 1.5 to 150 ng/ml. The curves were linea","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":57,"endOffset":65,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"                                                         ","suffix":" is a commonly prescribed anticoagulant for the prevention o","exact":"Warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":57,"endOffset":65,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":"                                                         ","suffix":" is a racemic mixture of S- and R- enatiomers with S-warfari","exact":"Warfarin"},{"setid":"PMC3091944","drugname":"rifampin","startOffset":87,"endOffset":95,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","prefix":"                                  In the presence of 100 μM ","suffix":", the uptake of 1 μM racemic warfarin was decreased by 23% i","exact":"rifampin"},{"setid":"PMC3091944","drugname":"rifampin","startOffset":112,"endOffset":120,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[1]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[1]/p[2]","prefix":"             Analysis of all concentration-time data showed ","suffix":" significantly decreased the AUC","exact":"rifampin"},{"setid":"PMC3091944","drugname":"rifampin","startOffset":276,"endOffset":284,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[2]/p[1]","prefix":" 7.5 mg warfarin alone or with a single intravenous dose of ","suffix":" are shown in ","exact":"rifampin"},{"setid":"PMC3091944","drugname":"rifampin","startOffset":333,"endOffset":341,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","prefix":"strated that co-administration of the potent OATP inhibitor ","suffix":", given as a single intravenous dose, had no effect on the A","exact":"rifampin"},{"setid":"PMC3091944","drugname":"rifampin","startOffset":266,"endOffset":274,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","prefix":" atorvastatin and glyburide with hepatic OATP inhibition by ","suffix":"(","exact":"rifampin"},{"setid":"PMC3091944","drugname":"rifampin","startOffset":87,"endOffset":95,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[6]","prefix":"                              Intravenous administration of ","suffix":" conceivably minimized any potential confounding interaction","exact":"rifampin"},{"setid":"PMC3091944","drugname":"rifampin","startOffset":289,"endOffset":297,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[6]","prefix":"lack of an interaction cannot be fully confirmed. By giving ","suffix":" as a single dose, we attempted to avoid the well-described ","exact":"rifampin"},{"setid":"PMC3091944","drugname":"rifampin","startOffset":120,"endOffset":128,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[9]","prefix":"conclusion, our single dose clinical study of the effect of ","suffix":" on warfarin pharmacokinetics in healthy volunteers suggests","exact":"rifampin"},{"setid":"PMC3091944","drugname":"rifampin","startOffset":349,"endOffset":357,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[9]","prefix":"lized, narrow therapeutic index, anticoagulant. Single-dose ","suffix":" may induce metabolizing enzymes such as CYP2C9 and CYP3A4. ","exact":"rifampin"},{"setid":"PMC3091944","drugname":"rifampin","startOffset":187,"endOffset":195,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/p[2]","prefix":"a 37°C water bath with either control (0.1% DMSO) or 100 μM ","suffix":". The 100 μM concentration of rifampin was chosen to maximiz","exact":"rifampin"},{"setid":"PMC3091944","drugname":"rifampin","startOffset":225,"endOffset":233,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/p[2]","prefix":"(0.1% DMSO) or 100 μM rifampin. The 100 μM concentration of ","suffix":" was chosen to maximize OATP inhibition and any effect on wa","exact":"rifampin"},{"setid":"PMC3091944","drugname":"rifampin","startOffset":57,"endOffset":65,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","prefix":"                                                         ","suffix":" was chosen as a model OATP inhibitor to block the ","exact":"Rifampin"},{"setid":"PMC3091944","drugname":"rifampin","startOffset":307,"endOffset":315,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/p[2]","prefix":" maximize OATP inhibition and any effect on warfarin uptake ","suffix":" is a known inhibitor of the 3 major human OATPs, being a mo","exact":"Rifampin"},{"setid":"PMC3091944","drugname":"atorvastatin","startOffset":207,"endOffset":219,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","prefix":"demonstrated significant changes in the pharmacokinetics of ","suffix":" and glyburide with hepatic OATP inhibition by rifampin(","exact":"atorvastatin"},{"setid":"PMC3091944","drugname":"atorvastatin","startOffset":396,"endOffset":408,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[2]/p[1]","prefix":"mportance of OATP hepatic uptake in healthy voluneteers for ","suffix":"(","exact":"atorvastatin"},{"setid":"PMC3091944","drugname":"glyburide","startOffset":224,"endOffset":233,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","prefix":"ificant changes in the pharmacokinetics of atorvastatin and ","suffix":" with hepatic OATP inhibition by rifampin(","exact":"glyburide"},{"setid":"PMC3091944","drugname":"dmso","startOffset":171,"endOffset":175,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/p[2]","prefix":"for 5 minute in a 37°C water bath with either control (0.1% ","suffix":") or 100 μM rifampin. The 100 μM concentration of rifampin w","exact":"DMSO"}],[{"setid":"PMC3612775","drugname":"cholesterol","startOffset":187,"endOffset":198,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":"pproach to lowering blood levels of low-density lipoprotein ","suffix":" (LDL-C) and the risk of vascular events.","exact":"cholesterol"},{"setid":"PMC3612775","drugname":"cholesterol","startOffset":290,"endOffset":301,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","prefix":" eligible for inclusion if they had non-fasting blood total ","suffix":" concentrations of at least 3.5 mmol/L (135 mg/dL) and eithe","exact":"cholesterol"},{"setid":"PMC3612775","drugname":"cholesterol","startOffset":178,"endOffset":189,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","prefix":"ndard spectrophotometric enzymatic methods to measure total ","suffix":" and lipid fractions (including LDL-C directly) and immunotu","exact":"cholesterol"},{"setid":"PMC3612775","drugname":"cholesterol","startOffset":84,"endOffset":95,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","prefix":"                                         Statins reduce LDL ","suffix":" (LDL-C) and the risk of vascular events, but it remains unc","exact":"cholesterol"},{"setid":"PMC3612775","drugname":"cholesterol","startOffset":187,"endOffset":198,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":"pproach to lowering blood levels of low-density lipoprotein ","suffix":" (LDL-C) and the risk of vascular events.","exact":"cholesterol"},{"setid":"PMC3612775","drugname":"cholesterol","startOffset":290,"endOffset":301,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","prefix":" eligible for inclusion if they had non-fasting blood total ","suffix":" concentrations of at least 3.5 mmol/L (135 mg/dL) and eithe","exact":"cholesterol"},{"setid":"PMC3612775","drugname":"cholesterol","startOffset":178,"endOffset":189,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","prefix":"ndard spectrophotometric enzymatic methods to measure total ","suffix":" and lipid fractions (including LDL-C directly) and immunotu","exact":"cholesterol"},{"setid":"PMC3612775","drugname":"simvastatin","startOffset":336,"endOffset":347,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","prefix":" identify genetic variants related to the lipid response to ","suffix":" and assess their impact on vascular risk response.         ","exact":"simvastatin"},{"setid":"PMC3612775","drugname":"simvastatin","startOffset":144,"endOffset":155,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":" of the LDL-C and apolipoprotein B (ApoB) response to 40 mg ","suffix":" daily was performed in 3895 participants in the Heart Prote","exact":"simvastatin"},{"setid":"PMC3612775","drugname":"simvastatin","startOffset":240,"endOffset":251,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"d there were similar large reductions in vascular risk with ","suffix":" irrespective of genotypes associated with the lipid respons","exact":"simvastatin"},{"setid":"PMC3612775","drugname":"simvastatin","startOffset":316,"endOffset":327,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"spective of genotypes associated with the lipid response to ","suffix":". Consequently, their value for informing clinical decisions","exact":"simvastatin"},{"setid":"PMC3612775","drugname":"simvastatin","startOffset":268,"endOffset":279,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","prefix":"sociation analyses of the LDL-C and ApoB responses to 40 mg ","suffix":" daily in 3895 participants in the Heart Protection Study an","exact":"simvastatin"},{"setid":"PMC3612775","drugname":"simvastatin","startOffset":721,"endOffset":732,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","prefix":"assessed among 18 705 genotyped patients randomly allocated ","suffix":" vs. placebo for an average of 5 years.                     ","exact":"simvastatin"},{"setid":"PMC3612775","drugname":"simvastatin","startOffset":776,"endOffset":787,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","prefix":"involving 4 weeks of placebo followed by 4-6 weeks of 40 mg ","suffix":" daily, after which fully compliant individuals were randoml","exact":"simvastatin"},{"setid":"PMC3612775","drugname":"simvastatin","startOffset":868,"endOffset":879,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","prefix":"ully compliant individuals were randomly allocated to 40 mg ","suffix":" daily or matching placebo for ∼5 years. A non-fasting blood","exact":"simvastatin"},{"setid":"PMC3612775","drugname":"simvastatin","startOffset":1058,"endOffset":1069,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","prefix":"atin therapy) and at the end of run-in (i.e. while on 40 mg ","suffix":" daily). The pre-specified primary outcome for assessing the","exact":"simvastatin"},{"setid":"PMC3612775","drugname":"simvastatin","startOffset":228,"endOffset":239,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[1]","prefix":"l/L reduction in LDL-C between participants allocated 40 mg ","suffix":" daily vs. placebo.","exact":"simvastatin"},{"setid":"PMC3612775","drugname":"simvastatin","startOffset":126,"endOffset":137,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":"nt study identified associations with the lipid response to ","suffix":" for SNPs in three genes-","exact":"simvastatin"},{"setid":"PMC3612775","drugname":"simvastatin","startOffset":110,"endOffset":121,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/div[5]/p[1]","prefix":"           The present large study of the lipid response to ","suffix":" therapy was undertaken in a fully compliant population with","exact":"simvastatin"},{"setid":"PMC3612775","drugname":"quad","startOffset":224,"endOffset":228,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[1]/p[1]","prefix":"re selected, and genotypes measured using the Illumina 610K ","suffix":" panel. Genome-wide data were available for 3895 individuals","exact":"Quad"}],[{"setid":"PMC2686068","drugname":"simvastatin","startOffset":200,"endOffset":211,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"udy in 12 healthy subjects was performed. Subjects received ","suffix":" 40 mg alone or anacetrapib 150 mg co-administered with simv","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":267,"endOffset":278,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"atin 40 mg alone or anacetrapib 150 mg co-administered with ","suffix":" 40 mg, once daily. Both treatments were administered follow","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":452,"endOffset":463,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"sh-out period of at least 14 days. Safety and tolerability, ","suffix":" and simvastatin acid concentrations, and lipoproteins, were","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":126,"endOffset":137,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"oth treatments were well tolerated. The pharmacokinetics of ","suffix":" and simvastatin acid were similar with and without anacetra","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":399,"endOffset":410,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","prefix":"aluate the potential for a pharmacokinetic interaction with ","suffix":".                                                           ","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":200,"endOffset":211,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"udy in 12 healthy subjects was performed. Subjects received ","suffix":" 40 mg alone or anacetrapib 150 mg co-administered with simv","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":267,"endOffset":278,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"atin 40 mg alone or anacetrapib 150 mg co-administered with ","suffix":" 40 mg, once daily. Both treatments were administered follow","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":452,"endOffset":463,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"sh-out period of at least 14 days. Safety and tolerability, ","suffix":" and simvastatin acid concentrations, and lipoproteins, were","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":468,"endOffset":479,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":" at least 14 days. Safety and tolerability, simvastatin and ","suffix":" acid concentrations, and lipoproteins, were assessed.      ","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":126,"endOffset":137,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"oth treatments were well tolerated. The pharmacokinetics of ","suffix":" and simvastatin acid were similar with and without anacetra","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":142,"endOffset":153,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"ere well tolerated. The pharmacokinetics of simvastatin and ","suffix":" acid were similar with and without anacetrapib administrati","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":169,"endOffset":180,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","prefix":" effect of anacetrapib on the pharmacokinetic parameters of ","suffix":". When co-administered with simvastatin, anacetrapib appeare","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":208,"endOffset":219,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","prefix":"inetic parameters of simvastatin. When co-administered with ","suffix":", anacetrapib appeared to exhibit incremental LDL-C-lowering","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":351,"endOffset":362,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","prefix":"ue to CETP inhibition. Co-administration of anacetrapib and ","suffix":" was well tolerated.                                        ","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":181,"endOffset":192,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","prefix":" quantify any potential pharmacokinetic interaction between ","suffix":" and anacetrapib, following multiple oral doses of each, whe","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":505,"endOffset":516,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","prefix":". Safety and tolerability of treatment with anacetrapib and ","suffix":" were also assessed.                                        ","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":242,"endOffset":253,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","prefix":"ment A, subjects received a once daily oral dose of a 40-mg ","suffix":" tablet (ZOCOR™) for 14 days in the morning. In Treatment B,","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":460,"endOffset":471,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","prefix":"les, co-administered with a once-daily oral dose of a 40-mg ","suffix":" tablet for 14 days in the morning. All doses were administe","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":95,"endOffset":106,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[2]","prefix":"                          Pharmacokinetic blood samples for ","suffix":" and simvastatin acid were collected on day 14 of Treatments","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":111,"endOffset":122,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[2]","prefix":"          Pharmacokinetic blood samples for simvastatin and ","suffix":" acid were collected on day 14 of Treatments A and B and pre","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":108,"endOffset":119,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":"             The safety and tolerability of anacetrapib and ","suffix":" were assessed throughout the study by physical examinations","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":96,"endOffset":107,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[2]","prefix":"                         The pharmacokinetic parameters for ","suffix":" acid and simvastatin, AUC","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":117,"endOffset":128,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[2]","prefix":"    The pharmacokinetic parameters for simvastatin acid and ","suffix":", AUC","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":102,"endOffset":113,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"               Anacetrapib administered in combination with ","suffix":" was generally well tolerated. There were no serious clinica","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":81,"endOffset":92,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"                                    The pharmacokinetics of ","suffix":" and simvastatin acid were similar with and without anacetra","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":97,"endOffset":108,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"                    The pharmacokinetics of simvastatin and ","suffix":" acid were similar with and without anacetrapib administrati","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":126,"endOffset":137,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":" explored primarily the pharmacokinetic interaction between ","suffix":" and anacetrapib, as it relates to the effect of anacetrapib","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":201,"endOffset":212,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":" anacetrapib, as it relates to the effect of anacetrapib on ","suffix":" pharmacokinetics. Simvastatin is a lactone that is readily ","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":176,"endOffset":187,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"meaningful effect of anacetrapib on the pharmacokinetics of ","suffix":" (simvastatin acid or simvastatin). This is not unexpected, ","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":189,"endOffset":200,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"fect of anacetrapib on the pharmacokinetics of simvastatin (","suffix":" acid or simvastatin). This is not unexpected, given data in","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":209,"endOffset":220,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"on the pharmacokinetics of simvastatin (simvastatin acid or ","suffix":"). This is not unexpected, given data in the literature show","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":307,"endOffset":318,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"given data in the literature showing drug interactions with ","suffix":" were metabolic in nature, as a result of inhibition or indu","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":183,"endOffset":194,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","prefix":"icularly the lipid-altering biomarkers, interaction between ","suffix":" and anacetrapib. Anacetrapib is an investigational CETP inh","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":72,"endOffset":83,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","prefix":"                                             In this study, ","suffix":" alone reduced LDL-C by 36% and Apo B by 29%, whereas in com","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":151,"endOffset":162,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[7]","prefix":"meaningful effect of anacetrapib on the pharmacokinetics of ","suffix":". When co-administered with simvastatin, anacetrapib appeare","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":190,"endOffset":201,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[7]","prefix":" pharmacokinetics of simvastatin. When co-administered with ","suffix":", anacetrapib appeared to exhibit incremental LDL-C-and Apo ","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":319,"endOffset":330,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[7]","prefix":"o B-lowering efficacy. Co-administration of anacetrapib and ","suffix":" was well tolerated.                                        ","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":339,"endOffset":350,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/p[2]","prefix":"ssistance of Rita Chiou and Jin Zhang in outsourcing of the ","suffix":" assay, and the assistance of Josee Cote at the conclusion o","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":231,"endOffset":242,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":" the effect of anacetrapib on simvastatin pharmacokinetics. ","suffix":" is a lactone that is readily hydrolysed ","exact":"Simvastatin"},{"setid":"PMC2686068","drugname":"cholesterol","startOffset":228,"endOffset":239,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":" for the treatment of dyslipidaemias including primary hyper","suffix":"aemia and mixed hyperlipidaemia that increase susceptibility","exact":"cholesterol"},{"setid":"PMC2686068","drugname":"midazolam","startOffset":59,"endOffset":68,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","prefix":"                                                         A ","suffix":" clinical study in healthy subjects for the assessment of ef","exact":"midazolam"},{"setid":"PMC2686068","drugname":"creatinine","startOffset":289,"endOffset":299,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":"s (serum sodium, potassium, chloride, bicarbonate, calcium, ","suffix":", blood urea nitrogen, fasting serum glucose, bilirubin, asp","exact":"creatinine"},{"setid":"PMC2686068","drugname":"urea","startOffset":307,"endOffset":311,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":"otassium, chloride, bicarbonate, calcium, creatinine, blood ","suffix":" nitrogen, fasting serum glucose, bilirubin, aspartate amino","exact":"urea"},{"setid":"PMC2686068","drugname":"alanine","startOffset":384,"endOffset":391,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":"sting serum glucose, bilirubin, aspartate aminotransferase, ","suffix":" aminotransferase, alkaline phosphatase, albumin; haemoglobi","exact":"alanine"},{"setid":"PMC2686068","drugname":"atorvastatin","startOffset":429,"endOffset":441,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","prefix":"ith dyslipidaemia, both alone as well as in the presence of ","suffix":" [","exact":"atorvastatin"},{"setid":"PMC2686068","drugname":"atorvastatin","startOffset":429,"endOffset":441,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","prefix":"ith dyslipidaemia, both alone as well as in the presence of ","suffix":" [","exact":"atorvastatin"},{"setid":"PMC2686068","drugname":"atorvastatin","startOffset":864,"endOffset":876,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","prefix":"with the findings observed with anacetrapib (10-300 mg) and ","suffix":" 20 mg in the Phase 2b study, wherein atorvastatin 20 mg red","exact":"atorvastatin"},{"setid":"PMC2686068","drugname":"atorvastatin","startOffset":914,"endOffset":926,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","prefix":"0 mg) and atorvastatin 20 mg in the Phase 2b study, wherein ","suffix":" 20 mg reduced LDL-C by approximately 42% and when atorvasta","exact":"atorvastatin"},{"setid":"PMC2686068","drugname":"atorvastatin","startOffset":977,"endOffset":989,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","prefix":"rvastatin 20 mg reduced LDL-C by approximately 42% and when ","suffix":" 20 mg was given with anacetrapib 150 mg, LDL-C was reduced ","exact":"atorvastatin"},{"setid":"PMC2686068","drugname":"atorvastatin","startOffset":141,"endOffset":153,"start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[6]","prefix":"ears to have less than additive lipid-altering effects with ","suffix":" [","exact":"atorvastatin"}],[{"setid":"PMC3056523","drugname":"itraconazole","startOffset":221,"endOffset":233,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"as to determine the importance of inhibitory metabolites of ","suffix":" (ITZ) in ","exact":"itraconazole"},{"setid":"PMC3056523","drugname":"midazolam","startOffset":282,"endOffset":291,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":"nal female subject was enrolled, but she withdrew after the ","suffix":" (MDZ) control session because of nausea and vomiting. No ot","exact":"midazolam"},{"setid":"PMC3056523","drugname":"caffeine","startOffset":382,"endOffset":390,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[2]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[2]","prefix":"ucts for the duration of the study and to avoid alcohol and ","suffix":" from 1 day before through the end of each urine-collection ","exact":"caffeine"},{"setid":"PMC3056523","drugname":"edta","startOffset":1056,"endOffset":1060,"start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[2]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[2]","prefix":"les were collected through indwelling venous catheters into ","suffix":"-containing tubes (BD Vacutainer; BD Biosciences, Franklin L","exact":"EDTA"}]]}